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Abstract
Aging is a complex physiological process that leads to the deterioration of all cells and
tissues throughout the body. Aging is a major risk factor for the onset of many degenerative
diseases in both the central nervous system (CNS) and the periphery, but even nonpathological
aging (“normal” aging) is associated with chronic inflammation, oxidative stress, and decreased
stem cell proliferation and regenerative capacity. This decreased regenerative capacity in stem
cell niches is thought to be a key component underlying the aging process and many disease
states associated with aging.
While the exact biological mechanisms underlying impaired stem cell proliferation and
regeneration with age remain unclear, two areas of investigation are being explored: cellautonomous changes and cell non-autonomous changes. Cell autonomous changes involve the
senescence of genes such as p53, p16INK4A, critical proteins involved in canonical pathways
such as the Wnt/β-catenin pathway, and others. Cell non-autonomous effects on stem cell
niches refers to various circulating factors, such as pro-inflammatory cytokines, chemokines,
and other proteins that may influence the microenvironment.
Highly relevant early examples of circulating factors impacting stem cell proliferation
come from heterochronic parabiosis studies. Heterochronic parabiosis entails the surgical union
of the circulatory systems of a young mouse and an old mouse. It was observed that exposure
to blood from old mice had a deleterious impact on stem cell proliferation in young mice,
however blood from young mice had a positive effect on old mice. Similarly, when young mice
were injected with plasma from old mice, their performance on cognitive behavioral paradigms
such as contextual fear conditioning and the radial arm water maze was impaired, thus
v

underscoring the fact that circulating factors in the aging systemic milieu can impact the CNS.
While parabiosis studies have proven useful for the study of circulating factors, they are
not highly translational. We and others have found that nutraceutical intervention is able to
reverse some of the age-related decline in the CNS observed in rats and human subjects. In
particular, we have demonstrated that a particular nutraceutical called NT-020, a proprietary
blend of blueberries, green tea, vitamin D3, and carnosine, is able to rescue age-related
cognitive decline, reverse impaired neurogenesis, and exert anti-inflammatory effects. In vitro, it
has been previously demonstrated that rat hippocampal neural progenitor cells (NPCs) and
bone marrow-derived mesenchymal stem cells (MSCs) cultured with serum from aged rats
showed decreased proliferation as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5dephyltetrazolium bromide (MTT) and 5-bromo-2’-deoxyuridine (BrdU) assays. However, when
NPCs and MSCs were cultured with serum from aged rats given a diet supplemented with NT020, the proliferation rates were not different from those of cells cultured with serum from young
rats.
In studies with rats maintained on a standard diet or an NT-020-supplemented diet for
one month, aged rats showed delayed ability to locate the platform in the Morris Water Maze
paradigm, whereas the performance of aged rats maintained on a diet with NT-020 did not differ
significantly from that of young rats (Acosta et al. 2010). This suggests that NT-020 may have
rescued learning and memory in the aged rats. Furthermore, when the brains were collected
and subjected to immunostaining, it was observed that aged rats on an NT-020-supplemented
diet had a greater number of dividing cells in the subgranular zone (SGZ) of the dentate gyrus
(DG) in the hippocampus, as determined by cell cycle marker Ki67 compared to the aged
control. Additionally, NT-020-treated aged rats showed decreased activated microglia as
indicated by fewer cells that expressed major histocompatibility complex II (MHCII) (by OX6
staining) in the DG than aged controls. Finally, NT-020-treated aged rats also showed
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increased proliferation of neural progenitors in the SVZ, as indicated by increased doublecortin+
(DCX) staining compared to aged controls. In a double-blind, placebo-controlled trial with older
adults 65-85 years of age, those taking the NT-020 supplement improved on two measures of
processing speed within the two-month test period, but did not show significant improvement on
other cognitive performance tests. These results collectively suggest that NT-020 exerts
therapeutic effects by reversing inflammation and increasing stem cell proliferation in the
neurogenic niches. While some of the therapeutic mechanisms of action for NT-020 have been
defined, a complete profile of circulating factors being affected by NT-020 supplementation has
yet to be elucidated.
The goal of the current study was to generate a complete list of factors from the
systemic milieu that could be altered as a consequence of aging and rescued by NT-020
supplementation. We used bottom-up, discovery-based proteomics to create a profile for the
entire proteome for serum derived from aged rats given NT-020 or a normal diet and young rats
given NT-020 or a normal diet. Our data suggest that there are age-related molecular changes
that can be rescued by NT-020 supplementation.
We designed a discovery-, mass spectrometry-based proteomics study to generate a
profile of the entire rat proteome for serum derived from young (3-6 months) control, old (20-22
months) control, and old male Fisher 344 rats given a diet supplemented with NT-020. We
identified some proteins that were differentially expressed between the old control and old diet
groups, specifically proteins that are involved in aging and inflammatory pathways such as
autophagy and complement pathways. While the findings suggest that NT-020 is exerting antiaging effects, depletion of albumin, the most highly abundant protein in serum, presented a
methodological challenge in the study. It is likely that, in spite of depletion steps undertaken to
remove high abundance protein from the samples, much of the albumin and other high
abundance proteins remained and may have prevented other proteins from detected.
vii

Chapter 1 – Introduction
Aging
Aging is associated with a progressive decline in function of all cells, tissues, and organ
systems throughout the body and, along with this decline in function, is an observed decrease in
regenerative capacity of stem cell niches. Aging is also the primary risk factor for developing
degenerative disease in both the periphery and the central nervous system (CNS). Some
chronic conditions that disproportionately affect aged populations include cardiovascular
disease, cancer, osteoarthritis, diabetes mellitus, Parkinson’s disease (PD), and Alzheimer’s
disease (AD) (Jaul and Barron 2017, Franceschi et al. 2018, MacNee, Rabinovich and
Choudhury 2014).

Figure 1. Prevalence of disease by age. Age is a significant risk factor for a number of chronic diseases.
Prevalence rates of some age-related conditions are shown. Data sourced from (Harris 2013), (Alzheimer's
Association 2019), (American Heart Association 2019), (Virani et al. 2020).
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According to the Centers for Disease Control and Prevention, with AD alone, age is a
significant risk factor for the development of the disease and symptoms can first appear at the
age of 60. As of 2014, approximately 5 million Americans were living with AD and that number is
expected to triple to approximately 14 million people by the year 2060 (Centers for Disease
Control and Prevention 2019). According to the Alzheimer’s Association, the greatest risk
factors for developing late onset AD are: old age, carrying the e4 form of the APOE gene, and
having a family history of AD. However, of these three risk factors, age is the greatest of them
all, with the majority of those affected being age 65 or older. The risk for developing AD
increases exponentially with age. Of the 5.8 million Americans living with AD in 2019, an
estimated 5.6 million are age 65 and older. An estimated 81 percent of that 5.8 million are age
75 or older (Alzheimer’s Association 2019).
While the exact biological mechanisms driving the aging process are unknown, there are
several theories that relate to damage or error, and some of these include: 1.) Programmed
longevity, which states that aging is a result of specific genes selectively being switched off or
on, 2.) the endocrine theory, which maintains that our hormones drive our biological clocks and
this determines the rate at which we age, 3.) the immunological theory that states the immune
system is programmed to decline as we age which leads to increased susceptibility to infectious
diseases and being immune compromised, 4.) the “wear and tear” theory that states our cells
and tissues have vital parts that simply “wear out” over time, 5.) the rate of living theory which
postulates that any organism’s lifespan is determined by rate of oxygen basal metabolism, 6.)
the free radicals theory that is centered around evidence that free radicals called reactive
oxygen species (ROS) are able to damage cells and eventually tissues and organs (Harman
1956), 7.) the cross-linking theory that proposes there are cross-linked proteins that accumulate
and damage cells and tissues over time, and 8.) the somatic DNA damage theory which states
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that so much DNA damage can occur over time, and more quickly than they can be repaired,
that the negative effects are cumulative and may result in mutations with age (Jin 2010).
Additionally, there is the Hayflick limit theory of aging, which was originally proposed by
Dr. Leonard Hayflick in 1961. He observed that cells in culture are able to divide approximately
fifty times, after which, they become senescent (Shay and Wright 2000). Another popular theory
of aging is the telomere theory, which arose because telomeres have been shown to shorten
with each cell division and, when telomeres become too short, cells become senescent. Some
cells use the enzyme telomerase to repair telomere ends and restore length, but this function is
usually limited to reproductive cells. Experiments have shown that telomerase alone cannot
sufficiently restore telomere length after extensive cell division to prevent senescence (Jin
2010). A study in the central nervous system (CNS) has also shown that telomerase-deficient
mice had decreased hippocampal neurogenesis and decreased neuronal differentiation (Ferron
et al. 2009, Jin 2010).
The physiological processes that are thought to contribute to aging in the CNS in
particular include increased oxidative stress (Zuo et al. 2019, Marosi et al. 2012), microglial
activation (Angelova and Brown 2019, Wang et al. 2019), increased proinflammatory factors
(Milan-Mattos et al. 2019, Tsui, Richards and Davis 2018), and decreased blood-brain barrier
(BBB) integrity (Erdo and Krajcsi 2019, Bartels et al. 2009), which have been shown to result in
decreased global stem cell proliferation (Wagner et al. 2019, Ahmed et al. 2017) and blunted
neuroplasticity in the CNS (Acosta et al. 2010, Apple, Solano-Fonseca and Kokovay 2017).
While there are many biological theories underlying aging, the exact mechanisms are
unclear. However, there is sufficient evidence to suggest that aging is complex, with more than
one process occurring simultaneously, and that many of these occur at the cellular level. What
is clear is that there is an overall decrease in regenerative capacity with aging.
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Cell Autonomous and Cell Non-Autonomous Changes: Effects on the Stem Cell Niche
This decline in stem cell niche function is of particular significance because it results in
overall decreased regenerative capacity. A number of plausible explanations, including those
listed above, have been put forth in the literature to describe increased cellular senescence with
age. These changes in physiology with age are often referred to as cell autonomous changes
and cell non-autonomous changes. Examples of cell autonomous changes include decreased
expression of tumor suppressor genes including p16INK4A, p53, ARF, and p21, as well as
alterations to the Wnt/-catenin and other canonical pathways. Cell non-autonomous changes
are defined precisely how the term sounds in that they are the result of multidirectional
communication between different cells and tissue or organ systems (Medkour, Svistkova and
Titorenko 2016). Some cell non-autonomous changes discussed in the literature include
increased CCL11 (eotaxin) which negatively impacts neurogenesis, increased presence of the
pro-aging factor beta2-microglubulin (B2M), decreased brain-derived neurotrophic factor
(BDNF) which is associated with age-related decreases in the volume of the hippocampus and
neurogenesis (Erickson et al. 2010), decreased nerve growth factor (NGF) which is associated
with decline in cognitive function (Terry, Kutiyanawalla and Pillai 2011), and decreased
presence of the anti-aging growth differentiation factor 11 (GDF-11) (Katsimpardi et al. 2014,
Smith et al. 2015, Villeda et al. 2011, Villeda et al. 2014). Furthermore, the neurotrophic factors
BDNF and NGF have been found to be integral to the release of the neurotransmitters
dopamine (DA) and glutamate (Glu) in the hippocampus and age-related loss of this function
could have further implications for learning and memory in older adults (Paredes, Granholm and
Bickford 2007).
Some important early research on cell non-autonomous changes has come from
parabiosis studies.
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Parabiosis Studies
Parabiosis studies have laid the foundation for studying the aging systemic milieu.
Parabiosis entails the surgical union of the circulatory systems of two animals. Isochronic pairs
consist of two animals from the same age group (young with young or old with old).
Heterochronic pairs consist of a young animal and an old animal (Figure 2a). In one such study,
three pairs were created by surgical parabiosis of C57BL/6 mice: young-young isochronic, oldold isochronic, and young-old heterochronic in order to study the impact of the systemic milieu
on the central nervous system (CNS) (Villeda et al. 2011). There were a greater number of
doublecortin (DCX)-positive stained neural cells in the dentate gyrus (DG) of the hippocampus
of old mice from heterochronic pairs than old isochronic mice. In contrast, there were
significantly fewer DCX+ cells in the DG of the hippocampus of young heterochronic mice than
young isochronic mice. Similarly, 5-bromo-2’-deoxyuridine (BrdU) staining of the DG of the
hippocampus showed that old heterochronic mice had a greater number of BrdU+ cells in the
DG than old isochronic mice. Again, young heterochronic mice had fewer BrdU+ cells in the DG
than young isochronic mice. The results of the staining show an increase in cell proliferation and
an increase in new neurons in the DG of the hippocampus of old heterochronic mice and a
decrease in both cell proliferation and neurogenesis in young heterochronic mice. These data
suggest that there are circulating factors in young blood that had a beneficial effect on the CNS
of old mice and that there are deleterious factors in old blood that have a negative effect on the
CNS of young mice (Villeda et al. 2011).
In the same study, young C57BL/6 mice were injected with either young or old plasma
and subjected to the contextual fear conditioning and radial arm water maze (RAWM)
behavioral paradigms. Contextual fear conditioning is a behavioral paradigm during which the
animal is conditioned to associate a certain environmental context, which is the chamber, with
an aversive stimulus, which is a mild foot shock, on the first day. One the second day, the
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animal is put into the chamber and should exhibit freezing behavior, which is a sign of fear and
anticipation of an associated foot shock. Absence of freezing behavior indicates that the animal
may have impaired learning and memory. Young animals injected with old plasma displayed
significantly less freezing behavior than young animals injected with young plasma, suggesting
that factors, such as pro-inflammatory cytokines and chemokines, in the old plasma may have
impacted learning and memory (Villeda et al. 2011).
The RAWM is a behavioral paradigm that assesses spatial learning and memory. In this
test, there are multiple arms (six in this study) submerged in a pool of water, with one arm being
designated as the “goal arm” with an escape platform for the animal to swim onto. Mice were
trained for 3 h with 15 trials with the platform being alternated between being hidden or
exposed. Swimming to an arm other than the goal arm was counted as an error. Mice injected
with old plasma made significantly more errors than mice injected with young plasma in the
RAWM test. This suggests that old plasma contains factors that were deleterious to spatial
learning and memory (Villeda et al. 2011).
Additionally, Villeda and colleagues used proteomics to compare plasma from young
and old mice to plasma from human patients in order to identify possible circulating pro-aging
factors. Factors common in normal aging and parabiosis included: CCL2, CCL11, CCL12,
CCL19, haptoglobulin, and -2 microglobulin (b2M). The authors identified CCL11 (eotaxin) as a
pro-aging factor associated with decreased neurogenesis. To examine the effect of CCL11 on
the brain, young mice were stereotaxically injected with CCL11 in the DG. A decreased number
of DCX+ cells were observed in the DG compared with the contralateral side where only a
vehicle control was injected. To assess the impact of CCL11 on behavior, young mice received
intraperitoneal (i.p.) injections of recombinant CCL11 or vehicle control and were subjected to
fear conditioning and RAWM. Animals that received CLL11 showed impaired learning and
memory on both tests compared to vehicle-treated control mice. Though there are many factors
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that have been identified in the literature, these data suggest that the presence of just one
systemic pro-aging factor in the CNS can significantly impact neurogenesis and learning and
memory (Villeda et al. 2011).
In a follow-up study by the same group, old isochronic parabionts were compared to old
heterochronic parabionts to determine the beneficial effects that exposure to young blood could
have on the aged CNS (Villeda et al. 2014). Immunohistochemical (IHC) staining showed an
increased number of cells that expressed the genes Egr1, c-Fos, and Creb in the DG of old
heterochronic compared to old isochronic mice. Additionally, Golgi staining was performed and
showed increased dendritic spine density in the DG, but not CA1 region, of the hippocampus of
old heterochronic mice compared to old isochronic mice.
Additionally, extracellular electrophysiology was performed to determine functional
changes in the DG as a result of exposure to young blood. Isochronic parabionts had long-term
potentiation that was equal to baseline levels, however heterochronic parabionts maintained
LTP recordings above baseline for the whole duration, suggesting that synaptic plasticity is
increased in old mice after exposure to blood from young mice (Villeda et al. 2014).
In this study, contextual fear conditioning and RAWM were carried out again to assess
cognitive function, and showed the same results as before. Heterochronic old mice
demonstrated increased freezing behavior in the contextual fear conditioning paradigm,
suggesting increased learning and memory. In the RAWM, old heterochronic mice made fewer
errors compared to isochronic old mice. These data again suggest that exposure to young blood
has a positive effect on learning and memory in old mice (Villeda et al. 2014).
Based on the knowledge gleaned from their previous parabiosis studies, the group then
sought to apply what they learned about the beneficial effects of young blood on old animals to
Alzheimer’s disease (AD), as age is the primary risk factor for the non-familial form of AD
(Middeldorp et al. 2016). Young wild-type mice were surgically joined with amyloid precursor
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protein (APP) transgenic mice with the familial London and Swedish mutations, an APP mouse
model which closely mimics the cognitive impairment seen in human patients with AD. As
synaptic and calcium-binding proteins are downregulated in early stages of AD, staining was
carried out for synaptophysin and calbindin in the DG. APP male isochronic parabionts had
significantly less synaptophysin and calbindin expression in the DG, and this effect was
significantly reversed in heterochronic male parabionts. The same trends were observed in
female parabionts, suggesting that the beneficial effects of young blood are not sex-specific.
Interestingly, high levels of amyloid- (A) remained in the hippocampus of APP heterochronic
parabionts and microglial activation, as indicated by positive staining of CD68, remained. This
suggests that young blood was able to restore synaptic proteins even with high levels of A and
inflammation.
The authors also performed genome-wide microarray analysis in order to determine
genes that were differentially expressed between APP heterochronic parabionts and isochronic
parabionts with the goal of identifying gene expression that was induced by exposure to young
blood. The most changed were -secretase-activating protein (GSAP) and the synaptic lipid raft
adaptor protein (PAG1), both of which are associated with the -seceretase pathway, which
cleaves APP to a form that can produce A (Middeldorp et al. 2016).
Plasma injection experiments were also repeated in which middle-aged female APP
mice were injected with young plasma or PBS twice a week for a month. Treatment with young
plasma rescued hyper-phosphorylated ERK and returned it to the levels observed in wild-type
mice, depleted synaptophysin levels were restored, and depleted calbindin levels were restored.
Additionally, behavior tests were carried out in order to determine the cognitive effects of young
plasma on APP mice. The Y-maze spontaneous alternation test is used to measure spatial
working memory by observing an animal’s willingness to explore new environments and, in this
test, there are three arms. The animal is placed in the center and allowed to freely explore the
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arms. The animal should show a tendency to enter an arm that has not been recently visited as
continuing to enter the same arm is indicative of cognitive impairment. APP mice treated with
young plasma showed a similar number of arm entries to wild-type mice, while PBS-treated
control mice performed at “chance level.” In addition to the Y-maze, mice were subjected to
contextual fear conditioning and APP young plasma-injected mice showed increased freezing
behavior compared to PBS controls, suggesting that young plasma had a positive effect on
hippocampus-dependent learning and memory (Middeldorp et al. 2016). Together these data
suggest that factors in young blood could have the potential to ameliorate disease progression
in a mouse model of AD.
Collectively, data from these parabiosis studies suggest that there are circulating factors
in the systemic milieu of old blood that have a deleterious, pro-aging effect and, conversely,
there are circulating factors in young blood that have a beneficial, rejuvenating, and anti-aging
effect. This opens up the possibility of manipulating the aged systemic milieu by introducing
rejuvenating factors or somehow downregulating deleterious factors in order to restore the
microenvironment to a state that is conducive to increased regeneration and repair.
Sex Differences
It is important to note, that while the aforementioned studies did not discuss sex
differences and the current work will also not address sex differences, there are physiological
differences between males and females with regard to aging and proteomes, and future work
with microglia from the same animals will address some of these differences.
There are many sex differences in age-related diseases. For instance, women have a
higher incidence of developing Alzheimer’s disease than men. However, women are at lower
risk for stroke, though their outcome after stroke is poor compared to men (Mangold et al.
2017). As sex hormones help to drive development of the immune system, the inflammatory
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response is fundamentally different between males and females and these differences are
thought to contribute to disparities in disease incidence as well as differences in disease
progression between males and females (van Lunzen and Altfeld 2014). In the brain, the
resident immune cells, microglia, also display key differences between the sexes with regard to
cell density, localization of the cells, transcription, and translation (Guneykaya et al. 2018). A
previous study showed male and female mice had 1,209 differentially expressed genes in the
hippocampus alone, 55 in the cortex, and 46 differentially expressed genes in both regions of
the brain. In proteomic analysis with microglia from whole brain samples, 268 proteins were
found to be expressed at significantly higher levels in microglia from male mice and 96 proteins
were found to be expressed at significantly higher levels in microglia from female mice
(Guneykaya et al. 2018).
Another study analyzed the sex differences in the neuroinflammatory responses of
microglia in the hippocampi of young (3 months), adult (12 months), and old (24 months) mice
(Mangold et al. 2017). Whole hippocampi were used for bioinformatic analysis of gene and
protein expression. Female mice had an overall greater change in gene expression with age
compared to males with age and that change was significant between young and adult and
adult and old, suggesting the change was age-dependent across the lifespan. Male mice had
more variability in gene expression between animals. Pathways associated with inflammation
were activated in an age-dependent fashion in both males and females, but with females there
was an even greater immune activation later in the lifespan. There was also significant agedependent differential microglia-specific gene and protein expression between the sexes, with
more increases in expression of microglial ligands and pro-inflammatory genes in females than
males. In addition, females showed significantly greater age-dependent expression of
complement protein C1q than males (Mangold et al. 2017).

10

Females and males clearly experience different physiological changes with age and
present a different phenotype with respect to microglia in preclinical research, which also
suggests that activation state may not be the only important piece of information to glean about
microglia. Bioinformatics provides a unique opportunity to further elucidate some of these sex
differences. Future work from our group will aim to elucidate some of these age-dependent sex
differences using microglia from the animals used in the present study.
Graft Studies
In addition to parabiosis studies, studies of graft transplantation have also demonstrated
that there are deleterious factors in the aged milieu, such as circulating pro-inflammatory
cytokines and reactive oxygen species. These circulating factors can impact survival of the graft
in the aged host. One study showed that transplantation of hippocampal embryonic neuronal
cells resulted in significantly less microglial activation (shown by Ox6 and Iba1 staining) after
cells were transplanted intraocularly into 17-18 month-old rats after the rats were maintained on
a 2% blueberry-supplemented diet than age-matched controls. In addition, blueberrysupplemented aged rats had less astrogliosis, as determined by staining for glial fibrillary acidic
protein (GFAP) than age-matched controls. Futhermore, these effects were significantly more
pronounced when rats were maintained on the blueberry diet long term (8-12 weeks) as
opposed to short-term (1-2 weeks) (Willis et al. 2010). Blueberry supplementation has also been
shown to support the survival and growth of these grafts (Willis et al. 2008)These findings
support that there are negative factors in old blood and that they can be ameliorated by dietary
supplementation with antioxidants.

11

Nutraceuticals for Aging and Age-related Degenerative Disease
The term “nutraceutical” is a broad, umbrella term for all types of food with health or
medical benefits and many are being applied to conditions affecting older adults (VranesicBender 2010). Some of the conditions that disproportionately affect aging populations include
hypertension, diabetes, dementia, osteoporosis, respiratory problems, cataract, and heart
disease (Gupta and Prakash 2014). Most nutraceuticals are hypothesized to target free radicals
or reactive oxygen species (ROS) which result in oxidative stress in aging. A beneficial effect of
using a nutraceutical is thought to be the result of antioxidant activity, and some of the types of
substances that are used for their antioxidant activity include flavonoids, carotenoids, vitamins,
and minerals. In addition to the oxidative stress hypothesis, genetic factors termed “longevityrelated genes” have also been shown to play a role in the health and lifespan of yeast, C.
elegans, flies, and rodents. There is also the “hormesis” hypothesis of aging which states that
protective mechanisms can be elicited, in this case by dietary supplements or nutraceutical
intervention, to influence expression of genes.
Chemically, nutraceuticals may be classified in a number of ways including: isoprenoids
(carotenoids, saponins, terpenes, etc.), phenolic compounds (tannins, anthocyanins,
isoflavones, flavones, flanvonoids, etc.), carbohydrates (ascorbic acid, oligosaccharides,
nonstarch polysaccharides), fatty acids (n-3 polyunsaturated fatty acids, etc.), amino acid
derivatives (folate, choline, etc.), microbes (prebiotics and probiotics), and minerals (Ca, Zn, K,
etc.) (Gupta and Prakash 2014).
One study found that with aging there were increased levels of the pro-inflammatory
cytokines tumor necrosis factor-alpha (TNF-), interferon-gamma (IFN-), interleukin-6 (IL-6),
and IL-8 in serum from aged rats as determined by enzyme-linked immunosorbent assay
(ELISA). Additionally, there was decreased expression of upstream antioxidant genes DJ-1 and
NRF2 and increased expression of apoptosis-related genes p53 and Bax (mRNA) in the
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thymus, as determined by quantitative real-time polymerase chain reaction (RT-PCR). Rats
were either untreated (control), Given ethanol and phosphate buffered saline (PBS) (vehicle
control), had 10mg/kg body weight melatonin added to their diet (Aged+Mel), or had 2%
turmeric added to their diet (Aged+Tum). Treatment with either the antioxidants melatonin or
turmeric reversed these age-induced changes in physiology (Ismail, El-Bakry and Soliman
2018).
Another study showed that standardized turmeric extract HSS-888 was able to reduce
A deposition and neurofibrillary tangle-producing phosphorylated tau in a transgenic model of
Alzheimer’s disease (AD) (Shytle et al. 2012). A diet supplemented with HSS-888 resulted in
reduced presence of amyloid in the cerebrum of transgenic mice as determined by
immunohistochemical (IHC) staining. Additionally, treatment with HSS-888 resulted in reduction
of both soluble and insoluble forms of A, as determined by ELISA. Furthermore, HSS-888 diet
supplementation resulted in significantly decreased phosphorylated tau protein in brain
homogenate, as determined by Western blot. Microglia from the animals were subjected to
cytokine analysis by ELISA and it was found that mice treated with HSS-888 had significantly
increased expression of anti-inflammatory cytokines IL-2 and IL-4. These data suggest that
HSS-888 had therapeutic effects in transgenic AD mice by direct disease-specific mechanisms
such as reducing plaque and neurofibrillary tangle burden, but also indirectly through antiinflammatory mechanisms (Shytle et al. 2012).
Another nutritional approach to combating oxidative stress and inflammation in the
periphery as well as the CNS is the ketogenic diet or supplementation with exogenous ketones.
One trial showed that giving patients a mixture of medium chain triglycerides (MCTs) improved
memory and attention in AD patients (Reger et al. 2004). In transgenic APP+ presenilin 1
(APP+PS1) mice, however, MCT treatment only improved motor function and not cognition on
behavioral paradigms, nor did it have any effect on neurogenesis, astrocytosis, nor microglial
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activation (Brownlow et al. 2013). However, MCT dietary supplementation has been shown to
mediate inflammation by blocking activity of the NLRP3 inflammasome, which controls
activation of caspase-1 and macrophage production of pro-inflammatory cytokines IL-1 and IL8 (Youm et al. 2015). Moreover, the risk for developing cancer increases with age and
exogenous ketone supplementation has been shown to be anti-tumorigenic in mice (Poff et al.
2014).
Polyphenolic Compounds and Diet
In addition to the compounds mentioned, polyphenolic compounds have also been
shown to increase rejuvenation in aging and age-related diseases. Polyphenols are naturally
occurring compounds that are plant secondary metabolites and are considered anti-aging
supplements due to their ability to modulate some of the physiological hallmarks of aging
including inflammation, oxidative stress, cellular senescence, and autophagy (Russo et al. 2019,
Tressera-Rimbau et al. 2017). Polyphenol-rich foods include berries, green tea, fruit juice,
coffee, nuts, and cocoa (Rajaram, Jones and Lee 2019).
In a recent study, young and old male Wistar rats were given grape juice orally for 28
days (10 L/g body weight). Ferric reducing ability of plasma (FRAP), ROS, plasma membrane
redox system (PMRS), glutathione (GSH), osmotic fragility, and decrease in lipid peroxidation
by malondialdehyde (MDA) levels were measured. There was a significant increase in the
antioxidants FRAP, PMRS, and GSH and a significant decrease in ROS and MDA in treated
rats versus controls, suggesting that grape juice was able to quell oxidative stress signaling
(Kumar, Bhoumik and Rizvi 2019).
Another study examined the anti-aging and microbiome effects of life-long consumption
of polyphenols from lemon (LPP) when administered to a mouse model of aging, the
senescence-accelerated mouse prone 1 (SAMP1) and a resistant strain, senescence-
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accelerated resistant mouse 1 (SAMR1) (Shimizu et al. 2019). The SAMP1 mouse model shows
early signs of aging including senile amyloidosis, impaired immunity, and decreased motor
function and the SAMR1 model is often used as an age-matched control. LPP (0.1%) was
added to tap water and mice were allowed ad libitum access. Grading of age-related changes
was accomplished by calculating scores for skin and hair condition (glossiness, coarseness,
hair loss), ulcers, condition of the eyes (cataract, lesions, clarity of cornea, ulcers), and skeleton
(spinal curvature) every month up to 88 weeks of age. Mice were subjected to the behavioral
paradigms novel object recognition test (ORT) and object location test (OLT) at various
timepoints throughout the lifespan in order to assess spatial cognition. Normal mice should
spend more time exploring a novel object than a previously encountered object on the ORT and
normally functioning mice should be able to recognize when an object has been moved to a new
location in the OLT. Locomotor activity was measured by movement inside the ORT box.
Analysis of the microbiome was carried out by isolating bacterial DNA from feces and
conducting PCR. The LPP-treated SAMP1 group was significantly lower in age-related scores
for periophthalmic lesions, hair coarseness, and hair loss than the plain water control group.
LPP-treated SAMP1 mice also showed significantly greater motor activity compared to the plain
water control group, although it did not reach the levels of the SAMR1 age-matched control.
LPP treatment also significantly improved long-term object memory and spatial recognition, as
measured by ORT and OLT, in SAMP1 mice. The gut microbe Lactobacillus increases with age
in human subjects and, interestingly, the Lactobacillus in SAMP1 LPP-treated mice at 70 weeks
of age, was significantly lower than those in the plain water control group. Collectively, the
results of the study suggest that lifelong consumption of LPP had anti-aging effects on overall
health and on the intestinal microbiome in SAMP1 mice.
As previously mentioned, there is a preponderance of evidence that vulnerability to
oxidative stress is one major factor contributing to age-related decline, particularly in the CNS,
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and research on antioxidant-rich diets show a number of therapeutic effects. In a study where 6month-old rats were given a diet supplemented with strawberry extract (SE 9.5 gm/kg dried
aqueous extract), spinach extract (SPN 6.4 gm/kg dried aqueous extract), or vitamin E (500
IU/kg) for two months, SPN had the greatest effect on cognitive performance as assessed by
the Morris water maze paradigm, but vitamin E had the greatest effect on mitigating oxidative
stress as assessed by 2’7’-dechlorofluorescein diacetate analysis. This suggests that
phytochemicals in such compounds may be beneficial for decreasing oxidative stress (Joseph
et al. 1998). Another study by our group demonstrated that a diet supplemented with
antioxidant-rich blueberry and spirulina extract induced transient activation of microglia soon
after 6-OHDA injection into the dorsal striatum of normal rats, but the number of activated
microglia significantly decreased in diet-treated rats one month after lesion compared to
controls. The blueberry-spirulina diet group also had greater recovery of dopamine neurons, as
evidenced by tyrosine hydroxylase staining, in the striatum and the globus pallidus, than the
control group given a standard diet (Stromberg et al. 2005).
Transplantation of therapeutic cells or neural tissue have received attention as potential
therapies for neurodegenerative diseases, however the age of the host has a significant impact
on graft success and survival, with a more aged microenvironment having negative impacts on
transplants. A study using young and middle-aged female Fisher 344 rats as donors receiving
intraocular grafts from fetal hippocampi were randomly assigned to receive a standard NIH-31
chow or chow supplemented with 2 % blueberry, which are rich in antioxidants. Animals were
subdivided again to receive diet either short-term (1-2 weeks) or long-term (8-12 weeks). The
results revealed that compared to young animals, old control animals had significantly less graft
growth. However, blueberry-treated grafts in old rats had grafts that grew just as well as, and
sometimes even better than, young control rats. In addition, blueberry-treated rats also had
improved graft organization that resembled that of young animals compared to old control rats.
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Furthermore, the final size of the grafts was similar between blueberry-treated old rats and
young rats (Willis et al. 2008).
Together, these studies provide evidence that flavonoids and polyphenolic compounds
are able to reverse some of the deleterious processes that occur with aging such as increased
oxidative stress, decreased stem cell proliferation, and increased inflammation.
NT-020
NT-020 (NutrastemTM, Natura Therapeutics, Inc.) is a nutraceutical compound composed
of a proprietary blend of polyphenols blueberry and green tea, the amino acid carnosine, and
vitamin D3 that was developed at the Center of Excellence for Aging and Brain Repair at the
University of South Florida. The group had found that blueberry, green tea, catechin, carnosine,
and vitamin D3 synergistically induced the proliferation of human bone marrow cells, human
CD34+ , and human CD133+ cells in a dose-dependent manner compared to human
granulocyte-macrophage colony-stimulating factor (hGM-CSF) Furthermore, the combination of
the ingredients blueberry, green tea, vitamin D3, and carnosine produced greater proliferation in
CD34+ cells and CD133+ cells than each of the individual components alone. This demonstrates
that this combination, now NT-020, had a synergistic and additive effect on cell proliferation
(Bickford et al. 2006).
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Figure 2. NT-020 promotes CD34+ cell proliferation. Compounds in NT-020 promote proliferation of
CD34+ cells in a synergistic manner and its effect is greater than its individual ingredients. Image from
Bickford et al. (2006).

Treatment with NT-020 was also found to exert therapeutic and neurogenic effects in a
rat model of ischemic stroke. Adult male Sprague-Dawley rats were randomly assigned to be
treated with NT-020 or a vehicle control by daily oral gavage for two weeks prior to stroke
induction. On day 14, ischemic stroke was modeled by middle cerebral artery occlusion (MCAo).
Rats were subjected to behavioral tests, including the Bederson test and the elevated body
swing test (EBST), before and after MCAo surgery. The Bederson test is commonly used to
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measure outcome after stroke. Parameters include 1) observed spontaneous ipsilateral circling
(graded 0-3, 0 = no circling, 3 = continuous circling), 2) contralateral hindlimb retraction which
measures the rodent’s ability to replace the hindlimb after it has been displaced (graded 0
(immediate replacement) to 3 (replacement)), 3) beam walking (graded from 0 (rat walks across
a 2.4 cm-wide, 80 cm-long beam without an issue) to 3 (rat is unable to stay on the beam for ten
seconds (s)), 4) bilateral forepaw grasp which measures the ability to hold onto a 2 mmdiameter steel rod (graded 0 (for normal forepaw grasping) to 3 (for unable to grasp)). When the
tests are completed, the scores from all four tests are added and averaged to determine a
neurological deficit score. At 14 days after stroke surgery, both the NT-020 group and the
vehicle control group showed neurological deficits, however the NT-020 group had significantly
fewer neurological deficits, as determined by the Bederson test.
The EBST involves lifting the rodent by the base of the tail until the nose is about 2
inches about the surface. The direction that the animal swings (right or left) is recorded. After
each individual swing, the animal is set down to rest before re-testing, and the test is repeated
twenty times. Animals functioning normally will have a 50% swing bias for the right or left, but
MCAo stroke model animals tend to exhibit a 75% swing bias for a particular side. Similar to the
results of the Bederson test, both the NT-020 group and the vehicle control displayed motor
deficits, as determined by EBST, following stroke surgery, however NT-020-treated rats had
significantly fewer deficits than the vehicle-treated rats (Yasuhara et al. 2008).
Additionally, glial fibrillary acidic protein (GFAP) staining was used to visualize glial
scarring, and it was found that with NT-020 treatment there was significantly less glial scarring.
5-bromo-2’deoxyuridine (BrdU) labeling of brain tissue revealed that NT-020 increased the
number of proliferating cells in the subventricular zone (SVZ) and the striatum compared to the
vehicle-treated control group. The results also suggest that NT-020 treatment enhanced
differentiation of nascent cells to a neuronal phenotype in the striatum, as determined by
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increased double-positive staining of cells for BrdU and doublecortin (DCX) compared to
vehicle-treated controls. Furthermore, NT-020 treatment did not enhance differentiation of
nascent cells to a glial lineage, as exhibited by less double staining for BrdU and GFAP
compared to vehicle-treated controls. Altogether the results suggest neuroprotective effects of
NT-020 diet supplementation for stroke prophylactically (Yasuhara et al. 2008).
With aging there is a significant decrease in stem cell regenerative capacity and cells are
more vulnerable to oxidative stress. Blue-green algae is among some of the flavonoids
researched for its ability to aid in endogenous stem cell repair. As NT-020 was previously shown
to promote stem cell proliferation, a study was designed to ascertain whether blue-green algae
(Aphanisomenon flosaquae (AFA)) and NT-020 could synergistically promote cell proliferation.
Human bone marrow cells or human CD34+ cells were cultured with NT-020, different
concentrations of AFA, or both NT-020 and AFA (500 ng/ml), and MTT assays were carried out
to measure cell proliferation. The results showed that AFA and NT-020 significantly increased
cell proliferation in both human bone marrow cells and human CD34+ in an additive manner
(Shytle et al. 2010).
In a follow-up study, human neural progenitor cells, human bone marrow cells, and
human CD34+ cells were cultured with various doses of spirulina or NT-020, or a combination of
the two. Both spirulina and NT-020 increased proliferation of human bone marrow cells, as
determined by MTT assay. However, the combination of spirulina and NT-020 significantly
increased proliferation more than either spirulina or NT-020 alone. The same effect was
observed with CD34+ cells. However, surprisingly, for NPCs spirulina and NT-020 alone
increased proliferation significantly, however the combination decreased proliferation to levels
below the control (media alone) (Bachstetter et al. 2010).
NT-020 was also shown to enhance cognitive function, increase proliferation of neural
progenitor cells, and decrease inflammation in aged rats. Young (3-month-old) or old (20-month-
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old) rats were either treated with NT-020 or water (control) by oral gavage for four weeks.
Spatial memory was assessed by MWM, which was measured over 5 days of training with four
trials per day. Old rats treated with NT-020 performed better on the MWM test (Acosta et al.
2010).

Figure 3. Aged rats on NT-020 show improved cognitive function. Old rats on NT-020 made fewer
errors in locating the platform on the Morris Water Maze (MWM) than age-matched controls (Acosta et al.
2010).

Staining with the cell cycle marker Ki67 revealed a significant age-related decrease in
cell proliferation in the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus,
however in old rats treated with NT-020 there was a significant increase in cell proliferation
compared to age-matched controls. Similarly, staining with the marker for immature neurons,
doublecortin (DCX), significantly decreased with age. Treatment with NT-020 showed a
21

significant increase in DCX in the DG of the hippocampus in old rats compared to age-matched
controls (Acosta et al. 2010).
Ki67 staining was also performed to visualize cell proliferation in the subventricular zone
(SVZ), and like the SGZ of the DG, there was an overall age-related decrease in Ki67+ cells
compared to young rats. However, with NT-020 treatment there was an increase in cell
proliferation in old rats, as determined by Ki67 staining, compared to age-matched controls.

Figure 4. NT-020 increased neurogenesis in the hippocampus of old rats. Ki67, a marker of cell
proliferation and growth, was detected in the subgranular zone (SGZ) of the dentate gyrus (DG) in the
hippocampus. There was blunted Ki67 in the SGZ in old rats, however this was reversed with NT-020.
Likewise, there was blunted positive staining for doublecortin (DCX), a marker for immature neurons, in
the SGZ with age, however this was reversed with NT-020 (Acosta et al. 2010).

Aging is associated with an increase in inflammation, both in the periphery and the CNS.
The predominant immune cells of the brain are microglia, which express major histocompatibility
complex II (MHCII) when in the activated state. In order to determine whether NT-020 treatment
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decreased the number of activated microglia, OX6 staining was carried out to reveal the number
of MHCII-expressing cells in the DG. There was an age-related increase in OX6+ cells in the DG
compared to young rats, however with NT-020 treatment there was a decrease in the number of
OX6+ cells compared to age-matched controls. The evidence in the study demonstrated that NT020 treatment increased neurogenesis, decreased microglial activation, and enhanced cognitive
function in aged rats (Acosta et al. 2010).
In a double-blind, placebo-controlled clinical trial by our group and a partnering center,
one hundred and five older adults (aged 65-85 years) were randomized a pill-based form of 900
mg of blueberry, green tea, and carnosine plus 200 U of vitamin D3 (NT-020) and 40 mg Biovin
(grape extract) to assess the impact of NT-020 on cognitive function. Participants were
administered a battery of cognitive tests to establish baseline scores, and then they were given
NT-020 pills or placebo to take orally for two months total, with a blood draw at the one-month
point. Participants also kept a pill and symptom diary to track when they took the pill and any
adverse events throughout the course of the study. After the two-month period, participants
returned to have cognitive measures administered again. The cognitive measures assessed
episodic memory, processing speed, verbal ability, working memory, executive functioning, and
complex speed.
The NT-020 group displayed significantly better performance than the placebo group on
the Identical Pictures Test. There was also a trend towards significance for the NT-020 group
versus the placebo group on the Number Comparison task. Interestingly, both of these tests are
measures of processing speed. As the participants enrolled in the study did not have any
cognitive impairment, the absence of robust improvement across all domains may not be
surprising. Additionally, as processing speed is a domain that often significantly changes with
age, it may be expected that this domain would be amenable to change with a therapeutic
compound, such as NT-020 (Small et al. 2014, Lindenberger, Mayr and Kliegl 1993, Salthouse
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1996). The results of the study show that NT-020 was well-tolerated and facilitated
improvement in processing speed, suggesting that NT-020 is a promising potential intervention
for improving cognitive function in older adults (Small et al. 2014).
As previously discussed, aging is associated with decreased stem cell proliferation. This
is attributed, in part, to dysregulated signaling in stem cell niches. In particular, Wnt signaling
has been identified as neurogenic and declines with age. As NT-020 had previously been
shown to enhance stem cell proliferation in neurogenic niches, a study was carried out to
determine whether NT-020 could also enhance Wnt signaling in aged neurogenic niches. Young
(3-month-old) or old (20-month-old) male Fisher 344 rats were randomly assigned to be
maintained on standard NIH-31 chow or to be fed a chow supplemented with NT-020 (135
mg/kg body weight) for one month. Real-time reverse transcription polymerase chain reaction
(RT-PCR) was used to detect relative gene expression of WNT signaling targets. Several WNT
target genes changed with age. Genes associated with cell cycle including Cyclin D1 (-1.6 fold),
C-Myc (-2.1 fold), and AHR (-2.12) decreased. The growth factors glial cell line-derived
neurotrophic factor (GDNF, -2.7 fold) and insulin-like growth factor (IGF, -3.6 fold) decreased. In
old rats treated with NT-020, the growth factors GDNF (2.23 fold) and fibroblast growth factor 4
(FGF4, 1.89 fold) increased. GDNF and FGF4 are factors which promote the survival of neural
progenitor cells (Flowers et al. 2015, Flowers et al. 2016). Immunohistochemical (IHC) staining
was used to identify Wnt downstream targets Nrf2 or -catenin colocalized with newborn
neurons (doublecortin (DCX) NeuN, astrocytes (glial fibrillary acidic protein (GFAP), or microglia
(Iba-1) in the dentate gyrus (DG) of the hippocampus or the subventricular zone (SVZ). With
NT-020 treatment, Nrf2 colocalized with all cell types in both neurogenic niches, the DG and the
SVZ, compared to old controls. Similar to the results with Nrf2, compared to control, rats on the
NT-020 diet had a higher percentage of -catenin co-localization with all cell types. Both the
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Nrf2 and -catenin IHC results support increased overall Wnt activity in old rats as a
consequence of dietary supplementation with NT-020 (Flowers et al. 2015, Flowers et al. 2016).
As previously mentioned, chronic inflammation is considered a hallmark of aging. In
addition to the aforementioned measures, the expression of 84 cytokine and chemokine genes
in the hippocampus was measured using an RT-PCR cytokine array. The protein concentrations
of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-) and interleukin -1beta
(IL-1) were also measured using an enzyme-linked immunosorbent assay (ELISA). The results
of the cytokine array revealed that there was a significant increase in expression of the antiinflammatory cytokines IL24, IL4, and IL10 in the NT-020 old diet group versus controls.
Additionally, with NT-020 there was increased expression of CXC3CL1 (fraktalkine), LIF, and
GDNF, which suggests that there was pro-regenerative, alternative M2 activation of microglia.
Furthermore, there was decreased expression of the pro-inflammatory cytokines IL-1 and IL18
as well as decreased expression of the T cell chemokines CCL19 and CCL2 with NT-020 diet.
The results of the ELISA assay revealed that the protein levels of TNF- and IL-1 were
significantly increased in the hippocampus with age, however this was reversed with NT-020
diet. Taken together, the results of the study indicate that NT-020 is able to target signaling
pathways that are pro-neurogenic and modulate inflammation to improve outcomes for aging
(Flowers et al. 2015, Flowers et al. 2016).
As previously discussed, it has been suggested that one of the reasons for the decline in
function of stem cells niches with age is due to cell non-autonomous changes. That is, there is
evidence that there are negative factors in aged systemic milieu that impact stem cell niches.
Likewise, there is a lack of rejuvenating factors in aged blood that exist in young blood, and this
absence of rejuvenating factors may also contribute to age-related decline in stem cell
proliferation. To that end, a study was conducted to compare the effects of young blood, old
blood, and old blood from rats maintained on a diet supplemented with NT-020 on stem cell
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proliferation. Young (aged 3-6 months) and old (aged 20-22 months) rats were randomly
assigned to be fed a standard NIH-31 chow or NIH-31 chow supplemented with NT-020 with
Biovin (135 mg/kg/day body weight). Rats were sacrificed after being maintained on the diet for
28 days. Blood was collected by cardiac puncture and serum was isolated.
Rat hippocampal neural progenitors (NPCs) and rat mesenchymal stem cells (MSCs)
were cultured with serum from young control, old control, young-NT-020, or old-NT-020 serum.
5-bromo-2’deoxyuridine (BrdU) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assays were carried out to measure cell proliferation. With the MTT assay, NPC results
revealed a significant decrease in proliferation with age. However, interestingly, NT-020 not only
significantly increased proliferation of NPCs compared to old controls, but proliferation reached
levels greater than even young rats. With the BrdU assay, NPCs showed an age-related decline
in proliferation that was significantly reversed when NPCs were cultured with serum from old
rats maintained on an NT-020 diet. The results of the MTT assay with MSCs showed an agerelated decrease in proliferation, however the proliferation levels of MSCs cultured with serum
from young NT-020 rats and old NT-020 rats were comparable. The BrdU assay results for
MSCs showed that there was an age-related decrease in proliferation, however MSCs treated
with serum from old rats maintained on an NT-020 diet had significantly greater proliferation
than age-matched controls. There were no significant changes in serum metabolite levels with
NT-020 for CCL11 (eotaxin), CCL1 (MCP-1), BDNF, or CRP. Though there were no specific
mechanistic insights in the study, the data revealed a beneficial effect of NT-020 on stem cell
proliferation and the ability of NT-020 to reverse age-related dampening of proliferation (Bickford
et al. 2015).
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Figure 5. NT-020 rescues negative effects of old blood on NPCs and MSCs in vitro. The results of
MTT assays and BrdU assays show that exposure to old serum had a deleterious effect on cell
proliferation for both neural progenitor cells (NPCs) and mesenchymal stem cells (MSCs), but treatment
with serum from rats treated with NT-020 resulted in significantly improved cell proliferation (Bickford et al.
2015).

Thus far, the data obtained for NT-020 demonstrate that this polyphenol-rich
nutraceutical is able to increase stem cell proliferation, increase neurogenesis, decrease
oxidative stress, decrease inflammation, and improve cognitive function for aging and agerelated conditions such as stroke. While the data are indicative of therapeutic effects exerted by
NT-020, the mechanisms of action require further study. Previous studies showed that NT-020
is able to change the aged systemic milieu to one that supports stem cell proliferation, but
specific proteins and genes being affected within the aged milieu with NT-020 dietary
supplementation had not yet been fully elucidated.
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Summary of Approaches and Project Aim
With aging, there is a functional decline of all systemic cells, including stem cell niches,
both in the periphery and in the CNS. This decline in stem cell proliferation results in decreased
regenerative capacity. There are a number of mechanisms that underly this decreased cellular
regeneration with age, including cell autonomous changes as well as cell non-autonomous
changes. Parabiotic studies in which the circulatory systems of old mice were connected with
the circulatory systems of young mice revealed that young blood conferred benefits to old
animals, while old blood conferred deleterious effects to young animals in terms of
neurogenesis. Additionally, injection of young animals with old plasma resulted in poor
performance on cognitive behavioral paradigms. Thus, circulating factors in the blood can
impact the CNS. This is consistent with evidence that there is increased blood-brain barrier
(BBB) permeability with aging and, therefore, increased vulnerability of the CNS to molecules
and other environmental factors from the periphery.
A study conducted in our laboratory showed that when serum from old rats was used in
stem cell culture, the aged serum had a negative impact on stem cell proliferation. However,
when cells were cultured with serum from rats treated with NT-020, there was increased
proliferation. The beneficial properties of young blood and the deleterious properties of old blood
have not yet been fully elucidated, however there is such a preponderance of evidence that
oxidative stress and chronic inflammation contribute to aging that the term “inflammaging” has
been coined. This is particularly salient in the CNS, where inflammation is known to contribute
to a litany of age-related neurodegenerative diseases.
Our group has focused on age-related pathologies as well as non-pathological or
“healthy” aging (aging without the occurrence of disease). Our laboratory has studied various
nutraceutical compounds. NT-020, a proprietary blend of blueberry, green tea, carnosine, and
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vitamin D3, has been studied in particular for its ability to promote endogenous neurogenesis,
decrease inflammation, and contribute to recovery from age-related conditions such as stroke.
In a previous study, it was shown that neural progenitor cells (NPCs) and mesenchymal
stem cells (MSCs) cultured with serum from old rat serum had decreased proliferation
compared to those cultured with young rat serum. However, when NPCs or MSCs were cultured
with serum from old rats treated with NT-020, proliferation was shown to increase compared to
age-matched controls. However, there were no significant changes in the expression of the
factors CCL11, CCL2, BDNF, nor CRP with NT-020 treatment (Bickford et al. 2015).
Thus, while the data have shown a lot of potential for NT-020 as a therapeutic
compound, further study is needed to elucidate the specific factors underlying the increased
proliferation and other beneficial effects observed with NT-020 dietary supplementation.
Therefore, we designed a bottom-up, discovery-based, and mass-spectrometry-based
proteomics study to analyze the full serum proteome of aged rats treated with NT-020 versus
young control, young NT-020-treated, and age-matched control rats.
We predict that proteomic analysis will reveal that NT-020 treatment in aged rats is
associated with decreased inflammatory factors, increased anti-inflammatory factors, decreased
pro-aging factors, increased factors associated with stem cell proliferation such as growth
factors, and increases in anti-aging factors (such as factors that regulate oxidative stress).
Findings from this study could provide key mechanistic insights into, not only which
pathways are affected by NT-020 treatment, but may also serve to identify other potential
therapeutic targets for future studies of aging and age-related pathologies that affect the CNS or
the periphery. We anticipate that NT-020 will be associated with downregulation of inflammatory
and pro-aging factors such as factors promoting oxidative stress, or that inhibit stem cell
proliferation.
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Chapter 2 – Proteomics
Mass Spectrometry and Proteomics
Mass-spectrometry (MS)-based proteomics is a method that allows for the complete and
unbiased characterization of proteins on a large scale. This method also allows for the study of
expression changes, localization, interaction, domain structure, activity, and post-translational
modifications (PTMs). Unlike other methods, MS does not rely on antibodies to bind to proteins
in order to detect changes in expression and it achieves greater depth of analysis. This
technique also allows for the mass quantification of results and comparison between treatment
groups (Han, Aslanian and Yates 2008, Savaryn, Toby and Kelleher 2016).
MS creates ions from analyte (sample) molecules and then separates these ions based
on charge and mass. MS measures the mass-to-charge ratio (m/z) of ions in the gas phase.
Mass spectrometers have three basic parts: an instrument that converts the substance (the
analyte) into gas-phase ions, such as a liquid chromatographer, a mass analyzer that separates
the analytes based on the m/z ratio, and a detector that records the number of ions for each m/z
value (Han et al. 2008, Savaryn et al. 2016).
The mass analyzer is the most important component in MS and there are many different
types of mass analyzers, however one of the newest types being widely used is the Orbitrap,
which was invented in 1999 and just started being used for proteomics in 2005 (Hu et al. 2005).
The LTQ-Orbitrap (Thermo Fisher Scientific) is so named because ions are trapped within it and
orbit around an electrode in an oscillatory motion, producing a frequency that corresponds to
their respective m/z values. This induces a current in outer electrodes that is transformed into
mass spectra (Han et al. 2008, Pan et al. 2010).
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Fragmentation is necessary for analysis of proteins. Tandem mass spectrometry
(MS/MS) is a sequencing technique for proteins and peptides. With tandem mass spectrometry
(MS/MS), two mass analyzers from the same instrument generate fragments from an analyte in
order to give structural information about it. Collision-induced dissociation (CID) is the most
commonly used of these MS/MS techniques. CID involves internal heating of gas-phase peptide
ions by collisions, generating heat and breaking apart peptide backbones. Another
fragmentation technique that is newer is electron-capture dissociation (ECD) which involves
fragmenting peptide backbones by capturing thermal electrons (Han et al. 2008, Cappadona et
al. 2012, Pan et al. 2010).
Protein identification via M/S can be either top-down, which can be carried out by
analyzing whole proteins, or by bottom-up proteomics, which involves the analysis of peptides
fragmented either enzymatically or chemically. Bottom-up proteomics tends to be used with
more complex samples.
Top-down proteomics involves ionization of intact proteins without the need for prior
digestion, and high-resolution measurement of their mass. Afterward, they are fragmented
inside the mass spectrometer. This approach, however, is difficult for large proteins (>5kDa). In
this event, a “middle-down” approach can be undertaken in which there is partial digestion of
large peptides. Conversely, bottom-up proteomics entails digestion of proteins into peptides
before loading samples into the mass spectrometer, and the process involves the inference of
the presence of specific proteins by identification of constituent peptides. A previous method
used would involve pre-sorting and separating prior to protein digestion and then using peptide
mass fingerprinting (PMF) or peptide separation by mass using a liquid chromatographer
interfaced to a tandem mass spectrometer. Now, more commonly, the approach is to perform
protein digestion in advance and then allow proteins to be sorted and separated by multidimensional chromatography and then tandem mass spectrometry analysis. The data collected
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from tandem mass spectrometry are searched by an algorithm and compared to an existing
database of proteins that is based on genomes from multiple species to identify the peptides in
the sample.
Quantitative techniques allow for the comparison of control groups with treated groups,
and a number of quantitative techniques use isotope labeling of proteins or peptides, such as
isotope-coded affinity tags (ICAT). There are other techniques that have since been developed
and another involves labeling with amino acids (usually arginine and lysine), called stable
isotope labeling with amino acids in cell culture (SILAC). After the peptide backbone is cleaved
with trypsin, all resulting peptides have a label with an amino acid. However, a drawback is that
SILAC’s use is limited to cultured cells and it does not work well for other types of samples such
as tissue. There is also enzymatic labeling, which uses H218O as the peptide bond is hydrolyzed
and an additional 18O can be added. The reaction is less efficient than other methods and is
entirely dependent on enzymatic activity so it has not been a preferred method. Additionally, a
highly sensitive mass spectrometer is required to detect enzymatic labeling. Another method of
quantification is isobaric tags for relative absolute quantification (iTRAQ), which uses isotope
covalent tags to quantify peptides and, like previously mentioned methods, it can label peptides
after the digestion step. However, now the standard is to use label free quantification (LFQ).
Normalization of samples is important for obtaining accurate LFQ and normalization features
are included in software used to generate LFQ intensity values, such as MaxQuant, which was
created by the Max Planck Institute of Biochemistry (Han et al. 2008, Cappadona et al. 2012,
Krey et al. 2014).
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Figure 6. General workflow for mass spectrometry-based proteomics. Cells or tissue are lysed and
proteins are digested to peptides using a hydrolyzing protease, such as trypsin. Peptides are then
fractionated before being subjected to mass spectrometry. Raw data are compared to existing protein
sequence databases on different species (obtained from genome information) uploaded to software
programs. The result are identified proteins that can be used in analysis. The image is credited to the
Proteomics Core Facility, College of Arts and Sciences, University of South Florida, Tampa, FL, USA.

Tissue-Specific Proteomics Using Serum
Mass spectrometry proteomics using serum has many clinically relevant applications as
there are many biomarkers for disease that can be detected in serum. Furthermore, obtaining a
blood sample from which serum can be isolated is non-invasive and cost-effective so using this
biomaterial for MS-based proteomics could be highly useful for disease diagnosis and prognosis
(Del Pilar Chantada-Vazquez et al. 2020).
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However, working with serum presents some technical challenges and necessary steps
to address them. Both plasma and serum contain a large amount of high abundance proteins,
most notably albumin, the presence of which can interfere with detection of lower abundance
proteins. According to Han et al. (2008), not all digested peptides in a sample are observable
and it can be especially hard to detect proteins with unanticipated modifications. Additionally,
MS analysis by nature tends towards preferential sampling of peptides at high abundance over
those of low abundance. Moreover, according to the Broad Institute, LFQ is also tied to
abundance and results can vary depending upon instrument settings and the number of
peptides in a given protein. LFQ is considered reliable only for highly abundant proteins and the
results can produce a lot of missing data, particularly for lower abundance proteins (Carr).
Therefore, this necessitates the addition of a depletion step in which highly abundant proteins
are depleted in the samples before further processing (Lee et al. 2019).
Sample Preparation and Albumin Depletion
Over the course of the project, we tested the efficacy of a number of different high
abundance protein depletion methods in order to remove high abundance proteins, such as
albumin and IgG, from sera. The first depletion method we used was a homemade
trichloroacetic acid (TCA) precipitation of proteins, which is a method commonly used to remove
contaminants from samples. We tested 4% SDS and 8M urea to lyse and solubilize the sample
and ended up choosing SDS. Ultimately, the concern with using this method for depletion was
the non-specific precipitation, meaning proteins in the sample other than the high abundance
proteins could be precipitated as well (Liu et al. 2014) (Figure 7).
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Figure 7. TCA Precipitation for Albumin Depletion. Tricholoroacetic acid (TCA) precipitation was used
as a method to deplete the high abundance protein, albumin, in serum. A Coomassie Brilliant Blue stain
was used on an SDS-PAGE gel to visualize the efficacy of the TCA method. 15 µg of protein was loaded
on 4-20% SDS-PAGE gels. N/A = no protein precipitation. 1% = 1% TCA-IPA protein precipitation. 20% =
20% TCA-H2O protein precipitation. 4% SDS (w/v): 100mM DTT, Tris-HCl pH 7.6; 8M urea: Tris-HCl pH
76. Albumin is shown at 75 kD. Both 4% SDS and 8M urea were tested as potential solvents.

Given our concerns about non-specific precipitation using the TCA method, we next
used a commercially available albumin depletion kit from Pierce (P/N 85160), however the
results of Coomassie Brilliant Blue staining on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels showed that there was still a large amount of albumin in the
serum samples (Figure 8).
Next, we compared two commercially available depletion kits: the High Select
HSA/Immunoglobulin Depletion Kit (Thermo Fisher Scientific, P/N A36365) and the High Select
Top 14 Abundant Protein Depletion Kit (Thermo Fisher Scientific, P/N A36369). We compared
the two kits again on and SD-PAGE gel using Coomassie Brilliant Blue staining (Figure 9).
There was only a slight difference between the two kits on the gel, with the High Select
HAS/Immunoglobulin Depletion Kit only ever-so slightly showing better depletion, so we opted
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to use this kit in future experiments. To deplete samples, serum was pipetted over resin spin
columns from the kit, washed three times, and combined. Protein assays were then carried out
and samples were diluted 1:5-1:20 in H2O. For the assay, bovine serum albumin (BSA) was
used as the standard and sample was loaded into the wells of a 96 well plate. Absorbance was
read at 660 nm on a plate reader.
Serum protein was digested by filter-aided sample preparation (FASP). Samples were
loaded onto FASP filters with 200µL of urea and centrifuged at 14,000 x g for 15 minutes and
another 200µL of urea was added before samples were centrifuged again for 15 minutes.
Proteins were incubated in the dark with 100 mM iodoacetamide (IAA) for 20 minutes and
centrifuged once more for 15 minutes. Samples then received urea three times, followed by
three additions of ammonium bicarbonate (ABC), and they were centrifuged again for 15
minutes. This step was repeated two more times before adding NaCl and centrifuging once
more for 15 minutes. At the last step, 5 µL of formic acid was added.

Figure 8. Depletion of albumin in serum using a commercial kit. A commercial kit from Pierce (P/N
85160) was used for albumin depletion. The first lane is undepleted serum. The first band shows much
less albumin as it was run through the depletion column. Columns 2-4 are the same sample being eluted
again in order to see how many fractions were optimal. We retained fractions 1-4.
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After digestion with trypsin, samples were desalted to remove any contaminants using
C18 SPE columns that were placed under a vacuum manifold. One ml of acetonitrile (ACN) was
pipetted over the columns and then 2mls of H2O/0.1% formic acid (FA Sol) was added. The
sample was loaded into the columns once they were equilibrated with ACN and FA Sol. Then
the columns were washed and desalted with three additions of FA Sol. The sample peptides
were collected in microcentrifuge tubes. Peptides then received two additions of 500 µL buffer
(90:10 ACN:H2O + 0.1% formic acid).

Figure 9. Comparison of commercial HSA and Immunoglobulin versus Top 14 Abundant Protein
depletion kits. Two commercially available depletion kits: the High Select HSA/Immunoglobulin
Depletion Kit (Thermo Fisher Scientific, P/N A36365) and the High Select Top 14 Abundant Protein
Depletion Kit (Thermo Fisher Scientific, P/N A36369) were purchased and compared by Coomassie Blue
Staining on SDS-PAGE gels. The HSA/Immunoglobulin kit showed slightly better depletion and was
selected to be used for depletion in subsequent experiments. 5 µg of protein were loaded into each lane.
SDS gel is a 4-20% gel (Bio-Rad).
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LC-MS/MS
Peptides were separated using high performance liquid chromatography using a 50cm
reversed-phase C18 UHPLC analytical column with an EASY-nLC1200 HPLC (Thermo Fisher
Scientific). Peptides were subsequently analyzed on a hybrid-quadrupole-Orbitrap mass
spectrometer (Q Exactive HF-X, Thermo Fisher Scientific) with a 120 minute gradient at the
USF Morsani College of Medicine Proteomics Core Facility. Full MS survey scans were
acquired at 60,000 resolution. Samples were analyzed in duplicate, the first time using the
traditional DDA method, which selected the top 30 most abundant peptides (scan range 4001600 m/z). The segmented DDA method selected the most abundant peptides across 3 ranges
(375-600 m/z (top 20), 600-800 m/z (top 10), and 800-1200 m/z (top 10)). Raw data files were
searched and combined.
Analysis
Raw data files were run through a search using MaxQuant software (Max Planck
Institute of Biochemistry) against the Uniprot proteome database for the species Rattus
norvegicus. Modifications included in parameters were cysteine by carbamidomethylation,
variable modifications to methionine oxidation, and protein N-terminal acetylation. A 1% false
discovery rate was used for protein and peptide identification. The LFQ feature was used for
normalization.
Next, Perseus software (Max Planck Institute of Biochemistry) was used for filtering and
imputation of data. LFQ intensities were input as expression values and then log-transformed.
Data was filtered to only include proteins with LFQ intensities in at least 60% of samples within
at least one treatment group. Any samples that showed a skewed, non-normal distribution
following imputation were excluded from further analysis.
After Persues, data was exported to Microsoft Excel and ratios were generated between
comparisons using the LFQ intensity values for each comparison. Additionally, Welch’s t-tests
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were carried out in order to obtain p values for significance and z scores for directionality.
Proteins with a p < 0.05 were considered statistically significant.

39

Chapter 3 – Effects of Nutraceutical Intervention on Serum Proteins in Aged Rats
Abstract
Aging is associated with many pathophysiological changes that could lead to the onset
of degenerative disease. Some of the physiological changes that occur with aging include
increased inflammation and decreased stem cell proliferation, leading to decreased capacity for
tissue regeneration and loss of function. In previous studies, we and others have found
nutraceutical intervention to ameliorate some of the deleterious effects associated with aging. In
particular, we have previously shown that NT-020, a supplement composed of a proprietary
blend of blueberries, green tea, vitamin D3, and carnosine, is able to rescue age-related
cognitive deficits, impaired neurogenesis, and inflammation in rats. We have also previously
demonstrated that stem cells cultured with old serum showed decreased proliferation, however
when stem cells were cultured in serum from old rats given a diet supplemented with NT-020,
proliferation did not differ from that of cells cultured with serum from young rats. While it is clear
that NT-020 is exerting a therapeutic, anti-aging effect, the mechanisms of action were yet to be
fully elucidated.
To that end, in the present study, we conducted a bioinformatics experiment to examine
the rat proteome of serum from young and old control rats, and young and old rats given a diet
supplemented with NT-020.
Serum from old rats showed an increase in some inflammatory and pro-aging factors while
serum from old rats given a diet supplemented with NT-020 showed an increase in some antiaging factors, most notably proteins associated with the complement system and autophagy.
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Introduction
As the population ages, there is increased susceptibility to the onset of disease and agerelated degenerative conditions, making aging a central area of interest in medical sciences
research (Wagster et al. 2012, Flowers et al. 2016). Aging is a complex and multifactorial
physiological process associated with decreased stem cell proliferation in stem cell niches
throughout the body, leading to reduced tissue rejuvenation and loss of organ function (Murshid,
Eguchi and Calderwood 2013, Bickford et al. 2015). The decline in stem cell regeneration is
global, occurring both in the periphery (Ning et al. 2019, Jung et al. 2019, Chambers et al. 2007)
and in the central nervous system (CNS) (Villeda et al. 2011, Lazarov et al. 2010, Kozareva,
Cryan and Nolan 2019, Ayaz et al. 2019, Kase et al. 2019, Stankiewicz et al. 2019, Bickford et
al. 2015, Flowers et al. 2015, Acosta et al. 2010).

While the exact biological mechanisms

underlying dampened stem cell proliferation with age remain unclear, two areas of investigation
are being explored: cell-autonomous changes and cell non-autonomous changes. Cell
autonomous changes involve the senescence of genes such as p53, p16INK4A, critical proteins
involved in the Wnt/β-catenin pathways, and others (Sharpless and DePinho 2007, Bickford et
al. 2015). Cell non-autonomous effects on stem cell niches refers to various factors, such as
pro-inflammatory cytokines, chemokines, and other proteins that may influence the
microenvironment (Bickford et al. 2015). Very salient early examples of circulating factors
impacting stem cell proliferation come from heterochronic parabiosis studies. Heterochronic
parabiosis entails the surgical union of the circulatory system of a young mouse with an old
mouse. It was observed that exposure to blood from old mice had a deleterious impact on stem
cell proliferation in young mice. Conversely, exposure to blood from young mice had a positive
effect on stem cell proliferation in old mice, thus demonstrating how the systemic milieu can
impact stem cell proliferation (Conboy et al. 2005, Villeda et al. 2011). Additionally, Villeda et al.
(2011) injected plasma from either old or young mice into young mice four times over ten days
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and subjected the animals to contextual fear conditioning and the radial arm water maze. Young
animals injected with plasma from old mice displayed significantly less freezing behavior in the
contextual fear conditioning paradigm and made a greater number of errors in the radial arm
water maze paradigm, suggesting impaired learning and memory following intravenous injection
with old plasma. These studies further highlight how the aged systemic milieu can impact the
CNS by exerting a dampening effect on hippocampal neurogenesis. In addition to these in vivo
studies, the negative impact of the aged systemic milieu on stem cell proliferation has been
reproduced in vitro with various types of stem cells derived from mice or rats being cultured with
serum from old animals (Bickford et al. 2015, Villeda et al. 2014).
Many different factors from old blood have been identified as proteins of interest in terms
of their potential to impact stem cell proliferation. In their initial study, Villeda et al. (2011)
proposed that increased CCL11 (eotaxin) in old blood may be a key regulator impinging upon
the cellular microenvironment. Another negative regulator that was proposed is beta2microglobulin, a pro-aging factor (Smith et al. 2015). Additionally, at the same time, loss of
protective factors has also been implicated in aging. Several studies have found that there is
decreased expression of growth differentiation factor 11 (GDF-11) with age (Katsimpardi et al.
2014, Sinha, Patro and Patro 2019). Decreased expression of nuclear factor erythroid 2-related
factor 2 (Nrf2) has also been observed with aging. Nrf2 is a transcription factor that regulates
the expression of antioxidant proteins and, if it is downregulated with age, this is consistent with
the known age-related increase in oxidative stress (Huang et al. 2019, Fulop et al. 2018,
Flowers et al. 2016).
Polyphenols have been shown to rescue age-related dysfunctions within the CNS
including chronic inflammation, impaired synaptic plasticity, and decreased neurogenesis (Ayaz
et al. 2019, Flowers et al. 2015, Dias et al. 2012, Rahman, Biswas and Kirkham 2006, Vauzour
2012). Furthermore, polyphenolic compounds have also been shown to have beneficial effects
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in mouse models of Alzheimer’s disease (AD) (Rezai-Zadeh et al. 2005, Rezai-Zadeh et al.
2009, Rezai-Zadeh et al. 2008, Singh et al. 2008). Our group has demonstrated that a
proprietary blend of polyphenolic compounds including epigallocatechin gallate (EGCG) from
green tea, blueberry extract, vitamin D3, and carnosine, called NT-020, attenuates
inflammation, enhances hippocampal neurogenesis, and improves cognitive function in old rats
(Flowers et al. 2015, Acosta et al. 2010). In a rat model of stroke, rats given an NT-020supplemented diet showed increased neurogenesis compared to vehicle-treated rats (Yasuhara
et al. 2008). In in vitro studies, NT-020 and the blue-green algae spirulina were shown to
synergistically increase proliferation of human adult stem cells (Bachstetter et al. 2010, Shytle et
al. 2010).
Furthermore, when rat mesenchymal stem cells (MSCs) or neural progenitor cells
(NPCs) were cultured in serum derived from old rats, decreased proliferation was observed.
However, if serum from old rats given a diet of chow supplemented with NT-020 was added to
the culture, these effects were reversed (Bickford et al. 2015). Older adults given NT-020
supplementation in pill form in a double-blind placebo-controlled clinical trial demonstrated
improved cognitive function on a battery of cognitive tests compared to participants in the
placebo arm of the study, demonstrating the translational nature of nutraceutical research and
effectiveness of NT-020 supplementation (Small et al. 2014). While some of the mechanisms of
action for the therapeutic effects of NT-020 have been defined, such as the downregulation of
pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines, a complete profile
of circulating factors has not yet been generated.
The goal of the current study was to generate a complete list of factors from the
systemic milieu that could be altered as a consequence of aging and rescued by NT-020
supplementation. We used bottom-up, discovery-based mass spectrometry proteomics and a
bioinformatics program called Ingenuity Pathway Analysis (IPA, Qiagen) to create a profile for
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the entire proteome for serum derived from old rats given NT-020 or a normal diet and young
rats given NT-020 or a normal diet. Our data suggest that there are age-related molecular
changes that can be rescued by NT-020 supplementation.
Methods
Animals
To limit variability due to difference in sex that occur with age, male Fisher rats 3-6
months (young) or 20-22 months (old) of age were obtained from the National Institute on Aging
(NIA) contract colonies and were housed at the University of South Florida (USF) AAALACaccredited animal facility at the Morsani College of Medicine. All experimental procedures were
approved by the institutional animal care and use committee (IACUC). The rats were fed either
a standard NIH-31 chow or a NIH-31 chow supplemented with NT-020 (Natura Therapeutics,
Inc.) ad libitum at 135 mg/kg/day for 28 days. Rats were divided into three experimental groups
(n=10 per group): old rats given standard NIH-31 chow (old control), old rats given NT-020
supplementation (old diet), young rats given standard NIH-31 chow (young). Body weight and
food consumption were monitored throughout the week and measured three times per week. No
differences were observed in either body weight or food consumption for any of the groups.
Rats were sacrificed by CO2 euthanasia after 28 days. Blood was collected by cardiac puncture
into serum collection tubes. Tubes were spun at 3000 rpm for 10 minutes and serum was then
aliquoted and frozen at -80°C until use. Brains were also collected and stored in tubes at -80C
for use in a future study.
Sample Preparation
In order to prepare the serum samples for analysis on the mass spectrometer, the most
abundant proteins had to be depleted from the samples. A volume of 10 µl of sample was
added to each spin column containing resin filters from a High Select Top 14 Abundant Protein

44

Depletion Kit (Thermo Fisher Scientific, Inc., P/N A36369). Sample was pipetted over the resin
spin columns from the kit, washed three times with wash buffer, and combined. Protein
quantitation assays were carried out and samples were diluted 1:5-1:20 in H2O. Bovine serum
albumin (BSA) was used as a standard and 10 L of sample were added to each well of a 96
well plate. Pierce 660 Assay Reagent (150 L) supplemented with ionic detergent compatibility
reagent (IDCR) was added to the plate. Absorbance was read at 660 nm using a plate reader.
Serum protein samples were buffer exchanged and digested by filter aided sample
preparation (FASP). Samples were loaded onto FASP filters with 200µl of urea buffer and
centrifuged at 14,000 x g for 15 minutes. An additional 200µl of urea buffer was added to the
sample reservoir and centrifuged again for 15 minutes. Proteins were then alkylated with 100 L
of 100 mM iodoacetamide (IAA) in the dark for 20 minutes, followed by centrifuging at 14,0000 x
g for 15 minutes. After alkylation, samples were buffer exchanged with three additions of urea,
followed by three additions of ammonium bicarbonate (ABC), and then centrifuged at 14,000 x g
for 15 minutes after each addition. Finally, proteins were digested by adding Trypsin/Lys-C in a
1:50 ratio of trypsin:protein (w:w) and incubated overnight at 37C. After incubation, peptides
were collected by adding 40 L of ABC buffer and centrifuging at 14,000 x g for 10 minutes.
This was repeated for a total of two additions of ABC, before adding 50 L of NaCl and again
centrifuging for 15 minutes. Lastly, 5 L of formic acid was added to acidify the samples before
desalting.
Following tryptic digest, peptide samples were desalted using C18 SPE columns placed
on a vacuum manifold. The C18 SPE columns were activated with one ml of acetonitrile (ACN),
and then equilibrated with two volumes of H2O/0.1% formic acid (FA Sol). Once equilibrated,
sample was loaded onto the C18 SPE columns, and then washed/desalted with three volumes
of FA Sol. The flow-through collection tubes were then replaced with microcentrifuge tubes for
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peptide collection. Peptides were eluted with two additions of 500 L of elution buffer (90:10
ACN:H2O + 0.1% formic acid). Samples were dried completely in a vacuum concentrator and
then resuspended in 1%ACN/99%H2O/0.1% formic acid.
LC-MS/MS
Peptides were separated on a 50cm reversed-phase C18 UHPLC analytical column
using an EASY-nLC 1200 HPLC (Thermo Fisher Scientific) and analyzed on a hybridquadrupole-Orbitrap mass spectrometer (Q Exactive HF-X, Thermo Fisher Scientific) with a 120
minute gradient. Full MS survey scans were acquired at 60,000 resolution. Each sample was
analyzed twice, once using a ‘traditional data-dependent acquisition (DDA)’ method, and once
using a ‘segmented DDA’ method. The ‘traditional DDA’ method selected the top 30 most
abundant peptides across the full mass scan range of 400-1600 m/z. The ‘segmented DDA’
method selected the most abundant peptides across 3 different mass scan ranges: 375-600 m/z
(top 20), 600-800 m/z (top 10), and 800-1200 m/z (top 10). Raw data files for each method
were searched as technical replicates and combined.
Analysis
Raw data files were searched using MaxQuant software (Max Planck Institute of
Biochemistry) against the current Rattus norvegicus proteome database from Uniprot.
Parameters included the fixed modification of cysteine by carbamidomethylation, as well as the
variable modifications methionine oxidation and protein N-terminal acetylation. A 1% false
discovery rate was used for both peptide and protein identification. The MaxQaunt LFQ feature
was used for label free normalization.
Perseus software (Max Planck Institute of Biochemistry) was used for the filtering and
imputation of proteomics data as described previously (Tyanova et al. 2016). Briefly, label free
quantification intensities (LFQ) were used as expression values and log transformed. The data
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was filtered to include proteins that were identified with LFQ intensities (valid values) in at least
60% of samples within at least one treatment group, and missing values were then imputed
using the default settings. Samples that showed a skewed, non-normal distribution following
imputation were excluded from further analysis. The following number of samples remained per
treatment group: young control (n=6), old control (n=7), and old diet (n=5).
Following imputation in Perseus, the data was exported and Excel was used to generate
ratios between comparisons, as well as calculate Welch’s t-test p-values, and z-scores, as
previously described (Flowers et al., 2017). Briefly, ratios were generated using the LFQ
intensity values for each comparisons of interest. Proteins with a Welch’s t-test p < 0.05,
determined using log2-transformed LFQ intensities, were considered statistically significant.
Results
We detected a total of 210 proteins in all samples. There were 40 “unmapped” proteins
that were not identified by Persius. A full list of identified proteins is included (Table 3). We then
examined the proteins of interest that were found to be significantly different in the pairwise
comparisons of the groups.
Change of Protein Expression as a Function of Age
Complement C1r was significantly decreased in serum from old rats compared to young
(p < 0.05, Table 1). In addition, complement proteins complement 5 (C5), complement 6 (C6),
and complement 8 gamma chain (C8) decreased with age (p <0.05, Table 1). The protein
ceruloplasmin, which is a copper transporter and anxtioxidant protein, was also found to be
significantly decreased (p < 0.05, Table 1), which is consistent with the literature showing an
age-dependent decrease in this protein and, interestingly, a decrease in this enzyme is
associated with neurodegeneration (Musci et al. 1993, Connor et al. 1993, Jeong and David
2006). There was also a significant decrease in expression of insulin like growth factor binding
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protein acid labile subunit (IGFALS) (p < 0.05, Table 1). It is interesting to note that with
osteoporosis, there is a decrease in IGF-1 and its binding proteins in the serum (Fritton et al.
2010). Additionally, there was significantly decreased expression of maltase-glucoamylase
(Mgam), which is consistent with age-dependent impaired digestion of carbohydrates
(Fernandez-Alarcon et al. 2017).
In order to query how these changes affect functional pathways, the data were uploaded
into Ingenuity Pathway Analysis (IPA, Qiagen) and the p value cutoff extended to P<0.1 in order
to increase the number of proteins for functional associations. The changes can be viewed
graphically in Figure 10A. This figure illustrates the changes with the highest Z score all of
which were related to immune function. Five cellular functions were top hits and they are
shown at the center of the figure. The proteins driving these findings are illustrated on the
outside of the circle. The fold change is listed below each protein, green indicates a decrease
and red an increase. As illustrated all of the functional predictions are for an upregulation of
immune responses including activation of macrophages and phagocytes.
NT-020 Counteracts Upregulated Immune Response in Aged Rat Serum
We next compared changes in the old animals following treatment with NT-020. All of
the proteins that were entered into IPA for Fig 10A were also uploaded for the ratios in the old
diet treated rat serum versus old control diet, to explore how diet altered the expression ratio.
Only 7 of the 31 proteins that were significantly changed with age, were significant different with
diet treatment at p<0.05 and these are discussed below. For comparison with the change with
age in immune function pathways we illustrate the same function pathways in Figure 10B with
the same set of proteins used to generate Figure 10A. As is observed in Fig. 10B, all of the
immune functional pathways that were upregulated with age are down regulated in the aged
rats on the NT-020 diet. For example, cystatin 3 (CST3) changed from 3-fold increase with age
to a -1.6 decrease with diet treatment. CD5L was increased 2.2-fold with age and decreased
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1.9-fold with NT-020 diet treatment. Overall this led to a predicted functional down regulation of
the immune response with NT-020 diet in the old rats.
Autophagy Pathway Protein Cathepsin A is Upregulated with NT-020
The autophageal protein cathepsin A (CTSA) was shown to be significantly increased in
serum from old rats given a diet supplemented with NT-020 (p<0.05, Table 2). Autophagy is a
turnover process for protein aggregates and damaged organelles. This process is considered
protective and anti-aging, and inhibition or loss of autophagy occurs with age. Compromised
autophagy has also been linked to neurodegenerative diseases and metabolic defects that are
associated with aging (Martinez-Lopez, Athonvarangkul and Singh 2015, Boland et al. 2018).
Autophagy is driven by a number of different proteins, among which are cathepsins. CTSA is a
lysosomal protein that specifically triggers chaperone-mediated autophagy (CMA) through its
serine carboxypeptidase activity, which triggers the degradation of lysome-associated protein
type 2a (Cuervo et al. 2003).
Macrophage Stimulating 1 Decreases with NT-020
Macrophage stimulating 1/macrophage stimulating protein/hepatocyte growth factor-like
protein (MST1/MSP/HGFL) expression was found to be significantly decreased with NT-020
treatment in old rats compared to old control (p<0.05, Table 2). MST1 is a protein in serum that
is predominantly secreted by liver hepatocytes. Some studies have pointed to MSP as a
negative regulator of inflammation and a key protein in maintaining metabolic homeostatis (Li et
al. 2015). However, there is evidence that MST1/MSP activation increases pro-inflammatory
cytokine production in the liver and lungs (Li et al. 2016, Wang et al. 2015). In the CNS, it has
been found that there are receptors for MSP on microglia (Ron) and that MSP activation results
in increased mRNA expression of pro-inflammatory cytokines (Suzuki et al. 2008).
Complement System Proteins were Altered by NT-020

49

The complement system is part of the innate immune response and is considered
protective for the retina with aging (Mukai et al. 2018). However, it has also been proposed that
complement C1q promotes aging through interaction with the canonical Wnt signaling pathway
(Naito et al. 2012). Additionally, early components of the complement system have been shown
to increase with age in a mouse model of AD (Reichwald et al. 2009). There are many proteins
involved in the complement system, but two were found to be altered by NT-020: serpin G1,
which increased with NT-020 treatment in old rats, and complement factor H (CFH), which
decreased with NT-020 treatment in old rats (p < 0.05, Table 2). Both of these changes are
consistent with an improved complement function. Serpin G1, also called C1 inhibitor or C1
esterase inhibitor, is largely considered to be a protective factor and its inhibition has been
associated with impaired blood-brain barrier (BBB) integrity and neuroinflammation in the brain
(Farfara et al. 2019). Furthermore, deficient C1 inhibitor expression is linked to hereditary
angioedema (Mete Gokmen et al. 2019), further suggesting a protective function.
Complement factor H (CFH) is an important regulator of the alternative pathway of the
complement system. Interestingly, increased plasma CFH has been found to be correlated with
geriatric depression (Shin et al. 2019). Additionally, genetic variants of CFH are strongly
associated with age-related macular degeneration (AMD) and CFH has been shown to inhibit
the anti-inflammatory activity of CD47 (Calippe et al. 2017). It has also been found that
increased concentrations of complement 3 and CFH in the cerebrospinal fluid (CSF) of
Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy patients correlated with
disease severity (Wang et al. 2011).
Discussion
Aging involves multiple complex physiological changes that lead to increased
inflammation, loss of homeostasis and resilience, and impaired regenerative capacity. The role
of inflammation in aging has been widely researched and the term “inflammaging” has been
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coined to summarize how the inflammatory milieu leads to degeneration (Minciullo et al. 2016).
While there is an increase in pro-inflammatory and other pro-aging factors and a decrease in
anti-inflammatory factors with age, a complete profile of the aging milieu has yet to be identified,
although parabiosis studies have contributed significantly to this effort (Villeda et al. 2011,
Villeda et al. 2014, Smith et al. 2015). The current study sought to identify factors that were
significantly changed with age and could be ameliorated by treatment with the polyphenol-rich
dietary supplement NT-020, as NT-020 has been demonstrated to have beneficial effects in
vitro and in vivo (Yasuhara et al. 2008, Shytle et al. 2010, Bachstetter et al. 2010, Kaneko et al.
2012, Small et al. 2014, Bickford et al. 2015, Flowers et al. 2016).
Eleven proteins were found to change significantly when comparing old control rats to
young controls. Of these, ceruloplasmin, insulin like growth factor binding protein acid labile
subunit (IGFALS), and maltase-glucoamylase (Mgam) were the most noteworthy. The protein
ceruloplasmin, which is an enzyme that functions as a copper transporter and anxtioxidant
protein, decreased significantly with age, which would be expected and, interestingly, a
decrease in this enzyme is associated with neurodegenerative diseases (Musci et al. 1993,
Connor et al. 1993, Jeong and David 2006). There was also a significant decrease in
expression of IGFALS and decreased expression of IGF and its binding proteins in serum has
been liked with increased adipogenic potential of mesenchymal stem cells over osteogenic
potential in osteoporosis (Fritton et al. 2010). Additionally, there was a significant decrease in
expression of Mgam, which is consistent with age-dependent impaired digestion of
carbohydrates and susceptibility to type 2 diabetes (Fernandez-Alarcon et al. 2017, Ren et al.
2011). Collectively, these data suggest that the significantly changed proteins were impacted by
age as expected. However, complement proteins were observed to decrease with age, whereas
in the literature they have been shown to increase with age (Gaya da Costa et al. 2018). While
the reason for this disparity is unclear, the previously discussed proteins changed as expected
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with age. Further study is needed to determine whether this trend was global or tissue-specific,
and a future study is ongoing, as later discussed.
Interestingly, when the data were entered into IPA and the p value cutoff extended to
p<0.1 in order to increase the number of proteins identified and query functional pathways, the
results showed that the proteins identified drove upregulation of immune responses such as
activation of macrophages and phagocytes with age and that all of these functional pathways
became downregulated in the old NT-020 diet group. These data suggest that NT-020 was able
to dampen the immune response in old rats.
Autophagy is the pathway by which protein aggregates and damaged organelles are
degraded. With aging, there is decreased autophagy, leading to increased aggregation of
proteins, which results in a toxic microenvironment and cellular dysfunction. There are three
types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy
(CMA). Altogether, autophagy is critical for protein and cellular homeostasis. The exact
mechanisms underlying decreased autophagy with aging are unclear, however it has been
noted that autophagy is decreased in aging stem cell niches in particular, contributing to
decreased regenerative capacity (Revuelta and Matheu 2017). There are many proteins that are
involved in the autophagy pathway and among them are cathepsins. In the current study,
cathepsin A (CTSA), which triggers CMA (Cuervo et al. 2003), was found to be increased with
NT-020 treatment in old rats compared to age-matched controls.
Macrophage stimulating 1/macrophage stimulating protein/hepatocyte growth factor-like
protein (MST1/MSP/HGFL) is a serum protein that is primarily secreted by hepatocytes in the
liver. This protein has been previously speculated to have protective effects and to be a
necessary regulator of metabolic activity (Li et al. 2015). However, recent studies have shown
that MST1/MSP/HGFL increases pro-inflammatory cytokine production in the liver and lungs (Li
et al. 2016, Wang et al. 2015). Non-alcoholic steatohepatitis (NASH) is a liver disease
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characterized by inflammation and accumulation of lipids in the liver. NASH model mice treated
with MSP were found to have significantly higher levels of tumor necrosis factor- (TNF-),
chemokine (C-C motif) ligand 2 (Ccl2), intracellular adhesion molecule 1 (Icam1), interleukin
1beta (IL-1), interferon gamma (IFN), B cell lymphoma 2 (Bcl2), macrophage markers F4/80,
and cluster of differentiation 68 (CD68) (Li et al. 2016). Wang et al. exposed rats to combustion
smoke in order to create a model of smoke-induced airway inflammation and found that
MST1/MSP/HGFL and its receptor, RON, stimulated production of pro-inflammatory cytokines
TNF-, IL-8, IL-1, and IL-10 (Wang et al. 2015). In the current study, MST1/MSP/HGFL
decreased when old rats were given a diet supplemented with NT-020 compared to agematched controls. Given the role of this protein in inflammation, this finding shows a mechanism
by which NT-020 may resolve aspects of age-related inflammation.
The complement system constitutes part of the innate immune response. Some studies
have shown that the complement system is protective against age-related retinal degeneration
(Mukai et al. 2018). However, another study has shown that complement protein C1q promotes
aging through activation of the canonical Wnt pathway (Naito et al. 2012). Furthermore,
Reichwald et al. showed that expression of early complement proteins increased in an agedependent manner and may contribute to AD pathogenesis in amyloid precursor proteinoverexpressing mice (Reichwald et al. 2009). Together these findings suggest that proteins from
the complement system should be analyzed individually as to whether or not they are
contributing to the aging phenotype. In the current study, we found changes in the complement
proteins serpin G1/C1 inhibitor/C1 esterase inhibitor and CFH. Specifically, we observed a
significant increase in the protective protein serpin G1 in old rats treated with NT-020.
Knockdown of circulating plasma C1 inhibitor in the brain has led to decreased BBB-mediated
extravasation and infiltration of plasma proteins and immune cells, activation of glial cells,
impaired cognition, and depressive behavior in mice (Farfara et al. 2019). Interestingly, we also
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observed a significant decrease in CFH in serum from old rats given a diet supplemented with
NT-020 compared to old rats given a standard diet. CFH is critical for activation of the alternate
complement system. In a recent study, increased levels of CFH in plasma was positively
correlated with depression in geriatric patients (Shin et al. 2019). Genetic variants of the CFH
gene, which encodes the CFH protein, are associated with age-related macular degeneration
(AMD). Calippe et al. also demonstrated that one AMD-associated CFH variant was able to
suppress the anti-inflammatory activity of CD47 (Calippe et al. 2017). Another study examined
cerebrospinal fluid (CSF) samples taken from patients with Parkinson’s disease, Alzheimer’s
disease, and multiple-system atrophy and found that complement 3 (C3) and CFH were both
increased, though to varying ratios depending upon the disease. Interestingly, both C3 and CFH
concentrations correlated with disease severity in AD (Wang et al. 2011).
The results of the current study suggest that NT-020 is targeting multiple mechanisms
associated with aging including autophagy and the complement system. However, the study
was not without limitations. In spite of using a commercial kit to deplete the highly abundant
albumin in our serum samples as well as the other most abundant proteins in serum, our
detection of a low number of proteins suggests that albumin and other high abundance proteins
remained, preventing detection of other proteins in the samples. One reason for this could be
that the depletion kit used was optimized for human tissue and not rat, however there are no
commercially available depletion kits with specificity for rat protein. Prior to opting to use this kit,
we attempted to use an acid precipitation method, but found it to be non-specific, leaving the
possibility that we could be losing proteins we didn’t wish to deplete from the samples as well.
Thus, we opted to use the human-optimized kit from Thermo Fisher Scientific, Inc.
It is additionally worth noting that the proteins with a significant fold change that were
detected in the old rats were not the same proteins found to have a significant fold change in the
old rats given a diet supplemented with NT-020. Therefore, there was no detection of differential
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expression of individual proteins between these two groups. However, there were common
pathways between them, most notably the complement system.
In addition, upon collection of serum, a protease inhibitor was not added prior to storing
the samples at -80C before use. This could also have led to protein degradation prior to
analysis. Protease inhibitor was added after samples were thawed and processed for mass
spectrometry, however this step may have been undertaken later than would have been
optimal.
In spite of some of the methodological challenges involved with working with serum,
these findings contribute to the existing body of knowledge on how nutraceuticals impact the
aging milieu and exert therapeutic effects. In particular, we have found that NT-020 reverses the
negative effects of age on stem cell proliferation, enhances neurogenesis, and leads to
improved performance on cognitive behavioral paradigms (Acosta et al. 2010, Bachstetter et al.
2010, Bickford et al. 2015, Flowers et al. 2015, Flowers et al. 2016, Kaneko et al. 2012, Shytle
et al. 2010, Small et al. 2014, Yasuhara et al. 2008). These data provide insight into the
mechanisms of action underpinning NT-020-mediated therapeutic effects. Additionally, future
studies are needed to compare the proteome from serum to that of CNS tissue or cells in order
to determine whether circulating factors in the periphery have an impact on the brain. A study is
currently in progress to compare the results of the serum analysis to microglia from the same
animals.
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Table 1. Expression of proteins in old rat serum compared to young
Symbol
C1R
C5
C6
C8G
CP
CPN2
GC
IGFALS
Kng1/Kng2
Mgam

Protein name
Complement C1r
Complement C5
Complement C6
Complement C8 gamma chain
Ceruloplasmin
Caboxypeptidase N subunit 2
GC vitamin D binding protein
Insulin like growth factor binding protein
acid labile subunit
Kininogen 2
Maltase-glucamylase

P value
0.0466
0.0413
0.00148
0.0287
0.0358
0.0168
0.0164
0.0341

Fold change
-1.359
-1.271
1.57
-1.399
-1.299
-1.473
1.201
-1.305

0.0338
0.0236

-1.65
-1.799

Table 2. Expression of proteins in old NT-020 serum versus old control
Symbol
APOB
Apoc3
APOC4
Apon
CFH
CTSA
LOC259246
MST1
SERPING1

Protein name
Apolipoprotein B
Apolipoprotein C-III
Apolipoprotein C4
Apolipoprotein N
Complement factor H
Cathepsin A
Alpha-2u globulin PGCL1
Macrophage stimulating 1
Serpin family G member 1

P value
0.014
0.026
0.034
0.043
0.042
0.0085
0.0245
0.0319
0.0162

Fold change
1.633
2.066
1.42
1.61
-1.256
2.965
2.51
-1.361
1.313

Table 3. Complete list of proteins

P14841

Cst3

0.616

Welch’s
t-test
Old
Diet/Old
Control
0.19289

Q6AYS3

Ctsa

2.965

0.00850

2.34

0.408

0.00480

1.8731926

P01048

Map1

0.837

0.52004

0.159

2.082

0.00753

1.3693159

Q5EBC0 Itih4

1.069

0.67022

0.194

1.304

0.01129

0.4672

P05544

1.163

0.23630

0.441

0.627

0.01266

0.937833

Protein
ID

Gene
names

Serpina3l

Ratio
Old
Diet/Old
Control

Zscore
O-D
vs OC
1.245

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score
O-C vs YC

3.112

0.00404

2.4236845
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P04916

Rbp4

Ratio
Welch’s
ZRatio Old Welch’s tZ-score
Old
t-test
score Cntl/Young test Old
OC-vs YDiet/Old
Old
O-D
Cntl
Ctl/Young
C
Control Diet/Old vs OCtl
Control
C
0.906
0.48686 0.101 0.534
0.01353
1.1504985

P08932

Kng1l1

0.814

0.56965 0.169 2.092

0.01462

1.3137644

P05545

Serpina3k 1.235

0.16264 0.506 0.666

0.01543

0.7921914

P10959

Ces1c

1.338

0.07739 0.799 0.613

0.01920

1.047352

2.510

0.02454 3.882 0.256

0.02120

3.9838102

Protein ID

Gene
names

P02761
Q6P734

Serping1

1.313

0.01624 0.644 0.707

0.02178

0.6678694

Q5M891

C4bpa

0.926

0.56145 0.129 1.682

0.02218

1.0825587

O55004

Rnase4

1.192

0.50831 0.402 0.593

0.02226

1.0414808

G3V7K3

Cp

0.848

0.09529 0.247 1.321

0.02493

0.5116064

A0A0G2K151

Apoe

0.780

0.25864 0.368 1.784

0.02729

1.1910242

F1LQT4

Cpn2

1.156

0.58941 0.366 0.647

0.02803

0.9432507

A0A0G2K5D2

1.019

0.80678 0.054 2.000

0.03123

1.6249381

A0A0G2K980

0.512

0.15340 1.562 3.195

0.03162

2.8053642

G3V6K6

Egfr

1.014

0.80777 0.188 0.607

0.03537

1.0356462

P01015

Agt

0.978

0.89802 0.035 0.703

0.03621

0.7207409

P01836

0.920

0.53975 0.215 1.844

0.03921

1.4041058

A0A0G2K828

3.927

0.00362 7.88

0.730

0.04009

4.9155971

Q63041

A1m

1.054

0.44979 0.182 0.828

0.04065

0.3769135

A0A0G2JZ73

Serpina1

1.225

0.18030 0.503 0.662

0.04275

0.7832021

1.029

0.92142 0.191 2.644

0.04382

2.2639495

1.404

0.22576 0.777 0.705

0.04437

0.8487595

M0RAV0
Q6IE52

Mug2
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Protein ID

Gene
names

Ratio
Welch’s
ZOld
t-test
score
Diet/Old
Old
O-D
Control Diet/Old vs OControl
C
0.894
0.57090 0.23

G3V6G1

Igj

F1LR92

Serpina3m 1.175

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

1.867

0.04567

1.6557698

0.27725 0.428 0.564

0.04746

1.0159076

A0A0H2UHH2 Apcs

1.072

0.94676 0.108 1.362

0.04770

0.6041229

B1H260

F13b

0.829

0.33478 0.456 0.812

0.04853

0.4521103

P20761

Igh-1a

0.590

0.05724 0.838 1.897

0.04994

1.283275

F7FMS0

0.735

0.03188 0.526 1.270

0.05036

0.3865183

A0A0G2JVP4

0.791

0.26679 0.399 1.576

0.05873

0.9558463

P20767

0.449

0.11668 3.149 2.409

0.05988

2.6982493

Q4KM75

Cd5l

0.519

0.09032 1.446 2.234

0.06143

2.4810936

P55314

C8b

0.873

0.22394 0.168 1.240

0.06247

0.3578629

Q9EQV8

Cpn1

1.078

0.90797 0.135 0.741

0.06263

0.6016188

P14630

Apom

0.719

0.28044 0.488 2.099

0.06367

1.9558644

P06238

A2m

0.805

0.45151 0.298 1.748

0.06487

1.1100465

D3ZFH5

Itih2

1.158

0.51529 0.313 0.814

0.06556

0.4223003

F1LXY6

Ighv7-1

0.724

0.20231 0.868 1.629

0.07045

1.1267169

Q5EBA7

Hgfac

0.642

0.09925 0.759 1.601

0.07538

0.8452672

M0RBF1

C3

0.994

0.92199 0.065 1.151

0.07544

0.2391634

Q5M7T5

Serpinc1

1.123

0.43842 0.29

0.842

0.07584

0.3635991

Q64240

Ambp

0.805

0.15145 0.332 1.295

0.07619

0.4329801

1.069

0.64326 0.19

0.07854

0.4777579

F7FHF3
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Protein ID

A0A0G2K135

Gene names

Cfi

Ratio
Welch’s
Old
t-test
Diet/Old
Old
Control Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

0.851

0.46254 0.146 1.427

0.07977

0.5920274

A0A0H2UHK1 C1qc

0.779

0.47714 0.348 2.220

0.08109

3.2530761

G3V9R2

Cfh

0.796

0.04151 0.385 1.460

0.08121

0.8596222

F7FAY5

LOC360919

0.727

0.26016 0.855 1.360

0.08186

0.535541

A0A5C5

C4bpb

0.842

0.55628 0.863 2.949

0.08211

1.9250514

1.004

0.98828 0.071 1.635

0.08919

0.7981763

A0A0G2K290

A0A0H2UI19

F12

0.773

0.10376 0.438 1.241

0.08994

0.3479335

Q5M890

Apon

1.611

0.04260 1.275 0.621

0.09052

1.0333275

F1LTY5

LOC100361052 0.248

0.05435 3.776 1.820

0.09439

0.9655199

O35849

Lcat

0.823

0.40618 0.249 1.441

0.09679

0.6300198

D3ZWD6

C8a

0.786

0.15474 0.349 1.311

0.10186

0.4266257

P01946

Hba1

1.519

0.35627 0.804 0.573

0.10486

1.0575126

Q3B8R6

Azgp1

0.983

0.95002 0.067 0.808

0.10500

0.4371251
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Protein ID

Gene
names

A0A0G2JZV7

Zscore
O-D vs
O-C

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score OC vs Y-C

0.722

Welch’s
t-test
Old
Diet/Old
Control
0.61972

0.397

0.658

0.10698

1.2492004

Ratio
Old
Diet/Old
Control

P51886

Lum

0.949

0.74924

0.112

0.577

0.10778

0.958358

E9PSQ1

Amy1a

1.277

0.56537

0.581

0.682

0.10803

0.9897459

M0R979

Thbs1

0.894

0.35909

0.132

1.384

0.11009

0.7108787

A0A0G2K8Q1

Apoc3

2.066

0.02589

1.522

0.761

0.11435

0.6358906

F1M6Z1

Apob

1.633

0.01367

1.094

0.686

0.11478

0.6929707

Q5M8C3

Serpina4

1.047

0.89157

0.125

1.199

0.11528

0.3159751

Q99ME0

Ppbp

0.807

0.32703

0.575

1.697

0.11680

1.4317902

F7FMY6

Proc

0.819

0.36392

0.801

1.257

0.11727

0.3945845

G3V843

F2

1.001

0.87321

0.03

1.203

0.12457

0.3335053

D3ZQ25

Fbln1

0.806

0.69790

0.165

0.617

0.12802

1.0719687

A0A140TAI2

Btd

1.094

0.69820

0.328

0.644

0.12933

0.936426

P63259

Actg1

0.741

0.14213

0.58

0.734

0.13226

0.5757458

A0A0G2K531

Gpx3

1.155

0.63904

0.337

0.817

0.13496

0.5247342

O35217

Minpp

0.897

0.54680

0.392

0.741

0.14247

0.6717988

P16296

F9

0.950

0.91450

0.118

1.402

0.14287

0.4783127

Q6MG90

C4a

1.213

0.28603

0.691

0.552

0.14458

1.0808408

0.848

0.64800

0.269

1.681

0.15293

1.2240111

0.863

0.44430

0.182

1.288

0.15821

0.4126374

0.794

0.06876

0.391

1.173

0.15834

0.2750065

D3ZQR5
A0A0H2UHR6
A0A0G2K896

F10
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Table 3 continued
Protein ID

D3ZUU6

Gene
names

Ratio
Welch’s
Old
t-test
Diet/Old
Old
Control Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

LOC100912012 1.262

0.28932 1.106 0.687

0.15868

1.2982674

A0A0G2KB85

1.129

0.22485 0.337 0.851

0.16743

0.333981

A0A0G2JYC4

1.005

0.66051 0.382 1.803

0.16866

1.0100931

Q99J86-2

Atrn

0.964

0.78288 0.015 0.890

0.17500

0.2815746

P20059

Hpx

0.828

0.05891 0.292 1.142

0.17608

0.2119465

D4A3E0

Mmrn1

0.770

0.43950 0.475 1.536

0.17745

0.7639964

Q5FVS2

Klkb1

0.875

0.40201 0.147 1.221

0.18428

0.3095743

A0A0G2K477

0.936

0.97297 0.098 1.500

0.18774

0.6414648

A0A0G2JSW3

1.330

0.46382 0.659 0.636

0.19073

0.9304412

D3ZC54

0.772

0.70789 0.182 1.680

0.19658

1.1997988

P08934

Kng1

0.783

0.12446 0.453 1.190

0.19727

0.3237423

G3V7N9

C1qb

0.814

0.20030 0.352 1.229

0.19737

0.4131292

G3V836

Clu

1.086

0.56134 0.232 0.891

0.20028

0.2653976
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B0BNN4

Cfp

0.483

Welch’s
t-test
Old
Diet/Old
Control
0.11656

G3V9R9

Afm

0.870

0.41539

0.138

0.813

0.20736

0.4457456

P14046

A1i3

1.204

0.06919

0.474

0.885

0.21013

0.2764248

P25236

Sepp1

1.103

0.60776

0.268

0.805

0.21054

0.4324056

P55159

Pon1

1.126

0.65883

0.369

0.802

0.21075

0.629481

A0A0G2K7I1

1.262

0.97060

0.045

1.483

0.21098

0.7867911

M0RD98

0.990

0.71339

0.822

0.427

0.21179

2.555969

1.229

0.21800

0.467

0.799

0.21354

0.4042044

1.480

0.85001

0.265

0.536

0.21370

1.3106039

Protein ID

P02651

Gene
names

Apoa4

A0A0G2JTW9

Ratio
Old
Diet/Old
Control

Zscore
O-D vs
O-C

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score
O-C vs YC

1.908

1.627

0.20626

1.6176058

E9PSP1

Pltp

1.615

0.14454

1.041

1.415

0.21474

0.5043943

G3V8K8

Proz

0.798

0.11443

0.376

1.180

0.21982

0.2959161

Q80ZA3

Serpinf1

1.036

0.78307

0.143

0.892

0.22208

0.252169

D3ZBS2

Itih3

1.109

0.38716

0.275

0.873

0.22268

0.274455

Q03626

Mug1

1.106

0.67597

0.23

0.847

0.22444

0.3377679

P19999

Mbl1

0.845

0.47727

0.541

1.437

0.22561

1.1533726

Q6IRK9

Cpq

1.080

0.45757

0.403

0.688

0.23065

0.7244737

P06761

Hspa5

0.992

0.97856

0.092

0.847

0.24393

0.4203187

P07151

B2m

1.256

0.27176

0.594

0.650

0.24401

0.732201

P27139

Ca2

1.058

0.65518

0.465

0.726

0.24936

0.9402289

P48199

Crp

0.912

0.88908

0.172

0.829

0.25835

0.7031041
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Protein ID

Q62975

Gene
names

Serpina10

A0A0G2K6T8

Zscore
O-D vs
O-C

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score
O-C vs YC

1.151

Welch’s
t-test
Old
Diet/Old
Control
0.66190

0.278

0.828

0.26831

0.3785467

0.714

0.31061

0.447

1.467

0.26992

1.1605104

Ratio
Old
Diet/Old
Control

D3ZAF5

Postn

1.161

0.46049

0.742

0.853

0.27301

0.8395095

D4ACR1

Ighv7-1

0.937

0.88648

0.29

0.433

0.28104

1.7502376

G3V7L3

C1s

0.898

0.45836

0.432

0.873

0.28286

0.2813747

A0A0G2K8K3

Serpind1

1.063

0.66892

0.242

0.817

0.28553

0.4261533

M0R692

0.236

0.18670

2.093

3.084

0.28654

1.5694235

M0RCK5

0.323

0.35386

1.184

2.386

0.28847

1.6172733

P20762

2.784

0.03632

2.386

0.890

0.28986

0.8092868

Fcna;Fcn1 0.634

0.11117

1.096

1.275

0.29802

0.9659165

P11517

1.660

0.34697

1.215

0.512

0.29812

1.1972785

A0A0G2K5U5 Pigr

0.587

0.95655

0.013

1.588

0.30648

1.6685368

A0A0G2JX36

1.201

0.45010

0.763

0.721

0.31599

0.8767009

M0R9U2

1.021

0.83656

0.053

0.699

0.33012

0.5500487

0.659

0.20063

1.207

1.193

0.33244

0.6999253

A0A0G2JUY3

1.295

0.20325

1.646

2.053

0.35557

1.4269438

D3ZZ08

0.789

0.57478

0.414

0.668

0.36251

0.748622

Q5M8B4

Q01177

Plg

A0A0G2K9Y5

Hrg

1.090

0.62780

0.223

1.115

0.36889

0.2005308

P35859

Igfals

1.079

0.79618

0.183

0.896

0.37096

0.2573444

P15473

Igfbp3

0.583

0.26707

0.619

1.568

0.37119

0.598569
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Table 3 continued
Ratio
Old
Diet/Old
Control

Welch’s
t-test
Old
Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score OC vs Y-C

0.670

0.15130

0.812

1.206

0.37175

0.8427625

F1LPR6

0.915

0.71476

0.351

1.323

0.37324

1.0450244

A0A0G2K3W2

0.879

0.94252

0.121

0.873

0.37427

0.5369037

Protein ID

F1LVL2

Gene
names

Icoslg

Q08420

Sod3

0.726

0.22765

0.678

1.172

0.37871

0.4731787

F1LWS4

LOC683745

1.614

0.07724

1.51

1.564

0.38180

0.742153

P59996

Pcsk9

0.397

0.05786

1.64

1.409

0.38262

0.8223892

0.768

0.06580

0.42

0.856

0.38680

0.3046938

A0A0G2K7X7

Q6MG73

C2

1.011

0.83940

0.169

0.885

0.39522

0.3528023

G3V7P2

Fgl2

0.810

0.75374

0.163

0.895

0.39742

0.550406

P14480-2

Fgb

0.498

0.10332

0.96

1.269

0.40463

0.7812393

Q5I0M1

Apoh

0.667

0.17597

1.096

1.129

0.41835

0.5328964

M0RA79

LOC691828

0.683

0.21779

0.584

1.203

0.42065

0.4995496

0.817

0.51535

0.969

1.177

0.42287

1.2232824

0.288

0.63525

1.183

4.218

0.42365

1.8105074

D3ZEP5

Q9EPH1

A1bg
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Protein ID

Gene
names

Ratio
Old
Diet/Old
Control

Welch’s
t-test
Old
Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old
Ctl/Young
Ctl

Welch’s ttest Old
Ctl/Young
Ctl

Z-score
O-C vs YC

P32038

Cfd

0.930

0.68685

0.07

1.139

0.43743

0.1968286

P31720

C1qa

0.942

0.72367

0.026

1.122

0.44345

0.2063406

F1LST1

Fn1

1.060

0.76661

0.17

0.892

0.45604

0.2276018

A0A0G2JYK0

LOC299282

1.065

0.97743

0.093

1.108

0.45732

0.1796492

Q3KR94

Vtn

1.083

0.61025

0.234

0.934

0.46182

0.1834113

G3V8B1

Gpld1

1.020

0.86786

0.124

0.917

0.46940

0.200046

M0R485

Pglyrp2

1.130

0.20997

0.378

1.110

0.47328

0.1378002

D3ZF92

Tnfrsf21

0.882

0.44083

2.637

1.321

0.49233

1.6648587

F7F389

C9

1.130

0.60259

0.27

1.077

0.50309

0.1007931

D1M8S3

Il1rap

0.939

0.65152

0.407

1.295

0.50572

0.7875333

0.439

0.52888

0.782

2.246

0.50623

0.8086348

D3ZMS7
P06765

Pf4

1.055

0.90397

0.106

0.699

0.50631

0.7290455

D4A8G5

Tgfbi

1.771

0.08822

1.346

0.724

0.51648

0.5555122

Q7TPA5

Serpina11

1.006

0.69374

0.181

1.110

0.52691

0.2193226
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A2VCV7

Masp2

1.054

Welch’s
Zt-test
score
Old
O-D
Diet/Old vs OControl
C
0.47162 0.65

P24090

Ahsg

0.747

0.33258

1

1.064

0.53342

0.5268768

P12346

Tf

0.827

0.22432

0.254

1.110

0.53424

0.1103396

0.611

0.27634

0.698

0.867

0.54301

0.443586

Protein ID

Gene
names

M0R789

Ratio
Old
Diet/Old
Control

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

0.982

0.52742

0.4969146

B2RYM3

Itih1

0.992

0.86298

0.038

0.938

0.54505

0.1437581

Q5I0M3

Cfhr1

1.031

0.99818

0.079

0.890

0.54829

0.2281499

Q7TQ70

Fga

0.753

0.22534

0.486

0.898

0.54904

0.4785596

M0R816

0.868

0.47670

1.388

0.730

0.54907

1.323202

A0A0H2UHF8 Orm1

1.123

0.42344

0.6

0.970

0.54908

0.3802218

G3V811

F13a1

0.891

0.42289

0.98

0.742

0.58160

0.4392876

Q5M878

Hps5;Saa4 0.966

0.91719

0.014

0.966

0.58347

0.2625321

G3V615

C2

1.023

0.57404

0.907

1.096

0.58633

0.2830771

P20760

Igg-2a

0.797

0.34081

0.282

1.148

0.59401

0.1656879

Q6IRS6

Fetub

0.912

0.23594

0.106

0.961

0.59465

0.1078034

A0A0G2K4I9

F11

0.865

0.76695

0.281

1.069

0.60927

0.3584287

Q9EQV9

Cpb2

1.009

0.85464

0.185

1.209

0.61787

0.2131998

P31211

Serpina6

0.996

0.89696

0.139

0.940

0.62700

0.2219602

0.894

0.69481

0.386

1.398

0.63423

0.3016974

1.301

0.19174

0.958

0.821

0.63462

0.4096692

0.955

0.71399

0.058

1.049

0.65629

0.1381525

1.014

0.55820

0.512

1.290

0.68046

0.2976329

F1LZ11
G3V9H9

Gp5

A0A0G2JTG4
Q5M7T7

Pla2g7
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Protein ID

Gene
names

Ratio
Welch’s
Old
t-test
Diet/Old
Old
Control Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

A0A0G2JXF0

1.033

0.73003 0.147 1.021

0.69990

0.1130494

A0A0H2UHM3 Hp

1.296

0.26557 0.572 0.938

0.72937

0.1490008

P04639

Apoa1

0.986

0.73718 0.031 1.019

0.73817

0.0381929

P08649

C4

0.798

0.86789 0.061 0.967

0.73842

0.3032323

D3ZPI8

C8g

0.910

0.72197 0.057 1.106

0.75094

0.0596823

A0A1W2Q642

Pi16

0.777

0.18558 0.463 0.701

0.75444

0.3078264

Q62894

Ecm1

0.719

0.34410 0.936 0.963

0.76981

0.1673087

1.067

0.55262 0.461 0.987

0.78271

0.2279327

A0A0G2JY98

P53813

Pros1

1.064

0.88203 0.162 1.044

0.78479

0.0920178

A2VD04

Habp2

0.886

0.96266 0.136 1.090

0.80745

0.2710546

G3V8D4

Apoc2

0.965

0.77565 0.122 0.986

0.81844

0.1328498

0.809

0.39839 1.251 1.067

0.83645

0.1062425

A0A0G2K0N6

Q68FY4

Gc

0.926

0.25762 0.08

1.010

0.84220

0.0076133

P19939

Apoc1

1.707

0.13511 2.894 1.138

0.85887

0.3907949
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Protein ID

Gene
names

Ratio
Welch’s
Old
t-test
Diet/Old
Old
Control Diet/Old
Control

Zscore
O-D
vs OC

Ratio Old Welch’s tCtl/Young test Old
Ctl
Ctl/Young
Ctl

Z-score
O-C vs YC

G3V9J1

LOC297568 0.989

0.80230 0.013 1.005

0.86138

0.0193477

B5DEH7

C1r

0.863

0.39352 0.178 0.990

0.86580

0.0800695

D3ZQU7

Gp1ba

1.035

0.68825 0.31

0.866

0.89829

0.1281783

A0A0G2JSH5

Alb

0.752

0.25223 0.385 1.087

0.90193

0.0108793

0.392

0.17527 2.312 1.411

0.90849

0.0799086

M0RBK4

A0A096P6L9

C5

1.036

0.83211 0.126 0.977

0.92320

0.0498832

Q811M5

C6

0.764

0.16620 0.41

1.047

0.93102

0.007571

A0A0G2JW12

C4a

1.145

0.43414 0.313 0.928

0.93240

0.0616107

A0A0H2UHA1 Masp1

0.858

0.49787 0.208 1.018

0.93294

0.0009356

Q7TP05

0.973

0.82794 0.019 1.012

0.94250

0.0163455

1.110

0.77604 0.417 0.811

0.94326

0.1125163

Cfb

M0R7Q2

P02767

Ttr

0.881

0.38668 0.296 0.869

0.95048

0.0647254

P04638

Apoa2

1.024

0.78543 0.162 1.014

0.95321

0.0474816
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Protein
ID

Gene
names

D3ZTX4

Mgam

Ratio
Old
Diet/Old
Control
0.910

P55797

Apoc4

1.420

Welch’s
Z-score
t-test Old O-D vs
Diet/Old
O-C
Control
0.96669 0.11

Ratio Old Welch’s tZ-score
Ctl/Young test Old
O-C vs YCtl
Ctl/Young
C
Ctl
1.160
0.95981
0.0009356

0.03429

1.007

0.792

0.97009

0.0234919

Figure 10. Predicted Activation of Cellular Immune Functions with Age. As can be seen in this
graphic representation of the predicted activation (orange) or inhibition (blue) of cellular immune
functions, clustered in the middle of the graphic. In panel A there is predicted upregulation of phagocytes,
neutrophil adhesion, macrophages, binding of phagocytes and immune response that is driven by the
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proteins detected in the old rat serum compared to young rat serum as shown in panel A.

The proteins

driving these predicted changes in cellular immune function are shown surrounding the functions. The
fold change for protein expression is written below each protein along with the -Log p value. As shown in
the insert to the right, red indicates increased expression and green indicates decreased expression and
the intensity of the color reflects the degree of expression. For example, A2M is upregulated 1.75-fold in
the aged rat serum and CST3 is upregulated 3.11-fold. In panel B the same proteins used in panel A
were entered into IPA for the old vs old NT-020 treated comparison. As can be seen the changes in
protein expression following treatment with NT-020 now show a predicted inhibition of these same
pathways in the old treatment group. For example, A2M is not -1.24 and CST3 is -1.62-fold. This shows
an overall reduction in immune function predicted by the pattern of protein expression detected in the
aged rat serum in the NT-020 treated animals. Abbreviations: apolipoprotein E (APOE), complement
component 3 (C3), SERPINF2, SERPING1, complement factor H (CFH), cystatin 3 (CST3), SERPINA1,
alpha-2-macroglobulin (A2M), CD5 molecule like (CD5L), angiotensin (AGT), serum amyloid P
component (APCS).
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Chapter 4 – Conclusion and Future Directions
Conclusion
Overview
Aging is the main risk factor for cancer, cardiovascular disease, and neurodegenerative
diseases (Niccoli and Partridge 2012). As the life expectancy of the population continues to
increase, the need to address diseases that impact health span and quality of life for the elderly
continues to increase (Crimmins 2015, Centers for Disease Control and Prevention 2019). With
aging there is a progressive decline in organ function and homeostasis throughout all biological
systems in the body, leading to decreased cell proliferation and regeneration (Wang, Karpac
and Jasper 2014, Oh, Lee and Wagers 2014). The age-related decrease in renewal ability of
stem cells and the overall decline in function of stem cell niches, in particular, underlies the
reduced capacity for rejuvenation and repair (Ahmed et al. 2017).
While the exact mechanisms underlying aging are largely unknown, recent investigation
has focused on cell autonomous changes and cell non-autonomous changes. Cell autonomous
changes include senescence of genes and loss of function of critical proteins. Cell nonautonomous changes include effects on stem cell niches such as oxidative stress, proinflammatory cytokines, chemokines, and other signaling and environmental factors that can
impinge on and influence the microenvironment (Bickford et al. 2015, Cho et al. 2013, Demaria
et al. 2015). A lot of evidence for the cell non-autonomous effects on the aging
microenvironment have been provided by parabiosis studies. In these studies, heterochronic
pairs are created by surgical union of the circulatory system of a young animal with an old
animal (Villeda et al. 2011, Villeda et al. 2014).
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Previous studies have shown that old heterochronic rats have increased neurogenesis in
the subgranular zone of the dentate gyrus in the hippocampus compared to age-matched
isochronic (control) animals not exposed to young blood. Additionally, heterochronic young rats
have decreased neurogenesis in the hippocampus compared to age-matched isochronic
animals not exposed to old blood. Additionally, young mice injected with plasma from old mice
made a greater number of errors in the radial arm water maze (RAWM) paradigm and displayed
significantly less freezing behavior on the contextual fear conditioning paradigm than agematched controls, indicating decreased cognitive ability in young mice injected with old plasma
(Villeda et al. 2011, Villeda et al. 2014, Smith et al. 2015). In addition, graft transplantation
studies have shown that age can have a negative effect on graft survival and this can be
ameliorated by dietary supplementation (Willis et al. 2008, Willis et al. 2010). Together, these
data indicate that there are negative factors in old blood and positive factors in young blood.
This suggests that what may be driving aging is the loss of protective, rejuvenating factors from
the microenvironment and the emergence of deleterious, pro-aging factors.
Aging and NT-020
Given the evidence of decreased stem cell proliferation with aging and the emergence of
non-autonomous influences on the microenvironment, such as oxidative stress, it would seem
that an approach for quelling the negative effects of aging would be a method for increasing
endogenous stem cell proliferation. Previous studies by our group have shown that the
nutraceutical compound NT-020, a proprietary blend of blueberry, green tea, carnosine, and
vitamin D3, has increased proliferation of CD34+ cells in culture (Bickford et al. 2006).
Additionally, rats that were prophylactically treated with NT-020 by oral gavage prior to MCAo
stroke surgery had improved outcomes after stroke compared to vehicle-treated control stroke
rats (Yasuhara et al. 2008). In aged rats, oral gavage with NT-020 also resulted in increased
neurogenesis in the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus and
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in the subventricular zone (SVZ) compared to age-matched vehicle-treated controls. Old NT020-treated rats also made fewer errors on the Morris Water Maze paradigm than age-matched
controls, showing evidence of improved cognitive performance (Acosta et al. 2010).
Furthermore, when NT-020 was used in a double-blind placebo-controlled clinical trial,
older adults using the NT-020 supplement demonstrated improvement on two measures of
processing speed in cognitive testing and it was shown that NT-020 was safe and well-tolerated,
supporting NT-020 as a promising treatment for future clinical studies (Small et al. 2014).
Additional pre-clinical work using NT-020 has shown that NT-020 has recapitulated Wnt
signaling, which decreases with age, in old animals. Old rats maintained on a diet supplemented
with NT-020 additionally had significantly lower concentrations of pro-inflammatory cytokines
than old rats maintained on standard NIH-31 chow (Flowers et al. 2015, Flowers et al. 2016).
Additionally, it has been demonstrated in vitro that neural progenitor cells (NPCs) and
mesenchymal stem cells (MSCs) treated with serum from old rats had significantly decreased
proliferation compared to cells treated with serum from young rats. However, compared cells
treated with serum from old control rats, there was significantly greater proliferation when cells
were treated with serum from rats maintained on a diet supplemented with NT-020 (Bickford et
al. 2015).
Serum Data
The previous data from studies with NT-020 demonstrate a positive effect on
neurogenesis and cognition, however the precise mechanisms underlying the observed benefits
were not entirely clear. We therefore designed a bottom-up, discovery-based, mass
spectrometry-based bioinformatics study to profile the serum proteome of aged (20-22 months
of age) and young (3-6 months of age) rats maintained on a standard NIH-31 chow or an NIH31 chow supplemented with NT-020. Rats were maintained on their respective diet for 28 days
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prior to sacrifice and blood collection. Serum was isolated from blood and used for mass
spectrometry.
Serum was depleted with a commercial depletion kit to remove high abundance proteins
prior to further processing and analysis. As previously mentioned, the kit used to deplete
albumin and IgG was optimized for human, as are all commercially available depletion kits. The
lack of specificity for the species for which it was being used could have resulted in incomplete
depletion of high abundance protein from samples, which could have impacted the MS results.
We detected a total of 210 proteins in all samples, and there were 40 “unmapped”
proteins that were not identified by Perseus software. Of the proteins detected, there were 11
found to be significantly different between the old control rats and the young control rats and
there were 7 found to be significantly different between the old diet versus the old control group.
However, we did not find that there was differential expression of any of the same proteins
between any of the treatment groups. A full list of the proteins identified is available in Table 3.
Of the proteins found to be significantly different in the pairwise comparison of the old
control versus the young control, we noted changes in complement proteins complement C1R,
complement 5 (C5), complement 6 (C6), and complement 8 gamma chain (C8), all of which
decreased with age (p < 0.05, Table 1). The copper transporter, ceruloplasmin, also significantly
decreased with age (p < 0.05, Table 1), which in particular is consistent with findings showing
age-related decreases in expression levels of this protein (Musci et al. 1993, Connor et al.
1993). There were also significant decreases in insulin-like growth factor binding protein acid
labile subunit (IGFALS) and maltase-glucoamylase (Mgam), which are both associated with
age-dependent decline (Fritton et al. 2010, Fernandez-Alarcon et al. 2017).
As mentioned, there were only 7 proteins found to be significantly different in the
pairwise comparison between the old diet versus the old control groups. Of these proteins, the
most biologically relevant in terms of the anti-aging effect of NT-020 were the auotophageal
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protein cathepsin A (CTSA), macrophage stimulating 1 (MST1 also referred to in the literature
as macrophage stimulating protein (MSP) and hepatocyte growth factor-like protein (HGFL)),
and the complement proteins serpin G1 and complement factor H (CFH).
Autophagy and Aging
Autophagy is an important degradation process for the clearance of proteins from the
cytoplasm. There are different subtypes of autophagy, including macroautophagy,
microautophagy, and chaperone-mediated autophagy, but all of these processes involve the
degradation of proteins in the lysosome. Most of the literature focused on aging has centered on
macroautophagy in which the cell sequesters a part of its cytoplasm by forming an
autophagosome, which merges with the lysosome and degrades. Autophagy is considered a
maintenance and self-protective process and inhibition of autophagy is associated with aging.
There are age-related neurodegenerative diseases associated with the aggregation of proteins,
such as -synuclein in Parkson’s disease (PD), tau in Alzheimer’s disease (AD), and mutant
huntingtin protein in Huntington’s disease. One of the functions of autophagy is to prevent these
aggregrates from forming. Autophagy also removes dysfunctioning mitochondria to prevent any
pro-apoptotic signaling or oxidative stress. In these ways, autophagy functions to maintain
homeostasis (Rubinsztein, Marino and Kroemer 2011). Autophagy has cell non-autonomous
anti-aging effects including moderating the inflammatory response in several ways. Autophagy
is required for the clearance of dying cells, thus reducing inflammation by removing debris.
Autophagy also maintains intracellular levels of ATP, which produce lysophosphatidylcholine
and phosphatidylserine which further facilitate clearance of dying cells, avoiding a secondary
immune response.
As previously mentioned, autophagy can clear dysfunctioning mitochondria, thus
preventing the production of ROS (Rubinsztein et al. 2011).
Autophagy is driven by a number of different proteins, including cathepsins. CTSA is a
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lysosomal protein integral to the autophageal pathway in that it triggers chaperone-mediated
autophagy (CMA) through its serine carboxypeptidase activity. CMA is a process by which
damaged and malfunctioning intracellular proteins are degraded in lysosomes. Reduced CMA is
also associated with neurodegenerative diseases, including PD and AD (Cuervo and Wong
2014, Cuervo et al. 2003).
Macrophage Stimulating 1 and Complement Proteins
Macrophage stimulating 1 (MST1) was also found to be significantly decreased in old
animals maintained on an NT-020 diet compared to age-matched controls. MST1 is a serum
protein that is predominantly expressed in hepatocytes and functions to upregulate inflammation
by stimulating the release of pro-inflammatory cytokines (Wang et al. 2015, Li et al. 2016,
Suzuki et al. 2008). As previously mentioned, inflammation is central to hypotheses of aging so
this finding was of particular interest.
The complement system is part of the innate immune response. It has been suggested
that the complement system is protective for the retina with aging (Mukai et al. 2018), however
C1q may promote aging though its interaction with the canonical Wnt signaling pathway (Naito
et al. 2012) and early components of the complement system have been associated with the
pathogenesis of AD (Reichwald et al. 2009). The complement proteins found to change with NT020 diet in old rats compared to age-matched controls were serpin G1, which increased with
NT-020, and complement factor H (CFH), which decreased with NT-020. The inhibition of serpin
G1 has been linked to loss of blood-brain barrier integrity and neuroinflammation (Farfara et al.
2019). CFH is a regulator of the alternative pathway for the complement system and its
upregulation has been associated with geriatric depression, increased inflammatory activity, and
age-related macular degeneration (Shin et al. 2019, Calippe et al. 2017). Furthermore,
increased concentrations of CFH have been found in the cerebrospinal fluid of PD, AD, and
multiple-system atrophy patients (Wang et al. 2011). There is conflicting information on how the
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complement system behaves (whether its activity increases or decreases) with age and whether
the complement system is protective with aging or whether it contributes to age-related decline
and disease. It may be more useful to focus on the individual proteins than the system as a
whole, as the evidence obtained in the current study is what would be expected from the
literature on these two proteins.
Apolipoproteins
In addition to the proteins discussed, apolipoprotein B (apoB), apolipoprotein C3
(apoC3), apolipoprotein C4 (apoC4), and apolipoprotein N (apoN) also significantly increased in
serum from old rats maintained on an NT-020-supplemented diet compared to age-matched
controls. Age-related increases in apoB in serum from senescent mice have been observed
(Higuchi et al. 1992). Furthermore, age-related increases in apoB are associated with risk for
developing cardiovascular disease (Sniderman et al. 2016). The role of apoC3 in aging is not
well defined. There is some evidence of its decreased function negatively impacting mobilization
of lipids (Araki, Okazaki and Goto 2004). There is also evidence from a study with centenarians
and their offspring, that polymorphisms of the APOC3 gene confer a favorable lipoprotein
profile, promote a healthy cardiovascular system, and promote longevity (Atzmon et al. 2006).
The roles of apoC4 and apoN in aging and disease are not documented.
The data from individual proteins suggest an overall positive effect of NT-020 in aged
rats, and the data in the current study support the anti-aging effects of NT-020. With aging there
is an overall shift in cellular and molecular signaling towards inflammation and senescence and
away from processes that promote cellular homeostasis and regeneration (Hartl 2016). The
current study supports that a nutraceutical could correct this course and shift the
microenvironment back towards a more homeostatic state by promoting processes such as
autophagy, anti-inflammation, and antioxidant activity to combat oxidative stress. Furthermore,
as suggested by the data with NT-020, many nutraceuticals are considered to possess multiple
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health benefits, thus making it possible they can target myriad processes related to aging (Das
et al. 2012).
With the growing age of the population increasing healthcare expenditure, nutraceuticals
continue to be an area of interest for their ability to not only confer benefits for chronic
conditions, but also to be used prophylactically in order to prevent the onset of chronic disease
states (Nasri et al. 2014). Use of a nutraceutical in combination with exercise has also been
shown to prevent neurodegeneration (Malaguti et al. 2019). Informing the public of lifestyle
choices as a way of promoting healthspan is a valuable way to perhaps empower people to
make healthy choices that can enhance their quality of life as they enter late adulthood.
Future Directions
Study Limitations
As previously mentioned, the data from individual proteins, though not differentially
expressed in the old control versus young control compared to the old diet versus old control
groups, is promising in that it shows a trend towards anti-inflammation, pro-autophagy, and a
general anti-aging effect with NT-020 treatment in old animals, which is consistent with the
existing body of data on NT-020. However, the overall lack of significant results obtained makes
it difficult to draw any major conclusions without follow-up studies.
There are some potential methodological reasons for the small number of significant
proteins in the dataset. As mentioned earlier in the overview subsection, the commercially
available depletion kit from Thermo Fisher Scientific was optimized for human serum, as are all
other commercially available depletion kits. This makes working with serum from other species
for mass spectrometric analysis particularly challenging. Incomplete or insufficient depletion of
high abundance proteins in a sample can interfere significantly with detection of lower
abundance proteins (Han et al. 2008).
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Additionally, there are challenges already “baked in” to mass spectrometry itself. MS
analysis inherently preferentially samples peptides at high abundance over those of low
abundance. According to the Broad Institute, LFQ inextricably related to abundance and results
can vary depending upon instrument settings and the number of peptides in a given protein.
LFQ is considered reliable only for highly abundant proteins and the results can produce a lot of
missing data and variability, particularly for lower abundance proteins (Carr). The challenges
presented by lack of species specificity in the depletion kit as well as MS being inherently better
for analytes with high abundance peptides make it highly likely that lower abundance peptides in
the serum samples were present, but went undetected due to preferential sampling of the high
abundance peptides.
There were also some technical issues present when isolating the serum from the
blood by centrifugation. Some serum samples had a slight pink hue, indicating hemolysis of red
blood cells in the serum. Additionally, protease inhibitor was not added before freezing and
storing the serum samples. Protease inhibitor was added at a later stage, during processing for
MS, but the failure to add it before freezing and storing may have resulted in some protein
degradation.
Given the promising results of what proteins did show significance in the results, future
studies should be undertaken to overcome some of these methodological issues.
Future Studies
NT-020 was shown to be safe and well-tolerated in older adults in a double-blind,
placebo-controlled clinical trial (Small et al. 2014). One of the methodological limitations of the
current study was that serum depletion kits, which are necessary for MS studies with serum, are
all optimized for human serum and there are none available for murine studies. As NT-020 has
been shown to be safe and produced promising results, it may be beneficial to design another
clinical trial and, this time, retain some of the blood collected to isolate serum for MS.
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As one of the limitations discussed in the clinical study by Small et al (2014), was a lack of
robust results on cognitive tests because all older adult participants were typically functioning
and not impaired, it would be prudent to include a group of participants with clinical age-related
cognitive deficits, such as mild cognitive impairment (MCI).
Future studies should further explore the roles of autophageal proteins, complement
proteins, and other mediators of inflammation on aging and ascertain whether a polyphenol-rich
supplement exerts an overall anti-aging effect. Discovery-based studies should query the entire
human serum proteome for a full list of proteins that change with age and proteins that change
with diet. Overall the current study is suggestive of an effect on proteins in the autophagy
pathway and complement proteins in particular, indicating further potential anti-aging effects of
NT-020. This study provides further support to the existing body of literature indicating that
lifestyle, namely diet and exercise, contributes to healthy aging through dampening of
inflammatory pathways as well as augmentation of anti-aging pathways. In particular, it has
been observed that high antioxidant diets combined with physical activity stimulate neural
regeneration and have an overall anti-aging effect (Yasuhara et al. 2008, Tsivgoulis et al. 2015,
Garatachea et al. 2015, Gioscia-Ryan et al. 2016). Future studies will serve to clarify the effects
of NT-020 on the pathways discussed and further elucidate the compound’s beneficial effects.
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Abstract: Fragile X syndrome (FXS), one of the most common genetic causes of autism, results from a loss of fragile X
mental retardation protein (FMRP) expression. At the molecular level, abnormal neurodevelopment is thought to result from dysregulated protein synthesis of key neural synaptic proteins, however recent evidence suggests broader
roles for this protein including glutamate signaling, memory, and regulation of the critical serine/threonine regulatory
kinase, glycogen synthase kinase-3 (GSK-3). In this review, genetic and molecular features of FXS are detailed in the
context of FXS neuropathology. Additionally, potential mechanisms by which FMRP silencing impacts GSK-3 and GSK3-associated signaling pathways are discussed. As GSK-3 signaling represents a central regulatory node for critical
neurodevelopmental pathways, understanding how FXS results from FMRP-mediated GSK-3 dysregulation may provide novel therapeutic targets for disease-modifying interventions for FXS and related ASDs.
Keywords: Glycogen synthase kinase, fragile X, neuroinflammation, trinucucleotide repeat, microglia, lithium, flavonoids

Introduction
Fragile X syndrome (FXS), originally known as
Martin-Bell syndrome [1] was first characterized
in 1943 [2] is the most common cause of inherited mental retardation and is the first identified
autism-related genetic disorder. The primary
symptom of FXS is intellectual disability, but
patients also share characteristics commonly
associated with autism spectrum disorders
(ASDs), such as developmental delays, communication impairments, and anxiety [3-9]. The
most severely affected FXS individuals additionally display dysmorphic features, and other neurological pathology, including seizures. In this
review, genetic and molecular features of FXS
are detailed in the context of FXS neuropathology. Finally, potential mechanisms by which
FMRP silencing impacts GSK3 and GSK3associated signaling pathways are discussed.
As GSK3 signaling represents a central regulatory node for critical neurodevelopmental path-

ways, understanding how FXS results from
FMRP-mediated GSK3 dysregulation may provide novel therapeutic targets for diseasemodifying interventions for FXS and related
ASDs.
Eitiology of FXS
The first evidence regarding the molecular origin
of FXS was generated in 1969, at which time a
non-typical constriction, or fragile site, was observed at the end of the X chromosome in several affected individuals [10, 11]. In 1991, the
fragile site was mapped to a specific location in
the genome [10]. The fragile X mental retardation 1 (Fmr1) gene on the X chromosome was
found to yield a lack of the gene product, the
fragile X mental retardation protein (FMRP), an
RNA binding protein which regulates translation
[3, 12]. This functional loss typically occurs
when there is an expansion of the CGG trinucleotide repeat in the 5′ untranslated region (5′
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UTR) of the fragile X mental retardation 1
(FMR1) gene [13]. Healthy individuals usually
have between 5 to 54 repeats, but fully affected
individuals have greater than 200 CGG repeats
on what are known as “full mutation alleles” [14]. Permutation alleles (55-200 CGG
repeats) of the FMR1 gene contribute to the
FXS phenotype through genetic instability and
can expand into the full mutation during the
process of germline transmission [15, 16].
FMRP contains three RNA-binding domains and
binds to a significant number of mRNAs. In in
vitro studies, it has been found that dihydroxyphenylglycine-activated protein synthesis in synaptoneurosomes is reduced in a mouse model
of FXS (the Fmr1 knockout mouse), which cannot produce full-length FMRP, suggesting that
FMRP is involved in this process. FMRP is generated in synaptoneurosomes in response glutamate or metabotropic glutamate receptor
(mGluR) agonists. Moreover, Fmr1 knockout
mice demonstrate a substantial reduction in the
ability to translate mRNA in response to activation in an experimental synaptoneurosome
preparation as well as a reduction in the presence of postsynaptic polyribosomal aggregates
in vivo [17].
Neuronal morphology and function in FXS
FXS patients and murine models of FXS demonstrate increased long-term depression (LTD) in
hippocampal synapses [18]. FMRP functions to
inhibit the synthesis of proteins that stabilize
LTD. With functional loss of this protein, metabotropic glutamate receptor-5 (mGluR5) remains active and increases the synthesis of
proteins associated with LTD. Increased activation of mGluR5 (and consequent increase in
glutamate activity) has been implicated in
audiogenic seizure activity associated with FXS.
A study utilizing an mGluR antagonist and lithium to treat Fmr1 knockout mice found that the
treatment alleviated mGluR-induced LTD [18].
Visualization of dendrites and dendritic spines
can be performed using Golgi staining, which
allows for quantitative evaluation [19] of developmental pruning of neural processes [20-22].
In humans, spine density on the dendritic apical
shafts of cortical pyramidal cells increases
within the first few months of life [23]. Autopsy
tissue of normal human subjects ranging in age
from fetal to adult revealed synapse density
peaks between 3 months and 3.5 years, de-

141

pending on the cortical region in question [24,
25]. Following this initial burst of synaptic development, synapses are selectively pruned, leaving synapse density measures at approximately
60% of their original peak numbers [26, 27],
although somewhat smaller losses are observed
when neuron density is taken into account [25].
Regardless of the biological basis for this developmental delay, dendritic spine dysgenesis frequently characterizes neuronal morphology in
disorders associated with intellectual disability
[28]. Studies utilizing samples from patients
with FXS have suggested that dendritic spines
do not assume a normal mature size and shape
and that there are more dendritic spines per
unit dendrite length in the patient samples compared to unaffected individuals. Similar findings
on spine size and shape have come from studies of FXS model mice in which the development
of the somatosensory cortical region contains
barrel-like cell arrangements that process
whisker sensory information [29]. This suggests
that normal dendritic pruning is impaired in the
knockout mice [17] and indicates that FMRP
may be required for the normal processes of
maturation and elimination to occur in cerebral
cortical development [17].
Structural magnetic resonance imaging (MRI)
has shown a reduction in the size of the posterior cerebellar vermis which may result in the
enlargement of the fourth ventricle in males
with FXS [30, 31]. Such gross morphological
aberrations are not unique to the cerebellum,
because the volume of hippocampus [32], caudate nucleus, and lateral ventricles [33, 34]
also have all been noted to be enlarged in FXS
patients. The generalizability of these observations is controversial as several of these differences in brain morphology have not been replicated in a study using physical measurements
of autopsy material from one underpowered
study (2 FXS patients) [35].
At the molecular level, the consequence of the
aforementioned CGG trinucleotide expansion in
the 5' untranslated region of the FMR1 gene
leads to a hypermethylation of the promoter
region of the DNA, thus silencing transcription
of the gene and resulting in the absence of
FMRP. The function of FMRP has not yet been
fully elucidated, although it is found to be associated with polyribosomal complexes near synapses and contains mRNA-binding domains.
This suggests that it may be involved in mRNA
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transport or translation of proteins required for
synaptic plasticity [36]. FMRP's role as an
mRNA-binding protein is so critical for normal
development that a point mutation in one of its
RNA binding sites results in severe intellectual
disability [37].

tion with a variety of signaling pathways [4447]. GSK-3 is a partially constitutively active
serine/threonine kinase that is predominantly
modulated by inhibitory serine phosphorylation
of its two isoforms, serine-9 on GSK-3β and serine-21 on GSK-3α [48-50].

To test indirectly the role of FMRP in neuroplasticity, FMRP expression has been analyzed in
rats after exposure to experimental paradigms
known to induce synaptic plasticity. Regional
increases in FMRP immunoreactivity were observed after training on a motor learning task or
exposure to a complex environment [38]. It has
also been shown that cortical levels of FMRP
are elevated following sensory stimulation [39].
These observations suggest that the expression
of FMRP is activity-dependent, and that the protein is involved in processes underlying synaptic
plasticity [40]. Thus, it has been suggested that
the loss of FMRP may lead to deficits in synaptic
plasticity that could impair neuronal development [17].

FMRP is known to play a critical role in adult
hippocampal neurogenesis and regulates adult
neural stem cell (NSC) fate by modulating the
translation of glycogen synthase kinase-β (GSK3β) [51]. One study examined the effects of
GSK-3β inhibition on Fmr1 knockout mice [51].
GSK-3β inhibition increased hippocampal neurogenesis and improved performance in hippocampal-dependent learning tasks. It is possible
that while overall neuronal density is not significantly altered in FXS patients, a decrease in
hippocampal neurogenesis through loss of
FMRP and the resultant dysregulation of GSK3
contributes to the pathogenesis of the disorder.

Several other studies of FXS patients support
that the syndrome is associated with dendritic
spine dysgenesis, suggestive of abnormal neuronal development. In qualitative studies of
Golgi-impregnated cortical neurons from human
autopsy tissue, immature-appearing dendritic
spine morphology has been described [41, 42].
Specifically, long, thin, tortuous spines with
prominent heads and irregular dilations on apical dendrites of pyramidal cells in layers III and
V of parieto-occipital neocortex and in the pyramidal layer of allocortex have been observed.
Investigators noted that this spine morphology
was reminiscent of that described in children
and infants with other disorders associated with
intellectual disability, such as Down syndrome
and Patau syndrome [43]. Decreased synaptic
contact area also was found, but no other major
neuropathologies were observed. The lack of
altered neuronal density in FXS patients, with
the absence of significant cortical atrophy in the
MRI research, indicates normal neurogenesis
and cell migration and no prominent atrophy of
processes.
The role of GSK-3 in neurodevelopment
Glycogen synthase kinase-3 (GSK-3) regulates a
variety of developmental processes, such as
neurogenesis, gliogenesis, cell migration, cell
morphology, and axonogenesis through interac-
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Underlying this are changes in the inhibitory
serine-phosphorylation, which has a robust impact on GSK-3 activity, as this is the cardinal
mechanism by which it is regulated. The phosphoinositide-3-OH kinase (PI3K)/Akt pathway is
an essential pathway for neuronal and glial survival and is also one of the main regulatory
pathways for serine-phosphorylation of GSK3
[47, 52]. However, GSK-3β can also be regulated by p38 mitogen-activated protein kinase
(MAPK)-mediated inhibitory phosphorylation of
serine-389 [53]. While GSK-3β and GSK-3β are
expressed ubiquitously, GSK-3β2 is highly expressed in the central nervous system (CNS)
and is found in highest concentrations during
neurodevelopment [44].
GSK-3 inactivation has been associated with
increased neuronal progenitor proliferation and
suppressed neural differentiation. GSK-3 interacts with the canonical Wnt, sonic hedgehog
(SHH), and Notch pathways to regulate proliferation [22, 24, 43]. The canonical Wnt/β-catenin
signaling pathway involves Wnt binding to Frizzled receptors (Fzd) and Fzd binding to the protein Disheveled (Dvl). Dvl then binds and destabilizes the β-catenin destruction complex, which
includes GSK-3. Therefore, GSK-3 regulates the
canonical Wnt pathway by remaining bound to
the Wnt complex, preventing β-catenin from
translocating to the nucleus to induce gene
transcription [54]. Inhibition of GSK-3 is necessary for β-catenin-mediated transcription. Wnt/β
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-catenin signaling is vital for adult hippocampal
neurogenesis and is critical for CNS developmental processes, such as synapse and dendrite formation.
GSK-3 and fragile X syndrome
GSK-3 activity has been found to be elevated in
murine models of FXS [57]. A recent study
found that lithium administration increased inhibitory phosphorylation of GSK-3 isoforms, reduced audiogenic seizure activity, and improved
performance on open field, elevated plus maze,
and passive avoidance tests in Fmr1 knockout
(KO) mice, and passive avoidance tests [52].
Fmr1 KO mice also display impaired sociability.
Mines et al. (2010) found that GSK-3 inhibition
with lithium improved the previously impaired
social interaction of Fmr1 KO mice with a novel
mouse [58].
GSK-3 activity is also associated with mGluR5 in
that mGluR5 normally activates the PI3K/Akt
pathway, which induces inhibitory phosphorylation of GSK-3. However, it has been shown that
mGluR5 signaling and GSK-3 activities are both
elevated in Fmr1 KO mice [57]. A study utilizing
both lithium and the mGluR inhibitor 2-methyl-6phenylethynyl-pyridine (MPEP) found that the
inhibition of mGluR also led to the inhibition of
GSK-3. Both treatments led to decreased audiogenic seizure activity and improvement on open
field tests. However, treatment with both lithium
and MPEP did not have an additive effect, suggesting that the pharmacologic agents may target the same signaling pathway.
Likewise, long-term depression has been found
to be increased in Fmr1 KO mice [60]. One
study found that Fmr1 knockout mice displayed
less fear memory in contextual fear conditioning
than wild-type mice and decreased long-term
potentiation (LTP) in the anterior cingulated cortex and lateral amygdala (areas important for
associative learning) [61].
Another way in which GSK-3 may be culpable in
the cognitive deficits and altered brain pathology observed in FXS is through regulation of
glycogenolysis. GSK-3 inhibits glycogen synthase, thus reducing glycogenolysis. Inhibition of
glycogenolysis produces learning and memory
deficits. Thus, the increased GSK-3 activity observed in FXS patients and Fmr1 KO mice may
cause intellectual disability through negative
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regulation of glycogenolysis in the CNS.
While it is evident that GSK-3 inhibition has a
therapeutic effect in Fmr1 KO mice and that
GSK-3 plays a role in neuronal morphology and
proliferation, it is not clear whether and to what
extent GSK-3 is responsible for Fragile X neuronal and brain pathogenesis. Further analysis
is required to glean the role of GSK-3 in neurodevelopment in murine models of FXS (Figure
1).
Potential therapy and future directions
FXS is generally believed to be a neuronal disorder due to the aforementioned behavioral and
cognitive deficits and abnormalities in neuron
morphology. Neuronal function is modulated by
an array of immune cells and there is convincing evidence of neuronal dysfunction resulting
from neuroinflammation [41, 42]. Though a role
for immune activation and associated inflammation in autism is controversial [62-64], there
is evidence of activated glia in autism [65-68]
and disregulated plasma cytokines associated
with FXS [21]. Additionally, reactive astrocytes
have been found in many brain regions of Fmr1
knockout mice. This pathology was attenuated
with lithium treatment, providing further evidence of the involvement of GSK-3 in FXS [69].
Another study found that treatment of Fmr1 KO
mice with minocycline (an antibiotic that exerts
anti-inflammatory effects), improved dendritic
spine formation and performance on behavioral
tests [70].
It has been speculated that maternal immune
activation (MIA) may play a role in the development of autism through activation of inflammatory pathways in utero [71]. MIA can negatively
impact fetal brain development and may impair
social behavior [72]. A study of MIA in normal
mice revealed an increase in interleukin-6 (IL-6)
[74]. IL-6 is known to induce phosphorylation of
Janus kinase-2 (Jak2) and signal transducer
and activator of transcription-3 (STAT3), leading
to the release of proinflammatory cytokines,
such as TNF-α and IL-1β. Treatment with the
bioflavonoid diosmin reduced inflammation in
the brain tissue of MIA offspring [72]. Another
study found that GSK-3 and STAT3 enhance
production of IL-6 after immune activation, GSK3 was also found to be critical in the interferon-γ
(IFN-γ)-induced activation of STAT3 [51]. Therefore, it is possible that quelling the inflammatory
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Figure 1. GSK3 regulates a variety of pathways involved in neurodevelopment. Active GSK3 regulates the canonical
Wnt pathway by remaining bound to the Wnt/β-catenin destruction complex that includes APC and Axin. This complex
targets β-catenin for proteasomal degradation. Inhibitory phosyphorylation of GSK3 releases β-catenin from the complex. It is then recruited to the nucleus by TCF/LEF where it induces gene transcription. GSK3β is known to phosphorylate and inhibit Notch, resulting in the inhibition of many Notch target genes. This inhibitory phosphorylation is
reversed when Wnt1 is present. Inhibitory phosphorylation is induced by a number of kinases. The PI3/Akt pathway
regulates GSK-3 activity by inducing inhibitory serine-phosphorylation. FMRP is deficient in Fragile X syndrome and is
normally responsible for regulating mRNA transcription of metabotropic glutamate receptor-5 (mGluR5) and GSK3. It
has been shown that inhibition of mGluR5 leads to the inhibition of GSK3. In addition to regulating neurodevelopmental pathways, it has been shown that GSK3 is also involved in pathways that promote inflammation. GSK3 induces IL-6 production, leading to the subsequent phosphorylation of Jak2/STAT3.

environment through modulation of GSK-3 is a
mechanism by which a therapeutic effect may
be achieved in Fmr1 KO mice.
Another way to accomplish this may be to use
bioflavonoids to inhibit GSK-3 activity. It has
been shown that GSK-3β activity is decreased in
pancreatic cancer cells when they are treated
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with various citrus flavonoids [73, 74]. The impetus for targeting GSK-3 in pancreatic cancer
cells is that GSK-3β is over-expressed in the
nucleus of these cells and causes nuclear factor
-κB (NF-κB) to become active and induce an
inflammatory cascade. Thus, attenuation of the
inflammation leads to decreased cancer cell
proliferation. Treatment with the bioflavonoid
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luteolin has also been shown to reduce amyloid
plaques in a transgenic (Tg2576) mouse model
of Alzheimer’s disease through modulation of
GSK-3α [75]. To date, bioflavonoid-induced inhibition of GSK-3 has not been studied in other
CNS-related disorders.
As noted earlier, lithium has been shown to be
beneficial for Fmr1 KO mice in reducing the
occurrence and severity of audiogenic seizures
and ameliorating behavior deficits. However,
cessation of lithium treatment has led to the
reemergence of the FXS phenotype in Fmr1 KO
mice [76]. Thus, lithium would have to be
chronically administered to patients for the duration of the lifespan. Unfortunately, lithium can
be highly toxic and may not be feasible as a
prophylactic or therapeutic agent for pregnant
mothers or young children [18, 77]. Bioflavonoids and other anti-inflammatory agents that
serve as GSK-3 inhibitors may prove to be more
viable and safe therapeutic options in the future.
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Aims—Implicated in autoimmune encephalitis, neuromyotonia and genetic forms of autism, here
we report that contactin-associated protein-like 2 (CNTNAP2) contains a potential autoepitope
within the extracellular region.
Methodology—CNTNAP2 sequence-similar regions (CSSRs) from human pathogens were
identified. Sera from autistic and control children were obtained and analyzed for the presence of
antibodies able to bind CSSRs. One such candidate CSSR was evaluated for evidence of
autoimmune responses to CNTNAP2 in a mouse model of acute infection.
Results—Autistic and control children sera contained antibodies able to discrete regions of
CNTNAP2. In a murine model of acute infection, a CSSR derived from the N-terminal
extracellular region of CNTNAP2 resulted in anti-CNTNAP2 antibody production,
proinflammatory cytokine elevation, cerebellar and cortical white matter T-cell infiltration as well
as motor dysfunction.
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Conclusion—Taken together, these data suggest that CNTNAP2 contains a potential
autoepitope within the extracellular region.
Keywords
CNTNAP2; Caspr 2; autoantibody; molecular mimicry; autoimmune; autoepitope; autism;
encephalopathy

1. INTRODUCTION
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Molecular mimicry is a process whereby an amino acid sequence-similar region, or shapesimilar region, of a protein or other non-protein compound from an offending pathogen or
other agent induces the production of adaptive immune system elements such as antibodies
and/or T-cell receptors capable of cross-reacting with proteins or other compounds of the
host. This pathological mechanism is thought to be involved in several conditions including:
paraneoplastic cerebellar syndrome [1], autoimmune neuromyotonia [2], multiple sclerosis
and related disorders [3,4], NMDAR encephalitis, and other autoimmune encephalopathies
[5–7] as well as some developmental disorders including autism spectrum disorders [8–12].
Interestingly contactin-associated protein-like 2 (CNTNAP2), also known as Caspr2, is a
member of the neurexin family and the target of autoantibodies thought to result in
autoimmune encephalitis and neuromyotonia [2,13]. Furthermore, CNTNAP2 gene
mutations are associated with autism [14–16]. The CNTNAP2 protein is expressed on
neurons, neural stem cells, and astrocytes and is known to function in potassium channel
clustering on myelinated axons, neuronal migration, membrane excitability, and neuron-glial
interactions [17–19]. In early childhood, inflammatory insults may alter brain development
as significant cross-over exists between molecular signaling pathways critical for brain
development and those involved in immune responses [20–23]. Given its involvement in
autoantibody-mediated neuroinflammatory disease, the investigations presented here
evaluated CNTNAP2 for potential autoepitopes through a bioinformatics approach coupled
with characterization of human CNTNAP2 binding antibodies from autistic and non-autistic
children, and evaluation of a pathogen protein with similar linear protein sequences to
human CNTNAP2 in a mouse model of acute infection.
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2. METHODOLOGY
2.1 Cell Culture
Murine neuroblastoma cells (N2a) were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and were cultured in Dulbecco’s minimum essential
medium (DMEM, Life Technologies, Gaithersburg, MD) with 100 μg/mL penicillin and
streptomycin antibiotics at 5% CO2 and 37°C. N2A cells were induced to differentiate by
addition of 0.3 mM dibuturyl cAMP for 48–72 h. Cells were cultured in 24 or 96 well tissue
culture for experimentation.
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Mouse primary culture neuronal cells were isolated between E16 and E18 from cerebral
cortices of mice subjected to LPS pre-treatment and CSSR3 peptide immunization. Cortices
were incubated for 15 min in 0.25% trypsin at 37°C, and then mechanically dissociated.
Single cells were collected after centrifugation at 290 x g and resuspended in DMEM
supplemented with 10% fetal calf serum, 10% horse serum, uridine (33.4 μg/ml; Sigma) and
fluorodeoxyuridine (13.6 μg/ml; Sigma). Cells were then plated in collagen-coated 24-well
tissue culture plates at 2.5 × 105 cells per well for experimentation.
2.2 Enzyme-Linked Immunosorbent Assays
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CNTNAP2 sequence-similar regions (CSSR) were determined comparing human [NCBI
Reference Sequence: NP_054860.1] and mouse [NCBI Reference Sequence:
NP_001004357.2] CNTNAP2 proteins [24] against non-redundant protein sequences from
available bacterial and viral protein databases using the Protein-Basic Local Alignment
Search Tool (BLAST) [25] (Step 1). Resulting CSSRs (Table 1) at least 5 amino acids (aa)
in length, within the predicted extracellular region of both human and murine CNTNAP2,
were further analyzed by a battery of B-cell epitope prediction software tools [26–28] (Step
2). From those, only known human pathogens (bacterial or viral only) proteins were selected
and then further analyzed based on linear protein sequence similarity with known B-cell
epitopes [29] (Step 3). The final CSSRs from Step 3 were selected a priori and synthetic
peptides (Table 2) were designed to contain a given CSSR flanked by sufficient amino-acids
from human CNTNAP2 so as to generate peptides 8 amino acids in length.
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A region of human CNTNAP2 at amino acids (aa) 41–49, not containing sequence similarity
with the final CSSR peptides, was selected as a peptide control. Antibody titers were
quantified using ELISA whereby individual CSSR peptides were first diluted to 1 μg/mL in
50 mM carbonate buffer (pH 9.6) and then used to coat 96-well plates at 100μL per well for
18 h at 4°C. Plates were next washed 5 times with phosphate buffered saline (PBS), 0.05%
TWEEN-20, at pH 7.4 (wash buffer). Wells were blocked with 1% bovine serum albumin
(BSA) and 5% horse serum in PBS for 2 h at room temperature. Following blocking, the
plates were washed 5 times with wash buffer. Sera samples from autistic and control
children (Table 3) were diluted (1:100) with 1% BSA in PBS.
Samples and standards were incubated in plate for 2 h at room temperature. After this
incubation, the plates were washed 5 times with wash buffer, secondary antibody (antihuman IgG conjugated with HRP, produced in rabbit, 1:5000 dilution) incubation was
conducted for 2 h at room temperature then 5 further washes with wash buffer and finally
Br J Med Med Res. Author manuscript; available in PMC 2014 January 22.
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the plates were developed with tetramethylbenzidine substrate-chromogen (Dako,
Carpinteria, CA, USA). The reaction was stopped with 2 N sulfuric acid and the plates were
analyzed spectrophotometrically at 450 nm. Commercially available ELISA kits were used
to measure tumor necrosis factor-α (TNFα; eBioscience, San Diego, CA) and interferon-γ
(IFNγ; R&D Systems, Minneapolis, MN) levels in mouse sera and brain tissues.
Experiments were performed according to manufacturers’ instructions.
2.3 Cytotoxicity Assay
Sera from individual mice were pooled together based on treatment group after isolation.
Next 10 μL was diluted (1:100) in culture media and then incubated with N2a cells in 96
well plate for 24 h with and without 1 hour pre-incubation with CSSR3 or CNTNAP2 ctrl
peptides (5 μg/mL). Media were then collected and analyzed for lactate dehydrogenase
(LDH) release (Sigma) according to the manufacturer’s instructions.
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2.4 Mouse Husbandry and Treatment
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Wild-type C57BL/6 mice were purchased (Jackson Laboratories, Bar Harbor, ME) and
housed in a 12-h light-dark cycle. Mice (4 week old, n = 8, 4♀/4♂ per group, 6 groups, total
54 mice) were treated via intraperitoneal (i.p.) injection with PBS or LPS (10 μg/mouse);
and with and without immunization against (200 μg/mouse) synthetic peptides including
pathogen peptide (NCBI Reference Sequence: NP_880571.1, filamentous hemagglutinin
protein from Bordetella pertussis, 3034–3053 aa, sequence
AGTSVDAANVSIDAGKDLNL) containing CSSR or Control peptide (NCBI Reference
Sequence: NP_054860.1, CNTNAP2 31–50 aa, sequence TSQKCDEPLVSGLPHVAFSS);
a portion of CNTNAP2 found not to have significant linear protein sequence similarity to
known human bacterial or viral pathogen proteins. All treatments were repeated after one
week.
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For tissue collection, mice were anesthetized using gaseous isoflourane. Blood was collected
from the right ventricle of the heart and immediately placed into tubes containing 0.5 M
EDTA (BD Biosciences, San Jose, CA). Mice were transcardially perfused with cold 0.01 M
PBS (pH 7.4) and brains were rapidly removed and sagittally bisected. Left hemispheres
were separated into cerebrum and cerebellum regions before homogenization in 1 X lysis
buffer (Cell Signaling, Boston, MA) with 1% PMSF (Sigma), centrifuged at 14,000 rpm for
15 min and stored at −80°C. Right hemispheres were fixed overnight with 4%
paraformaldehyde and cryoprotected in a graded series of 10%, 20% and 30% sucrose
solutions, each overnight at 4°C. Right hemispheres were then embedded in Neg50 frozen
section medium (Richard-Allan Scientific, Kalamazoo, MI), and coronally sectioned on a
Microm HM 550 cryostat (Thermo Scientific, Richard-Allan Scientific, Kalamazoo, MI) at
25 μm thickness. Free-floating sections were preserved in PBS containing 100 mM sodium
azide at 4°C. All experiments and tissue collection were conducted in accordance with the
institutional guidelines and were approved by the University of South Florida Institutional
Animal Care and Use Committee.
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2.5 Immunohistochemistry
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Mouse brain tissue sections were washed in PBS, blocked in 5% horse serum/PBS for 1 h at
room temperature and incubated with primary antibodies against CD3 or CD4 (rat, 1:1,000)
overnight at 4°C in blocking solution. Sections were then washed and incubated for 1 h with
biotinylated secondary antibody (anti-rat, 1:200) that was viewed by the ABC kit (Vector
Laboratories) with diaminobenzidine (DAB). Slides were counterstained with hematoxylin.
Images were obtained using an Olympus BX-51 microscope.
2.6 Motor Function Analysis

Author Manuscript

Motor coordination and balance were tested by placing each mouse on a rotating drum
(RotaRod, UgoBasile, Stoelting, Wood Dale, IL) stationary and during acceleration from 0
to 40 rpms over a 5 minute period. Six mice per trial were randomly evaluated by a
technician blinded to their identities. Each mouse was subjected to this task 5 times with a
30-min interval between each trial on RotaRod. All mice were tested on the same day.
2.7 Human Sera Samples
Sera from autistic (n = 26) and non-autistic children (n = 18) aged 3–11 years (Table 3) were
obtained from the Autism Genetic Research Exchange (AGRE) [30]. Approval for study
involving these specimens was granted by the institutional review boards of the University
of South Florida, Morsani College of Medicine and AGRE. Autism diagnosis was
determined using the Autism Diagnostic Interview - Revised (ADI-R) [31].
2.8 Statistical Analyses
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All data were normally distributed; therefore, in instances of single mean comparisons,
Levene’s test for equality of variances followed by t-test for independent samples was used
to assess significance. In instances of multiple mean comparisons, analysis of variance
(ANOVA) was used, followed by post-hoc comparison using Bonferonni’s method. Alpha
levels were set at .05 for all analyses. The statistical package for the social sciences release
18 (SPSS, Chicago, IL) was used for all data analysis.

3. RESULTS AND DISCUSSION
3.1 CSSR of Proteins from Human Pathogens
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Molecular mimicry is a well-known phenomenon known to underpin many disorders. To
test the hypothesis that linear protein sequences from known human viral and bacterial
pathogens could be useful in predicting potential autoepitopes on human CNTNAP2 we
screened for CSSRs by comparison of human and mouse CNTNAP2 proteins against known
bacterial and viral protein databases using NCBI Protein-BLAST [25] (Table 1). The
candidate CSSR had to be at least 5 aa in length, within the predicted extracellular region of
both human and murine CNTNAP2, be within a predicted B-cell epitope [26–28], and be
from a known human pathogen. The final 8 aa peptides containing CSSRs were lastly
selected a priori for further evaluation (Table 2).
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3.2 CNTNAP2-binding Antibodies in Sera from Children with Autism and Non-autistic
Controls
Sera from children 3–11 years of age with autistic disorder (n = 26), and non-autistic
controls (n = 18), were obtained (Table 3) and screened by ELISA for the presence of
antibodies against 8 aa peptide targets of CNTNAP2 (Table 2) containing sequencesimilarity with proteins from known human pathogens. Compared with the CNTNAP2
control peptide target, significant elevations in antibody binding were only observed to
CSSR3 and CSSR4 in those with autism (Fig. 1). Although pathogen exposure profiles of
the individuals are unknown and the groups are characteristically dissimilar (Table 3) these
observations suggested that some children have circulating antibodies able to bind regions of
CNTNAP2 that are sequence-similar to proteins from known human pathogens.
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3.3 CNTNAP2 Binding Antibodies Generated in Mice Pre-injected with LPS and Immunized
with a Pathogen Peptide Containing the CSSR
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Next, given that some children displayed elevations in serum antibody binding to its target
sequence CSSR3 was selected for functional characterization in a mouse model of acute
infection. Four-week-old mice C57BL/6 mice were subjected to PBS or LPS pre-treatment
(10 μg/mouse) 2 days prior to immunization with a 20 aa peptide from pathogen peptide
containing the CSSR (PPC) or control peptide (a portion of CNTNAP2 found not to have
significant linear protein sequence similarity to known human bacterial or viral pathogen
proteins). The same procedure was repeated one week later and mice were sacrificed after
motor function testing; at approximately 8 weeks. Only those mice treated with both LPS
pre-treatment and PPC expressed significantly elevated levels of antibodies able to bind the
CSSR3 peptide (Fig. 2B) by ELISA. This suggested that in mice a peptide derived from a
pathogen protein with a CSSR could induce the generation of antibodies binding the
analogous region of CNTNAP2 with LPS pretreatment. As expected, LPS pre-treatment was
associated with serum TNFα elevations (Fig. 2A).
3.4 CSSR3 Peptide Binding Antibodies Injure Neuronal Cells
To further characterize the functional effects of CSSR3 binding, the pooled sera from the
same mice were further analyzed through incubation with neuronal cells to monitor cell
death by LDH release over 24 h. Sera from the PPC treated group pre-treated with LPS, but
not sera from the group treated with PPC alone or control peptide with or without LPS-pretreatment, displayed significant elevations in LDH release by differentiated neuron-like N2a
cells (Fig. 3A) and murine primary culture neurons (Fig. 3B).
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The LDH release of the sera from mice subjected to PPC immunization and LPS pretreatment could be mitigated by pre-mixing the sera, prior to incubation with neuronal cells,
with the CSSR3 peptide but not the CNTNAP2 ctrl peptide (Fig. 3C). These observations
suggested that CSSR3 binding antibodies produced in mice pre-treated with LPS displayed
neurotoxic properties dependent on their ability to bind a specific extracellular region of
murine CNTNAP2 (545–550 aa).
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3.5 Elevations in CD3+ Cells in Brains of Mice Treated with LPS and PPC
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Several brain regions were evaluated by immunohistochemistry (IHC) for CD3+
immunoreactivity. Although no differences were observed between the groups in the
analyzed regions of cortical gray matter (Fig. 4A), mice subjected to LPS pre-treatment and
immunization with PPC displayed increased cortical white matter as well as cerebellar
CD3+ (Fig. 4B) and CD4+ immunoreactivity (data not shown); whereas other groups
displayed predominately blood vessel associated T-cell CD3+ and CD4+ immunoreactivity.
3.6 IFNγ and TNFα Elevations in Brains of Mice Treated with LPS and PPC
Furthermore, dramatic elevations in central nervous system (CNS) levels of IFNγ (Fig. 5A)
and TNFα (Fig. 5B) cytokines were observed in the LPS pre-treatment and PPC group
compared with the LPS pre-treatment/control peptide group.
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3.7 LPS and PPC Treatment Results in Abnormal Motor Function in Mice
Observations of elevations in CNTNAP2 autoantibodies have been made in some patients
[13]; although often associated with muscular hyperactivity, including spasm, rigidity, and
myotonia, fatigue and exercise intolerance are also frequently observed. Thus, the same
C57BL/6 mice, 3 weeks after last treatment, prior to sacrifice, were evaluated for fatigue and
exercise intolerance by RotoRod analysis. Mice in the LPS pre-treatment, PPC
immunization group displayed significantly greater fatigue and exercise intolerance during
RotoRod analysis including shorter times before falling from a stationary RotoRod (Fig. 6A)
and shorter times before falling from an accelerating RotoRod (Fig. 6B) compared with
other groups evaluated.
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Autoantibodies observed in cases of autoimmune encephalitis and/or neuromyotonia have
not been shown to involve binding to the region of CNTNAP2 characterized here (545–550
aa) and to our knowledge this is the first study to screen for potential autoantigenic regions
of CNTNAP2 using the methods presented here. Known to be associated with immune
system dysregulation [8–11,22,32–34], subsets of children with autism tended to display
elevations of serum antibody binding to CSSR3 and CSSR4 (Fig. 1) compared with nonautistic children; however these data are hampered by the dissimilarity of non-CNTNAP2
binding antibody variables between the two groups evaluated (Table 3) and the unknown or
incomplete medical histories of the patients.
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Despite the relatively small region of similarity the 6 aa long CSSR of the PPC fulfills
known requirements for antigen function [35–37]. The PPC was used to immunize mice pretreated with LPS to further characterize the autoantigenic potential of a small segment (545–
550 aa) of the extracellular region of human and murine CNTNAP2. This treatment was
associated with elevations in antibodies able to bind the analogous region of CNTNAP2
(Fig. 2), CD3+ and CD4+ (data not shown) cells and inflammatory cytokines in CNS tissues
(Fig. 4, 5) and motor dysfunction (Fig. 6); only in the presence of LPS pre-treatment. LPS
and PPC treated mice showed signs of an encephalitis-like reaction with increased
parenchymal cortical white matter as well as cerebellar CD3+ (Fig. 4B) and CD4+
immunoreactivity (data not shown); whereas without the combination of LPS and PPC the
pattern was that of blood vessel associated T-cell CD3+ and CD4+ immunoreactivity;
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similar to untreated controls. These data together suggest that only in the presence of strong
inflammatory responses, mimicking acute gram-negative bacterial infection driven by LPS,
was immune tolerance to the CNTNAP2 self-antigen able to be broken.
Whereas in 4–8 week old mice treatment with LPS and PPC lead to encephalitis-like
responses and motor dysfunction, it is tempting to speculate whether earlier exposure,
perhaps in utero, would lead to more profound immune and nervous system dysfunction and
abnormal development. In light of the key role of CNTNAP2 in neuronal activation,
migration and neural-glial interactions [18,19,38] further studies are needed to determine
whether anti-CNTNAP2-mediated encephalopathy, if occurring during critical widows of
brain development, could represent a significant risk factor for abnormal neurodevelopment.
Prior studies present compelling evidence of a role for the immune system in the
pathogenesis of subsets of neurodevelopmental disorders [8–12,22,23,32–34].
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Importantly, the results have significant limitations including that a synthetic linear peptide
representing a small fragment of CNTNAP2, not in its native form, was used to immunize
and evaluate the effects of the CSSR in mice and detect CSSR-binding antibodies in human
samples. Although the antibodies binding to CSSR3 generated by LPS and PPC
pretreatment appeared to bind CNTNAP2 in its native form on neuronal cells (Fig. 3), it
remains to be determined whether the extracellular region of (545–550aa) CNTNAP2
analogous to the PPC would be available for antibody binding in its native conformation in
humans. Further, the human sample data contained within the present study is significantly
limited by the small sample size and dissimilarity between groups as well as the lack of or
incomplete medical histories. Further complete immunological characterization of the
evaluated mice was not completed prior or after LPS and PPC treatment.
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4. CONCLUSION
CNTNAP2 contains a potential autoepitope within the extracellular region.

5. FUTURE DIRECTIONS
Molecular mimicry is implicated in neurological disorders associated with anti-CNTNAP2
antibodies. Analysis of the relative affinity of antibodies from patients with autistic disorder
binding to the 545–550 aa region of CNTNAP2 against antisera from mice immunized using
the same region as well as analysis of antibody affinity-to-neurotoxicity relationships and
visualized regional binding characteristics on human neurons could support the hypotheses
that antibodies binding to the 545–550 aa region of CNTNAP2 are causative in human
neurological disorders.
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ADI-R

Autism Diagnostic Interview, Revised

ANOVA

Analysis of variance

BLAST

The Basic Local Alignment Search Tool

Caspr2

contactin-associated protein-like 2

CD3

cluster of differentiation 3

CD4

cluster of differentiation 4

CNS

central nervous system

CNTNAP2

contactin associated protein-like 2

CSSR

CNTNAP2 sequence similar region

DAB

3,3′-diaminobenzidine

EDTA

Ethylenediaminetetraacetic acid

h

hour(s)

IFNγ

interferon-gamma

IgG

immunoglobulin G

i.p

intraperitoneal

LDH

lactose dehydrogenase

LPS

lipopolysaccharide

M

molarity

N

Normality

NCBI

National Center for Biotechnology Information

PBS

phosphate buffered saline

PMSF

phenylmethylsulfonyl fluoride

PPC

pathogen peptide containing CSSR

TNFα

tumor necrosis factor-alpha
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CNTNAP2-binding antibodies in sera from children with autism and non-autistic controls.
Levels of serum antibodies binding to 8 aa CNTNAP2 autoantibody detection peptides
containing analogous CSSR sequence from corresponding pathogen proteins (Table 2) were
screened by ELISA. Each dot represents a mean optical density reading (O. D.; 450 nm;
1:100 dilution) for each individual (n = 26 for autistic children; n = 18 for non-autistic
controls) for a respective level of serum antibodies binding to a given CNTNAP2
autoantibody detection peptide (CR). Levels of CSSR3 (CR3) and CSSR4 (CR4)
autoantibody titers were significantly elevated in children with autism compared with nonautistic control sera (P < .05). There were no significant differences in autoantibody titer
binding to other CNTNAP2 autoantibody detection peptides compared to CNTNAP2 control
peptide (P > .05)
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CNTNAP2 binding antibodies generated in mice pre-injected with LPS and immunized with
PPC. Wild-type C56BL/6 (WT) mice (4 week old, n = 8, 4♀/4♂ per group) intraperitoneally
(i.p.) injected with PBS or LPS (10 μg/mouse) with and without control peptide (Ctrl) or
PPC (200 μg/mouse) immunizations. The same procedure was repeated one week later.
ELISA for TNFα (A) and CSSR3 binding antibody titer (B) were determined 3 weeks after
last immunization. The results are presented as mean ± SD of TNFα (pg/mL) for (A) and
mean ± SD of O.D. reading at 1:100 dilution for (B). ***P <.001
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Fig. 3.
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CSSR3 peptide binding antibodies injure neuronal cells. Pooled sera from control and PPC
immunized groups were collected 3 weeks after last immunization (8 week old, n = 8,
4♀/4♂ per group) and used to treat differentiated N2a cells (A) and mouse primary neuronal
cells (B) for 24 h and analyzed by LDH assay. Data are presented as mean ± SD of LDH
release (%) from each incubated group normalized by total cellular protein. (C) Mouse
primary neuronal cells incubated with sera from “control mice” (immunized with Ctrl
peptide + LPS pre-injection) or “PPC mice” (immunized with PPC + LPS pre-injection) for
24 hours with and without pre-incubation with CSSR3 or CNTNAP2 ctrl peptides (5 μg/mL)
for 1 h at 37°C. Ctrl sera, the pooled serum from “control mice.” Ctrl sera/CSSR3, pooled
serum from “control mice” pre-incubated with CSSR3 peptide. Ctrl sera/CNTNAP2 ctrl,
pooled serum from “control mice” pre-incubated with CNTNAP2 ctrl peptide. Sera, the
pooled serum from the PPC mice. Sera/CSSR3, the pooled serum from the PPC mice preincubated with CSSR3 peptide. Sera/CNTNAP2 ctrl, the pooled serum from the PPC mice
pre-incubated with CNTNAP2 ctrl peptide
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Elevations in CD3+ cells in brains of mice treated with LPS and PPC. (A) Representative
gray matter cortical regions from mice immunized with control peptide (Ctrl) or PPC
peptide with pre-treatment with LPS (8 week old, n = 8, 4♀/4♂ per group). Significant
CD3+ T-cell infiltration was not observed in the areas of cortical gray matter analyzed in
either group. (B) Representative cortical cerebellar and cortical white matter regions from
mice immunized with Ctrl peptide or PPC with LPS pre-treatment. Mice that received LPS
pre-injection and were immunized with PPC peptide displayed CD3+ T-cell infiltration in
the cerebellum and cortical white matter. Mice immunized with Ctrl peptide + LPS preinjection did not display CD3+ T-cell infiltration in these regions
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IFNγ and TNFα elevations in brains of mice treated with LPS and PPC. Mouse brain tissue
homogenates (8 week old, n = 8, 4♀/4♂ per group) were evaluated for IFNγ (A) and TNFα
(B) by ELISA. The results are presented as mean ± SD of brain IFNγ or TNFα (pg/mg total
protein). Both cytokines were not detectable in brain tissues from other control groups (data
not shown). *P< .05; **P< .005; **P< .001
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Fig. 6.

LPS and PPC treatment results in abnormal motor function in mice. Wild-type C56BL/6
mice were immunized with PPC or control peptide (Ctrl) with LPS or PBS pre-treatment
and subjected motor function testing (8 week old, n = 8, 4♀/4♂ per group). Motor balance
analysis was conducted using RotoRod. (A) Time before falling from a stationary RotoRod.
(B) Time before falling off an accelerating RotoRod. Results are presented as mean ± SD
from five trials. ***P <.001
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105 LKLDHYP 111
138 PWHLD 142
775 ARYVR 779
79YYCNCD 85
205 GRIGL 209
8 LVFSH 12
3041 ANVSID 3046
490 GCMES 494
493 GCMESI 498
919 YSQLF 923
1308 ARYVR 1312
1072 ARYVRI 1077
91 NQDLF 95
2004 SSFTT 2008
105 LKLDHYP 111
214 WHLDH 218
125 FLKLD 129
1134 VSYHLP 1139
421 PYHQD 425
278 KKAKL 282
131 YYCNCD 136

[YP_006827301.1] ABC transporter, Bacillus thuringiensis

[WP_006006950.1] aminotransferase, Desulfovibriopiger

[YP_005986680.1] beta-N-acetylhexosaminidase, Propionibacterium acnes

[WP_005989682.1] DNA/RNA helicase, Desulfovibrioafricanus

[NP_880571.1] filamentous hemagglutinin/adhesin, Bordetella pertussis

[NP_880571.1] filamentous hemagglutinin/adhesin, Bordetella pertussis

[NP_880571.1] filamentous hemagglutinin/adhesin, Bordetella pertussis

[ABX58360.1] hemagglutinin, Influenza A virus

[ADI46314.1] hemagglutinin, Influenza A virus

[WP_002570578.1] hypothetical protein, Clostridium bolteae

[WP_004614047.1] hypothetical protein, Clostridium nexile*

[WP_010496242.1] hypothetical protein, Paenibacilluselgii*

[AAF85674.1] large protein, Measles virus

[AAL83746.1] large protein, Mumps virus

[WP_001175565.1] NADH oxidase, Bacillus cereus

[O40955] non-structural polyprotein p200, Rubella virus

[AAG31334.1] ORF 169b, Lactobacillus phage mv4*

[WP_006763014.1] outer membrane protein, Burkholderia dolosa

[WP_002571612.1] polysaccharide deacetylase, Clostridium bolteae

[ABV01075.1] polymerase PB1, Influenza A virus

[YP_005052428.1] SNF2-related protein, Desulfovibrio africanus

800 YYCNCD 805

241 KKAKL 245

126 PYHQD 130

1134 VSYHLP 1139

1125 FLKLD 1129

1231 WHLDH 1235

1127 LKLDHYP 1133

1068 SSFTT 1072

391 NQDLF 395

156 ARYVRI 161

156 ARYVR 160

220 YSQLF 224

335 GCMESI 340

335 GCMES 339

545 ANVSID 550

410 LVFSH 414

170 GRIGL 174

800 YYCNCD 805

156 ARYVR 160

1230 PWHLD 1234

1127 LKLDHYP 1133

Human CNTNAP2

Not recognized as direct human pathogens.

*

Peptide sequences are identified by National Center for Biotechnology Information (NCBI) or GenBank accession numbers.

Pathogen Sequence

Protein

CSSRs from proteins from human viral and bacterial pathogens
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CNTNAP2 Autoantibody Detection Peptides
Pathogen NCBI accession #, peptide name

Peptide sequence

Human CNTNAP2 location

[NP_880571.1], CSSR1

GEGRIGLR

CNTNAP2-170

[NP_880571.1], CSSR2

GLLVFSHF

CNTNAP2-410

[NP_880571.1], CSSR3

FANVSIDM

CNTNAP2-545

[AAF85674.1], CSSR4

RLNQDLFS

CNTNAP2-391

[AAL83746.1], CSSR5

YISSFTTD

CNTNAP2-1068

[O40955], CSSR6

DPWHLDHL

CNTNAP2-1231

[NP_054860.1], CNTNAP2 Control

SGLPHVAF

CNTNAP2-41
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Characteristics of control and autistic children
Controls (n=18)

Autism (n=26)

p value

Female (%)

44.44

15.39

p<.01

Age (years)

5.71±1.42

4.00±1.366

p<.001
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GFAP Expression and Social Deficits
in Transgenic Mice Overexpressing
Human sAPPa
Antoinette R. Bailey,1,2 Huayan Hou,1,2 Min Song,1,2 Demian F. Obregon,1,2
Samantha Portis,1,2 Steven Barger,3 Doug Shytle,4 Saundra Stock,2 Takashi Mori,5,6
Paul G. Sanberg,4 Tanya Murphy,7 and Jun Tan1,2
Autistic individuals display impaired social interactions and language, and restricted, stereotyped behaviors. Elevated levels of
secreted amyloid precursor protein-alpha (sAPPa), the product of a-secretase cleavage of APP, are found in the plasma of
some individuals with autism. The sAPPa protein is neurotrophic and neuroprotective and recently showed a correlation to
glial differentiation in human neural stem cells (NSCs) via the IL-6 pathway. Considering evidence of gliosis in postmortem
autistic brains, we hypothesized that subsets of patients with autism would exhibit elevations in CNS sAPPa and mice generated to mimic this observation would display markers suggestive of gliosis and autism-like behavior. Elevations in sAPPa levels
were observed in brains of autistic patients compared to controls. Transgenic mice engineered to overexpress human sAPPa
(TgsAPPa mice) displayed hypoactivity, impaired sociability, increased brain glial fibrillary acidic protein (GFAP) expression,
and altered Notch1 and IL-6 levels. NSCs isolated from TgsAPPa mice, and those derived from wild-type mice treated with
sAPPa, displayed suppressed b-tubulin III and elevated GFAP expression. These results suggest that elevations in brain sAPPa
levels are observed in subsets of individuals with autism and TgsAPPa mice display signs suggestive of gliosis and behavioral
impairment.
GLIA 2013;61:1556–1569

Key words: sAPPa, astrogliosis, autism, behavior, IL-6, Notch

Introduction

A

utism is a heterogeneous neurodevelopmental disorder
characterized by impaired communication, social interaction, and restricted, repetitive behaviors and interests (APA,
2000; Steyaert and De la Marche, 2008). Patients with autism
exhibit varied patterns of aberrant neuroanatomical and
immunological features in addition to behavioral phenotypes
(Bailey et al., 1998; Bauman and Kemper, 2005; Casanova
et al., 2006; Amaral et al., 2008). Brain overgrowth followed
by decelerated development is frequently observed in some
autistic patients. This neuropathology is observed early in the

developmental course and is thought to involve defects in the
normal “pruning” of early neural network arbors. After proliferation and dendritic arbor formation, pruning and programmed cell death are highly regulated multifactorial
processes dependent on ordered molecular and cellular interactions involving various players including neural stem cells
(NSCs), astrocytes, and microglia.
Typically, glial cells are generated after neurogenesis in the
CNS (Sofroniew and Vinters 2010). The full complement of
neurons appears during the embryonic period while most gliogenesis occurs within the first month after birth (Jacobson,
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1991). Besides this sequential schedule of NSC differentiation,
astrogliogenesis can be prematurely induced. In murine embryonic Day 15 (E15) NSC cultures, treatment with IL-6 family
proteins that stimulate glycoprotein 130 (gp130) and activate
the Janus kinase-signal transducers and activators of transcription (JAK/STAT) pathway (Marz et al., 1999; Taga and
Fukuda, 2005), led to the upregulation of the astrocyte marker
glial fibrillary acidic protein (GFAP) (Bonni et al., 1997;
Deverman and Patterson, 2009; Kirsch et al., 2010).
The gp130 pathway cooperates with the Notch1 pathway, which also enhances NSC commitment to glial fate by
suppressing neuronal differentiation (Bhattacharya et al.,
2008; Sugaya, 2008; Rodriguez-Rivera et al., 2009). There is
also evidence of crosstalk between the Notch1 and gp130
pathways as increased Hairy and enhancer of split (Hes),
resulting from Notch1 activation, promotes phosphorylation
of signal transducer and activator of transcription 3 (STAT3),
a transcription factor for GFAP (Grandbarbe et al., 2003;
Nagao et al., 2007).
Given that astrocytes are important for synaptic pruning
during development, promotion of astrocytic differentiation
and abnormal glial activation or gliosis appears sufficient to
affect neurodevelopment (Oland and Tolbert, 2011; Stephan
et al., 2012). Several studies give evidence for gliosis in different brain regions of autistic patients (Ahlsen et al., 1993;
Sabaratnam, 2000; Laurence and Fatemi, 2005; Vargas et al.,
2005). How abnormal cellular, inflammatory, and neurotropic
signals align leading to excessive, aberrant dendritic connectivity via impaired pruning in autistic individuals is still unclear.
The amyloid precursor protein (APP) is a single-pass
transmembrane glycoprotein consisting of 695–770 amino
acids and existing in three main isoforms (Selkoe et al., 1988;
Turner et al., 2003). APP is processed according to two separate pathways that produce different protein fragments. Protein processing by the amyloidogenic pathway produces,
among other fragments, the amyloid-b peptides which constitute the cytotoxic plaques characteristic of Alzheimer’s disease
(AD) pathology (Mattson, 1997; De Strooper and Annaert,
2000). Conversely, the nonamyloidogenic pathway produces
secreted APPa (sAPPa), the a-C-terminal fragment (a-CTF)
and others (Mattson, 1997; De Strooper and Annaert, 2000).
In addition to many reported physiological functions of holoAPP, the peptide fragments each have distinct roles in a variety of cellular processes occurring in the brain and other
organs (Turner et al., 2003). Numerous reports of sAPPa
potentiating neurite outgrowth, preventing neuronal death
and aiding in NSC proliferation confirm its neurotrophic and
neuroprotective properties (Furukawa and Mattson, 1998; Fu
et al., 2002; Copanaki et al., 2010). Further, studies in isolated human NSCs suggest that sAPPa may promote astroglial cell-fate (Kwak et al., 2006a,b) via the IL-6/gp130
signaling pathway (Kwak et al., 2010).
September 2013

TABLE 1: Study Populations Characteristics

Characteristic

Autism

n

Control

P

6

8

Age, mean (6SD)

7.4 (2.2)

7.2 (2.5)

0.46

Gender, n (% female)

1 (16.7)

3 (37.5)

0.22

3 (50)

3 (37.5)

0.34

19.3 (7.4)

17.9 (8.7)

0.39

Nonwhite, n (%)
Postmortem interval,
mean hours (6SD)

In light of the role of sAPPa in CNS development, and
recent studies demonstrating elevations of sAPPa in the
plasma of autistic children (Sokol et al., 2006; Ray et al.,
2011), we hypothesized that autism patient subsets would
exhibit elevations in brain sAPPa and mice designed to overexpress human sAPPa in brain tissues would reveal signs suggestive of gliosis and autism-like behavior.

Materials and Methods
Human Sample Preparation
Postmortem specimens from the insular cortex brain region of 8 normally developed controls and 6 autism patients (Table 1) were
obtained from through the Autism Tissue Program from the
National Institute of Child Health and Human Development Brain
and Tissue Bank (NICHD, University of Maryland, Baltimore,
MD). Approval for studies involving these specimens was granted by
the institutional review board of the University of South Florida.
Autism diagnoses were determined using the Autism Diagnostic
Interview - Revised (ADI-R). Human brain samples were homogenized in 1X RIPA buffer (Cell Signaling Technology, Boston, MA)
with 1% PMSF, and centrifuged at 14,000 rpm for 90 min at 4 C
before storage at 280 C. Before use, samples were centrifuged at
14,000 rpm for 2 h at 4 C.

Enzyme-Linked Immunosorbent Assays
Human sAPPa expression in brain homogenates and cultured cells
was quantified using a highly specific assay kit (IBL-America, Minneapolis, MN). Levels of sAPPa were measured for each sample in
duplicate according to manufacturer’s instructions. Commercially
available enzyme-linked immunosorbent assay (ELISA) kits were
used for measurements of IL-6, IL-1b, IL-4, TNFa, and IFN-c
according to manufacturers’ instructions.

Mice and Genotyping
TgsAPPa mice were generated at the H. Lee Moffitt Cancer Center
Animal Core Facility (Tampa, FL) by standard pronuclear injection
using a 1.8 kb genomic fragment transcribing hsAPP-a695 subcloned into a MoPrP.Xho vector (Bailey et al., 2012). Mice were
housed in a 12-h light-dark cycle, and genotyped using quantitative
real-time PCR. All tissue collection and experiments were conducted
in accordance with institutional guidelines and were approved by the
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University of South Florida institutional animal care and use
committee.

Behavioral Tests
Open Field. Spontaneous locomotor activity and anxiety in mice
were assessed in an open field consisting of a 17 inch square arena
with plastic walls and floor evenly illuminated by white light. Each
mouse was placed in the center of the field and allowed to explore
for 10 min. Experiments were video-recorded and total distance traveled as well as time spent in center field was measured using Ethovision behavior analysis software (Noldus Information Technology,
Leesburg, VA).
Social Interaction. Test mice were first habituated to the 22 3
15 inch rectangular, three-chambered polycarbonate box with divider
walls containing doorways allowing access to each chamber for 10
min. Each of the two side chambers contained an empty wire cage
(Galaxy Cup, Spectrum Diversified Designs, Streetsboro, OH) that
was inverted and weighted down. After habituation, test mice were
enclosed in the center and an unfamiliar mouse of the same strain
and gender was enclosed inside one of the wire cages. The location
for the “stranger” mouse was alternated between left and right sides
of the box. Test mice were allowed 10 min to explore. Experiments
were video-recorded and measurements of the time spent in each
chamber during both phases of the task were measured and analyzed
using Ethovision behavior analysis software (Noldus Information
Technology).

Mouse Brain Tissue Isolation and Preparation
Mice were anesthetized using gaseous isoflourane and transcardially
perfused with cold 0.01 M PBS (pH 7.4). Brains were rapidly
removed and sagittally bisected. Left hemispheres were separated
into hippocampus, striatum, cerebellum and cortex regions and each
region was homogenized in 1X lysis buffer (Cell Signaling Technology) with 1% PMSF (Sigma-Aldrich, St. Louis, MO), centrifuged at
14,000 rpm for 15 min and stored at 280 C. Right hemispheres
were fixed overnight with 4% paraformaldehyde and cryoprotected
in a graded series of 10, 20, and 30% sucrose solutions, each overnight at 4 C. Right hemispheres were then embedded in Neg50 frozen section medium (Richard-Allan Scientific, Kalamazoo, MI), and
sectioned sagittally on a Microm HM 550 cryostat (Thermo Scientific, Richard-Allan Scientific, Kalamazoo, MI) at 25 lm thickness.
Free-floating sections were preserved in PBS containing 100 mM
sodium azide at 4 C or PBS with 30% glycerol and 30% ethylene
glycol at 220 C.

Immunohistochemistry
Sections were washed in PBS, blocked in 5% horse serum in PBS
for 1 h at room temperature and incubated overnight at 4 C in
blocking solution containing one of the following antibodies: mouse
monoclonal anti-Ab1-17 (6E10, 1:2,000, Covance Research Products,
Emeryville, CA); mouse monoclonal anti-GFAP (1:500, Cell Signaling Technology) rabbit polyclonal anti-gp130 (1:200, Novus Biologicals, Littleton, CO). Sections were then washed and incubated for 1
h with biotinylated secondary antibody that was developed by the
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ABC kit (Vector Laboratories, Burlingame, CA) with 3,3 diaminobenzidine tetrahydrochloride (DAB, Vector Laboratories). Sections
were mounted on Permafrost slides and dehydrated with 2 min serial
emersions in 95 and 100% anhydrous ethanol and xylene. Some sections were counterstained with 0.1% cresyl violet (Sigma-Aldrich)
for Nissl staining (Zhu et al., 2011).

Western Blotting
Brain homogenates and cell lysates were subjected to SDS-PAGE on
10% glycine gels with Tris-Glycine-SDS buffer (BioRad Laboratories, Hercules, CA) and transferred to 0.45 lm nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ) in Tris-Glycine
buffer. After blocking with 5% milk in 1X TBS, blots were incubated overnight at 4 C with either of the following primary antibodies: mouse
monoclonal anti-Ab1-17 (6E10, 1:1,000, Covance
Research Products); mouse glial fibrillary acidic protein (GFAP)
(1:1,000, Cell Signaling Technology); mouse monoclonal antib-tubulin (1:1,000, Stem Cell Technologies, Tukwila, WA); rabbit
polyclonal anti-APP C terminus (pAb 396, 1:1,000, kindly provided
by S. Gandy and H. Steiner); rabbit polyclonal anti-Notch1
(1:1,000, Epitomics, Burlingame, CA); rabbit polyclonal anti-Notch
1 intercelluar domain (NICD, activated Notch 1) (1:500, Abcam,
Cambridge, MA); rabbit polyclonal anti-gp130 (1:1,000, Merck
Millipore, Darmstadt, Germany); mouse monoclonal anti-b-actin
(1:4,000, Sigma-Aldrich). After washing with ddH2O, blots were
incubated for 1 h at room temperature with one of the following
horseradish peroxidase-conjugated secondary antibodies: horse antimouse IgG-HRP linked (1:1,000, Cell Signaling Technology); goat
anti-rabbit IgG-HRP linked (1:5,000, Cell Signaling Technology).
Blots were developed using Supersignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).

Cell Culture
Cortical primary neurons were isolated from E14 embryos of
heterozygous-bred TgsAPPa dams. TgsAPPa and wild-type (WT)
littermate mouse embryonic brain tissues were mechanically dissociated. Both primary cortical neurons and commercially available
murine neurospheres (Stem Cell Technologies, Tukwila, WA) were
cultured in suspension in DMEM/F12 (Invitrogen, Camarillo, CA)
containing B27 (Invitrogen), 20 ng/mL human epidermal growth
factor (hEGF), and 10 ng/mL fibroblast growth factor (fGF) at
37 C in 5% CO2. Primary neuron cultures from each embryo
remained separate and genotypes were identified from embryo tails
using real time PCR (Bailey et al., 2012). For differentiation, neurospheres were mechanically dissociated and filtered with a 40 lm cell
strainer into single-cell suspensions in DMEM/F12 containing B27,
20 ng/mL hEGF, 10 ng/mL fGF and 10% fetal bovine serum and
plated in 24-well plates (Fisher Scientific) at a concentration of
1x105 cells per well and incubated at 37 C in 5% CO2. Human
HEK293-expressed human sAPPa (hsAPPa) was generated and purified as previously described (Barger et al., 1995; Furukawa et al.,
1996). N2a (murine neuroblastoma) cells (ATCC, Manassas, VA)
were grown in complete EMEM supplemented with 10% fetal calf
serum. Cells were plated in 24-well collagen coating culture plates at
a density of 1x105 cells per well. After overnight incubation, N2a
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cells were incubated in neurobasal media supplemented with 3 mM
dibutyryl cAMP in preparation for treatment. N2a cells stably overexpressing human sAPPa (N2a/sAPPa cells, named 6-1 cell clone)
were generated via liposomal delivery using Lipofectamine 2000
(Invitrogen) of a plasmid (pcDNA3.1-sAPP-a695) containing a
human sAPPa cDNA coding sequence based on the predicted cleavage of the 695 aa isoform of APP (a generous gift from Dr. Steven
Barger, University of Arkansas) into N2a cells followed by G418
(400 lg/mL) selection.

Immunocytochemistry
After 7 days in culture, neurospheres were gently and mechanically
triturated into single-cell suspensions, plated on chamber slides at a
concentration of 20,000 cells per well and incubated for 3–7 days at
37 C in 5% CO2. Cells were fixed with 4% paraformaldehyde
(Fisher Scientific) in phosphate-buffered saline (PBS) for 20 min at
room temperature, permeabilized with 0.2% Triton X-100 for 5 min
at room temperature, blocked in 5% horse serum for 1 h at room
temperature, and incubated overnight at 4 C in 5% horse serum
containing one of the following primary antibodies: monoclonal
anti-b-tubulin (1:1,000, Stem Cell Technologies), mouse monoclonal
anti-GFAP (1:500, Cell Signaling Technology). Cells were then incubated for 30 min at room temperature with fluorescein-conjugated
AlexaFluor 488, AlexaFluor 594, and AlexaFluor 555 secondary antibodies (Fluorescein-conjugated IgGs, Invitrogen) at a dilution of
1:200. Images were acquired on an Olympus FV1000 Confocal
microscope.

Statistical Analysis
Statistical differences between genotype groups were determined
using one-way analysis of variance (ANOVA) for multiple comparisons. Other statistical differences were determined using the Student’s t-test. Statistical analysis for behavioral experiments was
performed using GraphPad5 Analysis software. Analyses were performed on Microsoft Excel software.

corresponding increase in the levels of the APP a-C-terminal
fragment (a-CTF). Patient brain tissue samples were analyzed
by western blot using the polyclonal antibody 396 which
binds the APP C-terminal fragment. The results, along with
densitometric analysis, show significantly increased expression
of the a-CTF fragment in autistic patient brains compared to
normal control brains (Fig. 1C,D). This data suggests that
subsets of autistic patients have elevated brain levels of the
sAPPa and a-CTF fragments of APP, signifying a greater
inclination towards the non-amyloidogenic pathway in patient
brains and a potential role for the associated fragments in the
pathophysiology of autism.
TgsAPPa Mice Have Elevated hsAPPa Levels in the
Brain
To identify the potential role of elevated sAPPa levels on neurodevelopment, our group has studied a transgenic mouse
model that overexpresses human sAPPa in the brain (Bailey
et al., 2012). Brain sections and homogenates from a set of
3-month-old TgsAPPa littermates were studied by immunohistochemistry and Western blotting techniques using the
6E10 antibody which specifically binds human APP at the
Ab1–17 region. Homozygous TgsAPPa (TgsAPPa1/1) mouse
brains stained positive for 6E10 in both the cortex and the
hippocampus, confirming the expression of the human sAPPa
fragment in these brain regions (Fig. 2A). Western blot analysis and ELISA measurements further corroborated the expression of the protein fragment in TgsAPPa mice (Fig. 2B–E),
demonstrating its absence in WT littermates and genotypedependent levels of fragment expression in both cortex
(Fig. 2B,C) and hippocampus (Fig. 2D,E) regions. These
studies confirm the overexpression of hsAPPa in TgsAPPa
mice.

Results
Elevated sAPP-a and a-CTF Levels in Brain Tissues
From Autistic Children
Previous studies report elevated levels of sAPPa in the plasma
of children with severe autism (Ray et al., 2011). Since sAPPa
is an established neurotrophic factor (Mucke et al., 1996;
Turner et al., 2003), concentrations in autistic patient brains
may be affected. A commercially available human sAPPa
ELISA kit was used to measure the sAPPa concentrations in
brain homogenates from autistic patients and controls. Results
show that autistic patient brains contain a significantly
increased level of sAPPa compared to the mean level found in
the brains of normally developed controls (Fig. 1A). The distributions of individual patient sAPPa levels around the means
show that 4 of the 6 autistic patients had sAPPa levels greater
than the mean sAPPa levels of the controls (Fig. 1B).
In light of the nonamyloidogenic processing pathway,
increased levels of sAPPa in the brain should convey a
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Impaired Social Behavior and Hypoactivity in
TgsAPPa Mice
Social interaction deficits, increased anxiety and hypoactivity
are characteristic behaviors of autism patients. To examine
social functioning and motor activity in our transgenic mice,
we used mouse behavioral tests for open field and social interaction (Crawley 2004).
In the open field task, mice were placed in an open box
for 10 min and observed for locomotor activity and time
spent in the center of the field. There was no significant difference between groups in time spent in the center (Fig. 3A);
however, transgenic mice traveled significantly less distance in
the apparatus than WT littermate controls (Fig. 3B), suggesting hypoactivity.
For the social interaction experiment, test mice were
observed for 10 min in a 3-chambered apparatus containing
an empty wire cage on one end and a wire cage enclosing a
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FIGURE 1: Levels of human sAPPa (hsAPPa) and a-CTF are elevated in brain tissues from autistic children. A, B: Human sAPPa (hsAPPa)
levels in brain homogenates from 6 autistic and 8 age-matched typically developed children (see Table 1). A: Data are represented as
mean 6 sd or (B) dot-plot (hsAPPa ng/mg total protein). C: Western blot (WB) analysis shows increased a-CTF levels in autistic children
compared to controls. D: Densitometry analysis showing band density ratios of a-CTF to b-actin. This a-CTF band was further identified
by WB using Ab17–24 antibody, 4G8 (specifically selective for human a-CTF) (data not shown). **P < 0.01; ***P < 0.001.

stranger mouse on the other end. Whereas WT mice (n 5 5)
spent significantly more time in the chamber containing the
stranger mouse than in the chamber with the empty wire
cage, there was no significant difference in the periods of
time that TgsAPPa mice (n 5 4) spent in each of these chambers (Fig. 3C,D). Ratios of time spent with stranger/time
spent with empty wire cage showed a decrease in time spent
with stranger mice by TgsAPPa mice compared to WT littermates. This finding demonstrates a decreased preference for
sociability in TgsAPPa mice compared to WT controls.

of GFAP staining show that there are significantly more
GFAP-positive cells in the hippocampus and entorhinal cortex
of TgsAPPa mice compared to WT controls (Fig. 4C).
Immunohistochemistry findings were verified by Western blot
analysis on cortical and hippocampal brain homogenates and,
as expected, significantly increased GFAP expression was
found in TgsAPPa mice in both regions compared to WT
controls (Fig. 4D). This GFAP increase is also seen in 1month-old and 6-month-old TgsAPPa mice compared to
WT controls (data not shown).

Increased GFAP Expression in Brains of Adult
TgsAPPa Mice
An association between APP and increased GFAP expression
in the brain has been firmly established in studies on patients
suffering from AD and Downs Syndrome (DS) (Jorgensen
et al., 1990; Sugaya et al., 2007). To find out whether the
overexpression of sAPPa was associated with an increase in
this astrocyte marker, brain sections from 3-month-old
TgsAPPa mice and WT controls were subjected to immunohistochemical staining with GFAP (Fig. 4A). Other brain sections from these mice were double stained with GFAP and
Nissl, which identifies cell bodies and delineates morphology
in brain tissues (Fig. 4B). Image analysis and quantification

Increased Glial Differentiation in TgsAPPa Derived
Murine Neuronal Stem Cells
Murine NSCs derived from TgsAPPa and WT E14 embryos
were cultured under differentiating conditions for 3 days.
Using immunofluorescence techniques, these differentiated
stem cells were fixed and stained with antibodies against neuronal marker b-tubulin III and GFAP. Compared to murine
NSCs from WT embryos, there was less b-tubulin III expression and greater GFAP expression in murine NSCs derived
from TgsAPPa embryos (Fig. 5A). Immunofluorescence findings were verified by Western blot analysis on cell lysates prepared from mouse NSCs (Fig. 5B). As expected, significantly
increased GFAP expression was found in TgsAPPa mouse-
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FIGURE 2: Brain expression of human sAPPa (hsAPPa) in the TgsAPPa mouse. A: Brain sections from homozygous TgsAPPa mice stained
with Ab1–17 antibody 6E10. Cortical and hippocampal brain homogenates were prepared from a single family of 3-month-old TgsAPPa
mice and WT (WT) littermates (TgsAPPa1/1, n 5 3; TgsAPPa1/2, n 5 3; WT mice, n 5 2). The hsAPPa levels in cortical (B, C) and hippocampal (D, E) brain homogenates were determined by WB analysis and ELISA. For C and E, data are presented as mean 6 sd (sAPPa ng/mg
total protein). Similar results were also observed in littermates from three different families (data not shown). ***P < 0.001.

derived NSCs (Fig. 5C). The levels of human sAPPa
(hsAPPa) secreted into the media by the murine NSCs from
both groups of mice were measured using a commercially
available ELISA kit. The ELISA results confirmed that the
hsAPPa transgene is expressed in murine NSCs from
TgsAPPa embryos and that the protein fragment is secreted
from these murine NSCs (Fig. 5D). Overall, these results
support the association between sAPPa and increased GFAP
expression in vivo.
Increased Glial Differentiation in Wild-Type Murine
NSCs Treated With Recombinant sAPPa
Murine NSCs were treated with 2 nM concentrations of
recombinant human sAPPa (rhsAPPa) under differentiating
conditions composed of 2% fetal bovine serum (FBS) in
complete culture medium containing growth factors. In three
independent experiments using immunofluorescence staining
after 5 days of culture, enhanced GFAP (green) and suppressed b-tubulin III (red) expression were observed under
these conditions in murine NSCs treated with rhsAPPa compared to NSCs treated with heat-inactivated rhsAPPa (n 5 3
for each culture condition) (Fig. 6A). Western blot analysis
further confirmed this observation (Fig. 6B,C). These results
further suggest that excess sAPPa may promote glial cell fate
in isolated murine NSCs.
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Increased Expression of IL-6, NICD, and gp130
Correlated With Elevated sAPPa Levels
Standard mechanisms of action by which sAPPa achieves its
effects in the brain are still yet to be determined. With these
experiments, we aimed to identify possible signaling pathways
involved in sAPPa function. Previous studies implicate the
IL-6/gp130 pathway and the activity of Notch1 intracellular
domain (NICD, activated Notch1) in glial differentiation of
NSCs (Rodriguez-Rivera et al., 2009; Kwak et al., 2010).
IL-6 concentrations in cortical brain homogenates from 3month-old WT (n 5 4#) and TgsAPPa (n 5 4#) mice were
measured by ELISA. TgsAPPa mice demonstrated a significantly increased mean concentration of IL-6 per milligram of
protein than WT littermates (Fig. 7A). Brain homogenates
were also subjected to Western blot analysis using antibodies
against human sAPPa, gp130, NICD, and b-actin. The blots
exhibited greater protein expression of gp130 and NICD in
the TgsAPPa mice, which verifiably express hsAPPa, compared to WT littermates (Fig. 7B).
To determine whether this effect is specifically due to
the presence of hsAPPa, we transfected N2a neuroblastoma
cells with the hsAPPa gene to create a cell line, named clone
6-1, which overexpresses the hsAPPa protein fragment. Conditioned media from triplicate cultures of each of these two
cell lines were collected 18 h after plating (without treatment)
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FIGURE 3: TgsAPPa mice exhibit hypoactivity and social impairment. A, B: Anxiety and locomotor activity were observed in 3-month-old
TgsAPPa mice (n 5 13) and WT littermates (n 5 12). There was no significant difference between groups in time spent in the center (A).
Transgenic mice traveled significantly less distance compared to WT littermates (B). C, D: Mice were also subjected to social interaction
behavior testing. Mice from groups containing both males and females spent significantly more time in the chamber containing an unfamiliar mouse (stranger) compared to a chamber with an empty wire cage. A comparison of only males in each group showed that, for
TgsAPPa male mice, there was no difference between the times spent in the empty chamber (Empty) and the stranger chamber
(P > 0.05), while littermate control males spent significantly more time in the stranger chamber (**P < 0.01).

and subjected to IL-6 ELISA. The 6-1 cells secreted a significantly higher level of IL-6 than N2a cells under normal culture conditions (Fig. 7C). Lysates from each cell line were
analyzed by Western blot using antibodies against hsAPPa,
gp130, activated Notch1, and b-actin. Results confirm the
successful transfection of the hsAPPa fragment in the 6-1 line
and show increased expression of gp130 and NICD in this
cell line compared to the WT neuroblastoma line (Fig. 7D).
Finally, N2a cells and murine NSCs were treated with
0, 0.5, 1, and 2 nM doses of recombinant hsAPPa (rhsAPPa)
for 24 h. IL-6 concentrations secreted into the media were
measured by ELISA and the cell lysates were subjected to
Western blot analysis using antibodies against gp130, activated Notch1, and b-actin. Although the murine NSCs
secreted notably less IL-6 than the N2a cells, treatment with
rhsAPPa induced both types of cells to secrete increased levels
of IL-6 in a dose-dependent manner (Fig. 7E). Dosedependent increases in gp130 and activated Notch1 were also
evident in cell lysates after treatment with rhsAPPa (Fig. 7F).
In addition, we observed the cortical expression of
gp130 in TgsAPPa mice and WT controls by immunohistochemistry. TgsAPPa mice exhibit increased gp130-positive
staining compared to WT littermates (Fig. 8A,B). As further
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support, mouse brain homogenates were prepared from dissected cortical tissues and subjected to Western blot analysis.
Notably, these results confirmed the increased expression of
gp130 in the cortical region (Fig. 8C).

Discussion
This work reports the discovery of elevated levels of sAPPa
and a-CTF in the insular cortex of autism patients and suggests increased GFAP expression-associated hypoactivity and
social deficits in mice designed to over-express hsAPP in brain
tissues. The work further reveals that the observed GFAP
upregulation is correlated with elevations in IL-6, gp130, and
Notch1. These observations support our hypothesis that subsets of patients with autism exhibit elevations in CNS sAPPa
and mice generated to mimic this observation display markers
suggestive of gliosis and autism-like behavior.
Since the neurotrophic and neuroprotective functions of
the sAPPa fragment are generally accepted, previous studies
revealing the presence of sAPPa in autism patient plasma
raise questions about the association between the APP fragment and autism pathophysiology (Sokol et al., 2006; Bailey
et al., 2012). We discovered, in this study, that autism
patients exhibit elevated levels of sAPPa as well as notable
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FIGURE 4: Increased GFAP expression in brains of adult TgsAPPa mice. A, B: Brain sections from 3-month-old TgsAPPa1/1 mice and WT
littermates were stained with an anti-GFAP antibody (brown). C: Significant increases in the percentage of GFAP immunoreactive astrocytes from TgsAPPa mouse and WT littermate brain sections from hippocampus (top) and entorhinal cortex (bottom) regions (n 5 4$/4#,
per group). D: Entorhinal cortical and hippocampal homogenates subjected to WB analysis of GFAP reveal increased GFAP expression in
both regions from TgsAPPa mice. Similar results also observed in 1- and 6-month-old TgsAPPa mice (data not shown). Data are presented as mean 6 sd. **P < 0.01; ***P < 0.001.

increases in a-CTF compared to controls in a portion of the
insular cortex (Fig. 1) which is part of the gray matter in
the CNS. The insular cortex was selected because it is part of
the neocortex that shows neurobiological abnormalities in
some autistic populations and appears to be involved in language and attention (Bailey et al., 1998; Binstock, 2001).
The initial study proposing this unconventional association
mentioned that the presence of the sAPPa fragment could be
evidence of heightened a-secretase processing (Sokol et al.,
2006); and our findings, particularly the dramatic increase in
a-CTF levels, support this inference.
APP is in fact upregulated in the brain in response to
neural injury, but, as previously mentioned, sAPPa plays a
neuroprotective role (Mattson et al., 1993a). As Table 1
shows, several of the samples from both control and autistic
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cases involve causes of death that could impact brain APP levels. Some of the individual causes of death occur in both
groups of cases, thereby alleviating a potential confounding
variable. For example, a comparison of the levels of a-CTF in
control cases of drowning with the a-CTF level in the autism
case of drowning shows increases in a-CTF expression in the
control cases of drowning compared to control cases
with other causes of death. However, there is an even
greater increase in a-CTF expression within the brain sample
from the autistic case of drowning compared to the control
cases.
Our data confirms that the TgsAPPa mouse we generated
exhibits greater expression of hsAPPa in the cortex and hippocampus regions of the brain compared to WT littermate controls. In light of our observations of the autistic insular cortex,
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FIGURE 5: Suppressed b-tubulin III and elevated GFAP in TgsAPPa-derived murine NSCs. A: Representative photomicrographs of WT littermate and TgsAPPa mouse-derived NSCs under differentiating culture conditions (Day 3) showing increased GFAP (green) and
decreased b-tubulin III (red) expression by immunofluorescence (IF). B: WB analysis of GFAP and b-tubulin III expression in both NSCs. C:
Densitometric analysis revealed increased ratio of GFAP to b-tubulin III in TgsAPPa mouse-derived NSCs compared to WT littermate control. Data presented as mean 6 sd. D: Relative concentrations of sAPPa secreted by WT littermate and TgsAPPa mouse-derived NSCs
measured by ELISA and expressed as ng of sAPPa/mL media. TgsAPPa mouse NSCs secrete significantly greater concentrations of sAPPa
than WT. These results are representative of three independent experiments with each condition triplicated. ***P < 0.001.

the TgsAPPa mice mimic the human condition of elevated
cortical sAPPa levels. We have previously reported that these
mice also demonstrate high sAPPa levels in the plasma (Bailey
et al., 2012), which also mimics the original finding in autism
patient plasma (Sokol et al., 2006). It is worth noting that
hsAPPa in heterozygous TgsAPPa mice is expressed at over 10
times the sAPPa levels we observed in the human condition,
and homozygous mice have over 20 times greater hsAPPa
expression compared to patients studied here. This exaggeration of sAPPa overexpression in the model represents a significant limitation in the translation of the results to the human
condition.
Additionally, TgsAPPa mice demonstrate behavioral
impairments that simulate autistic behaviors in humans. In
addition to impaired social interaction, which is a cardinal
autistic behavioral phenotype, patients have also demonstrated
hypoactivity (Gillberg and Billstedt, 2000; Maestro et al.,
2005; Receveur et al., 2005). TgsAPPa mice exhibit reduced
preference for social interaction, indicating impaired sociability
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(Fig. 3A). Further, in the open field task, TgsAPPa mice demonstrated hypoactive exploratory behavior (Fig. 3C,D). Altogether, the neuropathological and behavioral features of
TgsAPPa mice are suggestive of components of an autism phenotype, however further studies are required to substantiate
sAPPa’s direct causation.
Evidence of increased GFAP and gliosis in autism patients
has been demonstrated in several studies (Bailey et al., 1998;
Sabaratnam, 2000; Casanova, 2006). One study shows that the
level of GFAP in the CSF of autism patients was at almost three
times the level normally developed patients (Ahlsen et al.,
1993). Vargas et al. and Fatemi et al. report increased GFAP
reactions in different regions of autistic patient postmortem
brains, including the middle frontal gyrus and the superior
frontal cortex (Laurence and Fatemi, 2005; Vargas et al., 2005).
These observations in autism patients may be related to the
longstanding theory that astrocytes participate in the brain’s
immune response and indicate tissue damage (Casanova,
2006). Adult TgsAPPa mice demonstrate increased GFAP
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FIGURE 6: Suppressed b-tubulin III and elevated GFAP in WT murine NSCs treated with recombinant human sAPPa (rhsAPPa). A: Representative photomicrographs of murine NSCs treated with 2 nM rhsAPPa protein under differentiating culture conditions (Day 5) revealed
enhanced GFAP (green) and suppressed b-tubulin III (red) expression by IF. B: WB analysis of GFAP and b-tubulin III after rhsAPPa treatment of NSCs. C: Densitometry analysis showed significantly increased ratio of GFAP to b-tubulin III in rhsAPPa treated NSCs compared
with heat-inactivated hsAPPa (heat inact.). Data presented as mean 6 sd. These results are representative of three independent experiments with triplicates for each condition. ***P < 0.001.

expression in the entorhinal cortex and hippocampus regions
compared to WT littermate controls (Fig. 4). These results suggest a possible role for the elevated levels of sAPPa and
increased GFAP expression observed in postmortem autism
brains.
There is minimal emphasis in the literature on sAPPa
function in other brain cells besides neurons. Its trophic and
protective effects on neurons have been well-documented (Masliah et al., 1992; Milward et al., 1992; Mattson et al., 1993b;
Roch et al., 1994; Smith-Swintosky et al., 1994; Luo et al.,
2001). Evidence exists supporting sAPPa activity on microglial
cells, stimulating the release of interleukin-1 (Li et al., 2000),
glutamate and markers of inflammation (Barger and Harmon,
1997; Barger and Basile, 2001). The cellular function of sAPPa
in astrocytes was introduced with reports that treatment of
human NSCs with recombinant sAPPa caused increased astrogliogenesis in vitro (Kwak et al., 2006a). More recently, sAPPa
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has been proven to increase subgranular zone (SGZ)-derived
neural progenitor cell (NPC) proliferation in culture, and treatment of these cells with sAPPa increased NPC differentiation
into astroglial cells (Baratchi et al., 2011).
We observed increased GFAP expression and decreased btubulin III expression by primary murine NSCs derived from
TgsAPPa mice (Fig. 5). We also detected dose-dependent
increases in GFAP-positive cells differentiated from WT murine
NSCs treated with rhsAPPa (Fig. 6), suggesting that in cell cultures sAPPa could promote glial cell fate. Despite these findings it is likely that upregulation of a-CTF itself (Fig. 1) has
effects on APP and its binding partners beyond those of sAPPa.
Interestingly, it is not known whether a-CTF and sAPPa can
bind together and form a heterodimeric receptor as in the case
of Notch1 and other similar receptors (Blaumueller et al.,
1997; Furukawa et al., 1996; Van Nostrand et al., 2002;
Shaked et al., 2006; Chen et al., 2006; Kedikian et al., 2010;
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FIGURE 7: Increased expression of IL-6, NICD, and gp130 correlated with elevated sAPPa levels. A: Cortical brain homogenates were
prepared from 3-month-old TgsAPPa mice and WT littermates. (n 5 4#) and subjected to IL-6 ELISA (mean 6 sd of pg of IL-6/mg total
protein). IL-6 production was enhanced in cortical tissues from TgsAPPa mice. B: WB analysis of these tissues for sAPPa (6E10), gp130,
NICD, and b-actin. C: Conditioned media collected after 18 h from N2a cells overexpressing human sAPPa (6-1 cell clone) show
enhanced IL-6 production by ELISA compared to N2a cells. Data presented as mean 6 SD (pg of IL-6/mg protein) from three independent experiments, with three replicates per group. D: WB analysis of these cells for sAPPa, gp130, NICD, and b-actin. WT N2a cells (E,
top panel) or murine NSCs (E, bottom panel) were treated with sAPPa at doses indicated for 24 h and subjected to IL-6 ELISA revealing
enhanced levels of IL-6 in sAPPa treatment groups. IL-1b, IL-4, TNFa, and IFN-c were undetectable (data not shown). F: In parallel, the
cell lysates were subjected to WB analysis using gp130 and NICD antibodies. Data presented as mean 6 sd (pg of IL-6 per mg total protein from three independent experiments, three replicates per group). **P < 0.01; ***P < 0.001.
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FIGURE 8: TgsAPPa mice show a marked increase in gp130 levels in entorhinal cortex. A: Representative brain sections from 3-monthold TgsAPPa mice and WT littermates (n 5 4$/4#, per group) stained with gp130 antibody (brown signal). B: Enhanced percentages of
gp130 immunoreactivity in the TgsAPPa group compared to WT littermate controls. C: WB analysis for gp130 from cortical tissues
showed increased gp130 expression in mice overexpressing hsAPPa. Similar results were also observed in TgsAPPa mice at 1 and 6
months of age (data not shown). **P < 0.01.

Isbert et al., 2012). Hence the properties of a-CTF in subsets
of individuals with autism remain elusive.
Several binding partners for sAPPa have been identified,
such as apolipoprotein E (Barger and Harmon, 1997), the
class A scavenger receptor (Santiago-Garcia et al., 2001), and
others (Kounnas et al., 1995; Knauer et al., 1996; Das et al.,
2002), providing a number of candidates that may be responsible for its cellular activities. However, none of these proteins
or receptors is involved in glial differentiation. IL-6 family
proteins promote the differentiation of NSCs into astrocytes
and inhibit neurogenesis through activation of the JAK-STAT
pathway (Bonni et al., 1997). The binding of leukemia inhibitory factor (LIF) ligand to its receptor recruits membrane
gp130 to form a complex that triggers the JAK-STAT pathway, leading to gliogenesis in NSCs (Taga and Fukuda, 2005).
Additionally, Notch1 inhibits neuronal cell fate and promotes
glial differentiation of NSCs via its intracellular domain
(Wang and Barres, 2000; Gaiano and Fishell, 2002). In particular, Notch1 guides cells that were already destined to become
glia towards an astrocytic rather than oligodendrocytic cell fate
(Grandbarbe et al., 2003; Lasky and Wu, 2005). Sugaya et al.
showed that sAPPa induces glial differentiation of human
NSCs by activating the IL-6/gp130 pathway (Kwak et al.,
2010). This group also reported that Notch1 signaling is
involved in sAPPa-induced glial differentiation of NSCs
(Kwak et al., 2011). Our findings confirm these sAPPa mechanisms of action in murine NSCs. We observe increased
expression of IL-6 and gp130 in NSCs from TgsAPPa mice
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and N2A cells treated with conditioned medium from NSCs
obtained from TgsAPPa mouse NSC culture. Moreover, our
observation of increased NICD expression after these experiments suggests that sAPPa operates through the Notch1 pathway (Fig. 7). The sAPPa fragment may not be directly
binding to the receptors that trigger either the IL-6 or Notch1
pathways; however, these findings imply that other sAPPa
binding partners exist. Velasco et al. reported that stimulation
of glial differentiation in rat NSCs via the Notch1 pathway is
more potent than stimulation via the IL-6/gp130 activated
pathway (Rodriguez-Rivera et al., 2009). Our results suggest
that sAPPa can promote glial cell fate of murine neural cells.
In addition to its well-established function in glial differentiation during development, gp130 participates in the
regulation of serotonergic gene expression in the mouse brain
(Kulikov et al., 2010) and, along with other constituents of
the IL-6 pathway, is activated in the astrocytic response to
traumatic brain injury (Oliva et al., 2012). Kirsch et al. previously reported that the IL-6/gp130 pathway regulates the
astrocytic response and axonal sprouting of neurons after
entorhinal cortex lesion in adult rats (Xia et al., 2002). Here,
we report that adult TgsAPPa mice demonstrated marked
increases of gp130 in the entorhinal cortex by immunohistochemistry (Fig. 8). This suggests that the overexpression of
sAPPa in the brain is associated with continually increased
presence of gp130, even after development. In light of the
aforementioned results (Fig. 4), this gp130 increase may correlate with the GFAP increase we observed in TgsAPPa mice;
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however direct causation is lacking. Whether excess sAPPa
may potentially be impacting gliosis and abnormal brain
development through upregulation of gp130 and consequently gp130-related pathways such as Notch1 and LIF in
some individuals with autism remains to be determined.
In summary, we have shown that subsets of patients with
autism exhibit elevations in sAPPa and a-CTF in the insular
cortex compared to normally developed children. Mice generated to mimic this observation show abnormal social behavior
and hypoactivity, increased GFAP expression, and decreased btubulin III with associated elevations in IL-6, gp130, and
Notch1. NSCs derived from sAPPa overexpressing mice, as
well as N2a cells treated with rhsAPPa displayed increased
markers suggestive of glial cell fate. Gliosis during critical windows of development may contribute to dysregulated synaptic
pruning, maintenance or function, leading to aberrant synaptic
connections and components of the autistic phenotype.
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